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AIM AND OUTLINE OF THIS THESIS 
Cancer is one of the most lethal diseases worldwide, affecting millions of people annually. The past 
three decades have witnessed a significant progress in the diagnosis and treatment of several 
cancer types. In spite of this progress, cancer is still a hard to treat disease. For instance, cancer 
that arises from organs confined within the peritoneal cavity (e.g. ovarian, pancreatic, colorectal 
and liver), leading to peritoneal carcinomatosis (PC), represents an enormous challenge for both 
the medical and scientific community due to its late stage of discovery and low survival rates of 
the treated patients. In this context, different post-surgical therapies are currently being employed 
in the clinic in order to prolong the survival of patients diagnosed with PC. Nevertheless, most of 
the patients relapse and succumb to their disease.  
Due to their potential to increase the specificity and consequently decrease the adverse effects of 
different drugs, nanoparticles (NPs) loaded with anti-cancer agents have been a topic of interest 
for many researchers and pharmaceutical companies during the last 30 years, leading to several 
products that are used nowadays in clinical oncology. The suitability of nanomedicines for the 
treatment of PC via the intraperitoneal (IP) route of administration, however, has not been 
thoroughly investigated yet. Also, the discovery of the RNA interference (RNAi) pathway about two 
decades ago has opened new avenues in cancer therapy. The RNAi mechanism involves the use of 
small interfering RNAs (siRNAs) or microRNAs (miRNAs) to knockdown a specific gene. To date, 
specific gene knockdown is mainly achieved using siRNAs. Therefore, in this project we will limit 
our focus on siRNAs.  
Therefore, the aim of this thesis was to shed the light on the ability of NPs loaded with small 
interfering RNA (siRNA) for IP therapy of PC. Specifically, we investigate the colloidal stability and 
biological performance of different lipid-based nano-sized formulations loaded with siRNA in a 
relevant model of ascites fluid obtained from a PC patient, as well as, we explore the behavior of 
NPs following IP administration in mice.  
In Chapter 1, we provide a brief introduction on PC, the anatomy and role of the peritoneal 
membrane, as well as on the current techniques used in the clinical management of PC following 
surgical debulking. Importantly, we focus on the hurdles of using nanomedicines for IP therapy of 
PC in suspension and suggest possible strategies to resolve these challenges.  
While Chapter 1 reports mainly on the use of nanomedicines for chemotherapeutic drugs, in 
Chapter 2, we review the recent progress in the use of nanomedicines for the delivery of nucleic 
acids, mainly plasmid DNA (pDNA) and siRNA, administered via the IP route for the treatment of 
PC. In Chapter 3, we evaluate the colloidal stability of model polystyrene (PS) NPs possessing 
cationic, neutral and anionic surface charge, as well as of nano-sized liposomes with different 
degrees of poly-ethylene glycol (PEG) surface coating in peritoneal fluids from murine and human 
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origin. The aggregation in peritoneal fluids obtained from mice and the ascites fluid obtained from 
a PC patient was assessed using an in-house advanced microscopy technique known as 
fluorescence single particle tracking (fSPT). Similarly, pre-mature release of the siRNA from the 
different liposomal formulations in undiluted mice peritoneal fluid and ascites fluid was determined 
using fluorescence correlation spectroscopy (FCS).  
In Chapter 4 and Chapter 5 we attempt to investigate the influence of the extracellular stability 
of different siRNA-liposomes complexes (i.e. lipoplexes) on the ability to knockdown a specific 
gene in the SKOV-3 human ovarian cancer cell line. In Chapter 4 we tested the colloidal stability, 
as well as the cellular uptake and knockdown efficiency of different lipoplexes (LPXs) following 
incubation in ascites fluid. We also provided an evidence that aggregation is not the sole 
determinant of the downregulation efficiency in vitro. The LPXs described in Chapter 4 were 
prepared using the classic method for the preparation of LPXs – electrostatic interactions between 
the positively charged liposomes and the negatively charged siRNA. A similar evaluation of the 
colloidal stability and knockdown efficiency was performed in Chapter 5 on LPXs prepared with 
the hydration method. In both cases the loss of cellular uptake following incubation in the ascites 
fluid but not in reduced serum medium was the bottleneck for achieving high gene knockdown.  
In Chapter 6, we elucidate the reason behind the loss of cellular uptake observed in Chapter 4 
and Chapter 5, and question whether this phenomenon is restricted only for liposomes possessing 
the specific lipid composition and biological fluid (i.e. ascites fluid) we used. We carry-out uptake 
and transfection experiments with LPXs with a different lipid composition in fetal bovine serum, 
ascites fluid and human serum. Furthermore, we analyze the composition of the proteins bound on 
the surface of LPXs (known as “protein corona”) qualitatively and quantitatively by SDS-PAGE and 
liquid-chromatography mass spectroscopy (LC-MS), respectively.  
In Chapter 7, we examine the effect of the carrier solution on the abdominal residence time and 
biodistribution of NPs following IP administration in mice. Size distributions of 200 nm PS NPs 
coated with PEG and a mixture containing different molecular weight of FITC-dextrans were 
obtained at different time points following injection using fSPT and fluorescence recovery after 
photobleaching (FRAP), respectively. The biodistribution of the PS NPs was determined by 
fluorescence imaging of the collected organs 24 h following administration.  
In Chapter 8, we discuss the significance and global impact of translating post-operative 
strategies for the treatment of PC into the clinic. Furthermore, we elaborate on the contribution of 
the data presented in this thesis on developing nanomedicine-based IP therapy for the treatment 
of PC, with emphasis on the hurdles and challenges to be overcome in future studies, in order to 
ensure successful translation into the clinic.    
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THERAPY FOR THE TREATMENT OF PERITONEAL 
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Abstract 
Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of 
peritoneal carcinomatosis (PC). Over the past decade, a lot of effort has been put both in the 
academia and clinic in developing IP therapeutic approaches that maximize local efficacy while 
limiting systemic side effects. Also nanomedicines are under investigation for the treatment of 
tumors confined to the peritoneal cavity, due to their potential to increase the peritoneal retention 
and to target drugs to the tumor sites as compared to free drugs. Despite the progress reported 
by multiple clinical studies, there are no FDA approved drugs or formulations for specific use in the 
peritoneal cavity yet. This review discusses the current clinical management of PC, as well as 
recent advances in nanomedicine-based IP delivery. We address important challenges to be 
overcome towards designing optimal nanocarriers for IP therapy in vivo.  
Keywords: Peritoneal Carcinomatosis, Intraperitoneal delivery, Sustained release, Biodistribution, 
Nanomedicines  
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1. Introduction  
Primary cancer occurring in organs confined to the peritoneal cavity (e.g. ovary, liver, colon, and 
pancreas) might lead to the migration of cancer cells to the peritoneal cavity. Attachment of free-
flowing cancer cells to the mesothelial layer of the peritoneal membrane results in the formation of 
peritoneal carcinomatosis (PC). In the USA alone, there are about 250,000 cases of cancer 
originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and 
liver)[1]. Unfortunately, most primary tumor sites do not cause clear clinical symptoms that enable 
the early detection of the peritoneal spread of cancer cells. The detection of PC thus mostly occurs 
at a later disease stage when a large amount of tumor nodules is already distributed over the 
peritoneal surfaces. The presence of these multiple peritoneal metastases confers a poor prognosis 
[2].  
 Selected patients with PC benefit from surgical cytoreduction, aiming to remove all visible 
peritoneal metastases. Depending on the histology and grade of the disease, either perioperative 
or postoperative intravenous (IV) chemotherapy can be administered. Despite macroscopically 
complete cytoreductive surgery (CRS), many patients develop recurrent PC [3]. Hence, active 
adjuvant treatments are needed to remove persisting minimal residual disease and improve the 
survival of patients diagnosed with PC. The past decade has witnessed a significant progress in 
developing IP adjuvant techniques. Most newly developed techniques focus on the local 
administration of chemotherapeutics. The rationale for IP therapy is the ability to achieve a high 
locoregional (peritoneal) drug concentration, while avoiding systemic toxicity [4]. Conventional 
chemotherapeutics might, however, rapidly leak from the peritoneal cavity and display little 
specificity towards cancer cells. Therefore, the use of nanomedicines to prolong the residence time 
in the peritoneal cavity and to specifically target tumor cells is being explored. In this review we 
aim to discuss the progress, barriers and challenges in employing nanomedicines for IP therapy of 
PC, with a special focus on strategies that are employed to increase the residence time of 
nanomedicines in the peritoneal cavity. To do so, we first focus on the main techniques that are 
currently used in the clinical management of PC using local administration of conventional 
chemotherapeutics. We also address the challenges and hurdles in tailoring nanomedicines for IP 
delivery in vivo, including biodistribution and tumor penetration. Finally, we discuss ongoing 
clinical trials with nanomedicines for PC therapy and reflect on the possible strategies to overcome 
current limitations upon administration of nanomedicines. 
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2. Anatomy and role of the peritoneal membrane 
The peritoneal membrane covers the visceral, abdominal and pelvic organs and has a total surface 
of 1.5 m² on average [5]. It is composed of several layers of connective tissue as demonstrated by 
Baron [6]. The first layer is comprised of mesothelial cells interconnected by tight junctions, which 
secrete surface hyaluronan as depicted in Figure 1A. The mesothelial layer functions as a barrier 
that protects from physical damage and surface adhesion [7]. A submesothelial basement 
membrane separates the mesothelial layer from the interstitial space, which contains fibroblasts, 
collagen and other molecules as a first “defense line” against macromolecules (Figure 1A). The last 
layer consists of vessels with negatively charged endothelial cells – a second “defense line” that 
prevents the passage of large macromolecules into the peritoneal cavity (Figure 1A).  
Under normal conditions (Figure 1A), the oncotic pressure that is exerted by plasma proteins 
(mainly albumin) across the peritoneal membrane (between the endothelial layer and the 
mesothelial layer) restricts the diffusion of water into the abdominal cavity due to the reabsorption 
of water that occurs into the capillaries from the interstitial space [8]. In the majority of the PC 
cases, however, this homeostasis is disrupted by an increased microvascular permeability which is 
believed to be mainly induced by the vascular endothelial growth factor (VEGF) [9, 10]. Together 
with the secretion of cytokines and chemokines in the surrounding of the peritoneum, the structure 
of the membrane is altered leading eventually to a net change in the flow direction of the fluid (i.e. 
oncotic pressure) into the peritoneal cavity and consequently, to the formation of an albumin-rich 
ascites fluid in the peritoneal cavity (Figure 1B). The exact mechanism by which the ascites fluid 
accumulates in the abdomen is very complex, and not fully elucidated yet. It is hypothesized that 
different factors play an important role in the formation of the ascites fluid, such as lymphatic 
obstruction and osmotic water transport following the leakage of proteins from microcapillaries into 
the peritoneal cavity [11].  
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Figure 1. The peritoneal membrane and formation of ascites fluid. (A) Structure of the peritoneal membrane 
under normal conditions and (B) disruption of the peritoneal membrane in peritoneal carcinomatosis, leading to the 
formation of ascites. 
Interestingly, it has been shown that the peritoneal membrane does not correspond to the classic 
semi-permeable model, but rather is highly permeable to both water, small solutes and proteins 
[7]. In fact, the peritoneal membrane does not represent a substantial physical barrier for IP 
administered low-molecular weight drugs, indicating that small chemotherapeutics can easily 
redistribute to the systemic circulation [7, 12, 13]. There is no consensus, however, as to which 
extent the peritoneal membrane poses a barrier to nano-or micrometer sized particles. Also, it is 
not known if the permeability of the peritoneal membrane changes in function of peritoneal disease 
progression due to the infiltration of tumor cells in the mesothelial cell layer and disruption of the 
basement membrane.  
3. Local chemotherapy for the treatment of PC 
3.1 Rationale behind using IP therapy 
IP therapy aimed at targeting tumors within the peritoneal cavity offers pharmacokinetic 
advantages when compared to systemic (IV) administration of chemotherapeutics. As postulated 
by Dedrick et al., higher concentrations of drug are expected to reach peritoneal tumors following 
IP delivery compared with the systemic delivery [14, 15]. Also, IP delivery increases the 
concentration of drug in the vicinity of hypoxic, small peritoneal metastases (less than 1 mm in 
diameter), which lack an established vasculature and are therefore difficult to treat using IV 
administration [16]. Finally, similar to any other regional cancer therapy, administration of drugs 
directly into the site of action lowers systemic toxic effects [17]. It should be noted that none of 
the available chemotherapeutics has been specifically approved for IP administration. Therefore, IP 
chemotherapy is currently used off label with agents developed for IV administration such as 
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Doxorubicin [18], Fluorouracil analogs [19], Paclitaxel (PTX) [20], and Platinum-based compounds 
[21]. 
3.2 Current clinical management of PC  
Nowadays, the most common IP delivery technique in many clinical centers is repeated IP 
instillation of chemotherapeutics using a port catheter after cytoreductive surgery (CRS) [22, 23]. 
During CRS, all macroscopic disease is removed by a combination of organ resections and 
peritonectomy procedures. The IP cycles are usually initiated 1-3 weeks after surgical debulking, 
and the catheter is removed after the last cycle of IP chemotherapy is completed. Another option 
for IP delivery of chemotherapeutics involves intraoperative continuous chemoperfusion (IPEC), 
immediately after CRS. Intraperitoneal chemoperfusion is usually performed under hyperthermic 
conditions (41.5°C), known as HIPEC [24] (Figure 2). It is assumed that HIPEC leads to a 
homogeneous distribution of the administered drug throughout the abdominal cavity and enhances 
penetration of the drug into the remaining solid tumor nodules [25, 26]. During the combined 
procedure, the peritoneal cavity is perfused during 30-120 min with chemotherapy using a closed 
or semi-open perfusion circuit consisting of inflow and outflow drains, a roller pump, reservoir, and 
heating element. In the largest single-center study, between the years 1991 until 2013, 1,000 
patients with PC underwent CRS followed by HIPEC [27]. The authors showed a significant 
improvement in the survival rate and a substantial decrease in complications, stoma creation and 
transfusion requirement over time. It should be noted that surgery combined with HIPEC is 
invasive and time consuming. Also, standardized treatment protocols regarding drug schedule and 
dose, perfusion temperature, and perfusion duration are currently unavailable [28].  
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Figure 2. Surgical procedure of HIPEC. (A) View of the open abdomen after cytoreductive surgery for peritoneal 
carcinomatosis. Then, hyperthermic intraperitoneal chemotherapy (HIPEC) is performed through inflow (white 
arrows) and outflow (black arrows) tubes that are inserted in the abdominal cavity and connected with a pump, 
which installs an ongoing circulation. Temperature is continuously measured using three probes (blue arrow) placed 
in the abdominal cavity. (B) A roller pump establishes a continuous circulation of chemotherapy in and out the 
abdominal cavity. 
A very recent new method of intraperitoneal cytotoxic drug delivery for the treatment of PC is 
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) [29], which is performed during 
laparoscopy. After creation of a standard CO2 pneumoperitoneum (working pressure of 12 mmHg), 
several balloon trocars are introduced into the abdominal cavity. A disposable nebulizer or 
micropump (MIP®, Reger Medizintechnik, and Rottweil, Germany) is positioned into the abdomen 
through one of the trocars connected with a high pressure injector through a dedicated high-
pressure line. The cytotoxic solution (Figure 3B) is injected under a pressure of 20 bar, and the 
resulting aerosol dispersed in the abdomen (Figure 3C). After complete administration, a generator 
(Ultravision, Alesi Surgical Ltd., UK) is activated, inducing electrostatic precipitation of the airborne 
particles on the peritoneal surface (i.e., electrostatic PIPAC or E-PIPAC). This pressurized state at 
12 mmHg is maintained for 30 min. Thereafter, the capnoperitoneum is deflated through a closed 
suction system. 
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Figure 3. Surgical procedure of E-PIPAC. (A) A capnoperitoneum is established during laparoscopy. A nebulizer 
(white arrow) placed in a 10 mm balloon trocar is connected with a high-pressure line (white arrowheads). A 5 mm 
camera (black arrow) is inserted in a 5 mm balloon trocar to inspect the nebulization in the abdomen. Once all the 
cytotoxic agents are injected, electrostatic precipitation of aerosol on the peritoneum is induced through a dedicated 
catheter (star) connected with a generator. After E-PIPAC, the abdomen is deflated through a closed aerosol waste 
system with filter (black arrowheads). (B) Double head injector (star) with 2 syringes for doxorubicin (black arrow) 
and cisplatin (white arrow) administration. Both syringes are connected with a high-pressure line (white 
arrowheads). (C) Intra-abdominal view of the tip of the nebulizer (white arrowhead) inserted in the 10 mm balloon 
trocar (white arrow) before initiation of E-PIPAC. (D) Intra-abdominal movement of airborne cytotoxic particles 
(multiple arrows) during injection.  
 
 
The working mechanism of PIPAC is based on local administration of cytotoxic agents on the 
tumoral surface in the abdominal cavity. The aerosol form accomplishes homogeneous drug 
distribution [30], while it is believed that the high intra-abdominal pressure enhances tissue 
penetration and antitumor effects [31, 32]. As a consequence, a low dose of chemotherapy can be 
used, causing low systemic drug uptake and toxicity [29, 33]. Interestingly, Solass and coworkers 
indeed showed that clinical PIPAC therapy with Doxorubicin achieves high tissue drug 
concentrations, even though a relatively low dose is nebulized [29].   
 Other possible advantages include minimal patient discomfort, the repeatability of the procedure, 
the global quality of life improvement, and the possibility to combine PIPAC with systemic 
chemotherapy [34, 35]. Experimental and clinical studies show that PIPAC has promising 
antitumor activity in ovarian, gastric, and colorectal carcinomatosis [36, 37]. Prospective studies 
(NCT02604784, NCT02320448, NCT01854255), investigating the efficacy of PIPAC in recurrent 
gastric cancer are currently recruiting patients. A phase 1 dose-escalation trial has been initiated 
recently in recurrent ovarian cancer (NCT02475772). It is clear, however, that PIPAC is still in its 
infancy and further clinical research is needed. 
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4. Future directions in PC therapy    
A major drawback of currently used local therapies for PC is the significant risk of recurrent 
peritoneal disease [38, 39]. Due to the short exposure time to conventional small 
chemotherapeutics, which rapidly leak from the peritoneal cavity, there is a need for therapeutic 
approaches that enable a prolonged residence time of chemotherapeutics in the peritoneal cavity 
following CRS. One such approach that is investigated, is the use of nanoparticles that carry and 
deliver chemotherapeutics specifically into tumors.   
4.1 Rationale for using nanomedicines for IP therapy  
Nanoparticles (NPs) are particles with a size that ranges from 1 to 1000 nanometer (nm) in 
diameter. Due to their size, versatility and the ability to easily modify their surface, NPs are 
excellent candidates to cross biological barriers and deliver different therapeutics into cells. Also, 
NPs can potentially slow down systemic absorption, decrease systemic toxicity [40] and extend the 
exposure time of the drugs to peritoneal tumors. Furthermore, NPs can be functionalized to 
selectively accumulate at tumor sites [41, 42]. NPs that are used as vehicles for the delivery of 
drugs and biopharmaceuticals are known as “nanomedicines”.  
 Generally speaking, NPs are roughly divided into two main types: (1) lipid-based NPs and 
(2) polymer-based NPs. The most used lipid-based nanomedicines for biomedical applications are 
liposomes [43], while Poly (lactic-co-glycolic acid) (PLGA) is one of the most successfully 
developed polymers used in drug delivery [44]. The choice of NPs for a specific application mostly 
depends on the physico-chemical properties of the desired cargo (e.g. 
hydrophilicity/hydrophobicity, charge, and solubility, etc.) and the route of administration, as well 
as on the extracellular and intracellular barriers it is expected to cross in order to successfully 
reach the site of action. To date, there are some nanomedicines approved for clinical use and 
several more in clinical trials [45]. Nanomedicines have also played a vital role in cancer therapy 
[41, 42], with a total of 12 clinically approved nanomedicines for anti-cancer therapies [46]. None 
of these nanomedicines, however, are intended for IP cancer therapy.  
Numerous attempts have been made to deliver chemotherapeutics into tumors confined to the 
peritoneal cavity using NPs (Figure 4A), via both IV and IP routes [47-49]. We have also recently 
reviewed different non-viral nucleic acid delivery systems that were IP administered for the 
treatment of peritoneal cancer [50]. In the current review, we do not aim to overview the different 
types of nanoparticle systems and their building blocks as such, but to focus on general in vitro 
and in vivo aspects related to IP delivery of nanomedicines that are currently still often 
overlooked.  
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4.2 In vitro stability and biological activity of NPs in the presence of ascites fluid 
Generally speaking, in vitro optimization of nanomedicines is required as a first development step, 
and this includes basic characterization of the size and surface charge, followed by toxicity, 
uptake, and biological activity assays in the relevant cell type. Nevertheless, in vitro optimization 
is often carried out in biofluids that do not resemble the in vivo situation, and the impact of the 
relevant biofluids that nanomedicines will encounter upon in vivo administration is often not 
investigated. It is becoming increasingly clear that NPs present in biofluids (e.g. blood, plasma, 
serum, saliva, and peritoneal fluid, etc.) interact with different components including proteins and 
degrading enzymes that may lead to their aggregation, premature release of cargo, loss of 
targeting capabilities, decrease of cellular uptake, and eventually dramatic limitation of biological 
activity [51-56]. In this context, we have recently established an in vitro model to evaluate the 
performance of NPs in the presence of ascites fluid obtained from a patient diagnosed with PC. By 
using advanced microscopy techniques, we were able to determine the aggregation and 
disintegration of NPs in the undiluted ascites fluid, as parameters to follow their colloidal stability 
in function of time [57]. Our data demonstrate that the ascites fluid does not only influence the 
colloidal stability of the NPs, but also drastically lowers cellular uptake of liposome-siRNA 
complexes. Thus, even NPs such as PEGylated liposomes that were colloidally stable in ascites fluid 
(in terms of aggregation and release), lost their ability to silence genes in SKOV-3 human ovarian 
cancer cells due to their incapability to carry the siRNA into the cells [51]. It should be noted that 
generally, only limited amount of ascites fluid has developed in the patients which are eligible for 
CRS and adjuvant IP therapy. Before the development of ascites, only a small amount of IP fluid is 
present, which cannot be extracted from patients to optimize in vitro performance of NPs. Whether 
or not the small amount of IP fluid limits the therapeutic potential of in vivo administered 
nanoparticles to the same extent as ascites fluid remains to be elucidated. Nevertheless, we do 
recommend to optimize the in vitro behavior of NPs in ascites fluid, before moving on to the in vivo 
evaluation of NPs.  
4.3 In vivo barriers and challenges upon IP administration of NPs 
4.3.1 Biodistribution of NPs following IP injection  
Apart from colloidal stability, an important feature in anti-tumor activity of nanomedicines is their 
fate following administration. Ideally, nanomedicines should circulate, extravasate (in the case of 
IV injection), accumulate and finally penetrate into the tumor. Unlike for IV administration, where 
tens of studies investigated the biodistribution and ability of different nanomedicines to accumulate 
at tumor sites [58, 59], only (very) limited data are available on the biodistribution of NPs 
following IP injection (Table 1). The biodistribution of non-PEGylated (450 nm in size) and 
PEGylated (30-100 nm in size) graphene oxide NPs was assessed in healthy animals following IP 
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administration [60]. Aggregated and immobile NPs were found in the abdomen for the non-
PEGylated formulation, whereas the mobile PEGylated formulations accumulated mainly in the liver 
and spleen. Langer and coworkers evaluated 265 nm PLGA NPs of 90 kDa as strategy to prolong 
drug delivery in the murine peritoneum and compared the biodistribution with 5-250 µm sized 
PLGA microparticles (MPs) [61]. All NPs were cleared from the peritoneum within 2 days after 
administration, and accumulated in the mononuclear phagocyte system (MPS) organs, namely the 
liver and spleen. MPs were retained in the peritoneal cavity for a longer time period, but a high 
incidence of adhesions 2 weeks after injection of the MPs made them unsuitable for long term 
delivery to the peritoneum [61]. Similarly, Tsai et al. examined the effect of carrier size on the 
disposition and anti-tumor activity of paclitaxel (PTX) [62]. In particular, PTX loaded gelatin MPs 
and NPs, as well as Cremophor micelles were systematically studied in mice bearing Hs766T 
pancreatic human cancer cells. Again, NPs were more rapidly cleared from the peritoneal cavity, 
with less than 0.1% remaining in peritoneal lavage samples 24 h following IP administration. MPs 
exhibited the slowest clearance and the longest residence time in the abdominal cavity, which was 
correlated with a ~2 fold increase in the survival time when compared to the NPs and Cremophor 
micelles. The authors attributed this clearance profile to the dimensions they found for the 
lymphatic duct openings (known as stomata) on the diaphragm of mice, which ranged on average 
from 0.7 to 15.5 µm in length and 0.5 to 8.2 µm in width. Therefore, NPs smaller than these 
openings were rapidly cleared into the systemic circulation, while a more slow absorption occurred 
for MPs which were similar in size to the openings [62]. Also, Hirano and Hunt investigated the 
size effect on the peritoneal retention of liposomes of 48, 170, 460 and 720 nm in rats [63]. They 
observed no size effect in this range, as all liposomes remained below the estimated size limits 
that would restrict their entrance into the lymphatic capillaries. When Sadzuka et al. investigated 
the size effect for negatively charged liposomes of 155, 605 and 4225 nm, they came to 
comparable conclusions [64]. Again, no significant difference in clearance was observed for the 
small and medium sized vesicles, while the larger liposomes indeed were retained for a longer time 
in the peritoneal cavity 8 and 24 h after injection. When neutral liposomes were used, Mirahmadi 
concluded that 1000 nm sized particles were the most optimal to achieve high peritoneal retention 
[65]. Dadashzadeh et al., however, looked into the effect of size, charge, lipid composition and 
PEG coating on peritoneal retention in healthy female NMRI mice using 100 nm and 1000 nm 
radiolabeled liposomes [66]. The charge of the liposomes seemed to be the most important factor 
that determined the retention in the abdominal cavity, with cationic liposomes being longer 
retained than negatively charged liposomes. The effect of size on peritoneal clearance was 
dependent on the charge of the liposomes. 100 and 1000 nm negatively charged liposomes were 
equally rapidly cleared, most likely through macrophage uptake. Size did matter for the cationic 
liposomes, where the 1000 nm cationic liposomes had the highest retention in the peritoneal 
cavity, with up to 25% of the initial dose still remaining 48 h following administration. For 100 nm 
cationic liposomes, 20% of the injected dose could still be retrieved after 24 h. In the first hours 
following injection, PEGylation of the cationic liposomes even further increased the peritoneal 
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retention, presumably because of interference with the uptake of PEGylated liposomes in the 
macrophages. The authors concluded, overall, that the 100 nm cationic liposomes are the most 
suitable for IP drug delivery due to uniform distribution in the peritoneal cavity and resistance to 
uptake by peritoneal macrophages. It should be noted that the authors did not determine the 
actual size of liposomes after injection into the abdomen. As we previously demonstrated that 
especially cationic liposomes are sensitive to aggregation, we speculate that the high retention of 
the 100 nm cationic liposomes observed by Dadashzadeh et al. could potentially be attributed to 
aggregation of the cationic liposomes in the peritoneal cavity to micrometer sized aggregates [57], 
which no longer efficiently cross the lymphatic openings. Also, it is of importance to mention that 
the vast majority of the above mentioned biodistribution studies were performed in healthy 
animals (see Table 1). Therefore, at the moment it is not clear whether or not the residence time 
of particles in the peritoneal cavity would be changed in the presence of PC, for example by 
changing the barrier function of the peritoneum, by altering the amount and activity of 
macrophages present in the peritoneal cavity or by changes in the content and composition of 
proteins in the peritoneal fluids, which might bind and alter the biological activity of NPs as 
mentioned under section 4.2.  
In general, two major mechanisms for drug clearance from the peritoneal cavity to the systemic 
circulation are suggested: (1) direct absorption through the peritoneum and (2) drainage via the 
lymphatic ducts. For small molecules with a molecular weight of less than 20 kDa, absorption 
through the peritoneum is the major pathway, as shown by Flessner and co-workers [12]. For 
larger compounds such as NPs and MPs, the studies above demonstrate that lymphatic drainage 
represents the major clearance pathway [63, 67]. The lymphatic drainage and rapid clearance of 
colloidally stable NPs (that are diffusing and do not form aggregates) from the peritoneal cavity 
seem inevitable, in such a way that NPs are cleared within several hours (depending on the size) 
following administration, resulting in a low residence time in the abdomen. Nevertheless, it should 
be noted that NPs that are larger than 500 nm in size tend to stay in the lymph nodes, while 
smaller NPs pass through the lymph nodes and end up in the systemic circulation [63]. This 
lymphatic targeting of NPs has long time ago already been proposed by Maincent et al. [68] as a 
promising strategy to treat tumors that make use of the lymphatic pathways to spread and 
metastasize in the peritoneal cavity. 
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Table 1. Biodistribution of NPs following IP administration  
Formulation 
Hydrodyna
mic 
diameter & 
surface 
charge (if 
available) 
animal 
model  
Outcome Reference 
PEGylated and non-
PEGylated Graphene 
oxide NPs 
25, 27, 50 
nm 
PEGylated 
450 nm 
negatively 
charged 
Healthy mice 
450 nm non-PEGylated 
formed aggregates in the 
abdomen, the PEGylated 
particles were cleared 
mainly in the liver and 
spleen 
[60] 
PLGA 
265 nm 
negatively 
charged 
Healthy mice 
NPs were cleared from the 
abdomen within 2 days and 
accumulated in the spleen 
and liver 
[61] 
Gelatin NPs loaded with 
Paclitaxel 
60, 90 nm 
Nude mice 
bearing 
human 
xenograft 
tumor model -
pancreatic 
Hs766T tumor 
cells 
Rapid clearance (within 24 
hours) of the NPs from the 
abdomen and poor efficacy 
in vivo compared with MPs 
[62] 
Egg lecithin liposomes 
encapsulating [14C] 
sucrose 
48, 170, 
460, and 
720 nm 
Healthy rats 
Rate and extent of 
absorption from the 
peritoneal cavity was 
independent on size. The 
Smallest liposomes 
accumulated in the lymph 
with little lymph node 
retention, larger liposomes 
were collected in the lymph 
nodes 
[63] 
Liposomes 
encapsulating 
doxorubicin (different 
lipid compositions) 
150, 605 
and 4225 
nm 
negatively 
charged 
liposomes 
CDF1 mice 
bearing 
Ehrlich ascites 
carcinoma 
tumors 
Lipid composition did not 
affect the clearance of the 
liposomes. Large liposomes 
were superior over the 
small liposomes and free 
drug solution in inducing 
cytotoxicity 
[64] 
99mTc DSPC/CHOL 
liposomes 
100, 400, 
1000 and 
3000 nm 
neutral 
liposomes 
Healthy mice 
Highest peritoneal 
concentration was 
measured for the 1000 nm 
liposomes. The 3000 nm 
sedimented upon abdominal 
organs 
[65] 
PEGylated and non-
PEGylated liposomal 
formulations 
100 and 
1000 nm 
PEGylated, 
cationic and 
Healthy mice 
Positively charged 
liposomes of 1000 nm 
exhibited the highest 
retention time in the 
[66] 
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negatively 
charged 
liposomes 
peritoneal cavity 
[14C] Polyacrylic 
polymeric particles 
composed of carbon-14 
polyhexylcyanoacrylate 
nanoparticles (PHCA) 
and 
polymethylmethacrylat
e (PMMA) 
543 nm for 
PHCA and 
1.4 µm for 
PMMA 
Healthy rats 
Targeting the lymphatics 
via the IP route was 70-
2000 fold higher when 
compared to the IV route 
[68] 
 
 
 
 
4.3.2 The size dilemma for optimal tumor penetration of NPs  
To ensure maximal efficacy of cytotoxic drugs, penetration of the drug deep into the tumor tissue 
is crucial. From a clearance point of view, ideally, large particles (above 1 µm) such as MPs and 
microspheres are used as depot systems to prolong the retention time of drugs in the peritoneal 
cavity. In this respect, different MPs loaded with chemotherapeutics were used for the treatment of 
abdominal cancer [49, 69, 70]. Nevertheless, it has been shown that micro-sized formulations 
bear the risk of inducing peritoneal adhesions and inflammations [4, 61, 71]. The optimal balance 
between retention time, adhesions and efficacy of MPs is currently a topic of interest for several 
research groups [72].  
With regard to nanomedicines, the size dilemma consists of having a delivery system that 
efficiently penetrates on the level of the tumor, but on the other hand, also sufficiently remains 
present in the peritoneal cavity for this penetration to take place. The poor retention time of 
chemotherapeutics and nanomedicines in the abdomen, however, is expected to limit peritoneal 
tumor penetration and anti-tumor activity of these nanomedicines. Also, the microenvironment of 
many solid tumors makes the penetration of drugs very difficult or even impossible in some cases 
[73]. Tumors are characterized by a dense extracellular matrix, limiting the penetration not only of 
cytotoxic drugs but also of nanomedicines [74]. Also, the abundant and leaky vasculature in 
tumors results in a high interstitial fluid pressure (IFP) which counteracts the penetration of drugs 
and nanomedicines into the tumors by convective flow [75]. It has been demonstrated that 
smaller sized nanomedicines penetrate into tumors more efficiently than larger ones [76, 77]. 
Apart from the size of the nanomedicines, it has been recently shown that the surface charge plays 
a very important role in tumor penetration. Wang et al. [78] provided a strong experimental 
evidence in different tumor models that 100 nm positively charged PEGylated nanomedicines are 
superior in terms of tumor penetration over their neutral and anionic counterparts, and 
consequently exhibit enhanced tumor killing efficiency. In the context of NPs penetration into 
peritoneal tumors, Ding et al. [79] studied the antitumor efficacy and tumor penetration of 100 nm 
negatively charged (at pH 7.4) cisplatin-loaded gelatin-poly(acrylic acid) NPs in mice bearing 
hepatic H22 tumors. The nanoparticulate system significantly decreased the tumor volume when 
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compared to the cisplatin solution. However, tumor sections obtained 2 days following IP 
administration, showed that NPs are not able to effectively permeate the tumor deeply, but rather 
affect the cells near the vasculature. This suggests that IP injected NPs first entered the systemic 
circulation before reaching the tumor site. On the other hand, a recent study demonstrated that 
nanoscale PTX-polymersomes [80, 81] were detected deep inside the tumor’s parenchyma, 
indicating efficient tumor penetration [82] . Interestingly, the fluorescence signal showed higher 
accumulation of PTX-polymersomes in tumors compared with other organs (lung, kidney, heart, 
liver and spleen). Following IV administration, however, PTX-polymersomes accumulated less in 
peritoneal tumors and more in other organs. Overall, the data suggest that NPs penetrated into 
the tumor nodules both (1) directly, from the peritoneal cavity and (2) systemically after clearance 
from the peritoneal cavity, so that both small poorly vascularized and large vascularized tumors 
are affected by the drug.  
A possible strategy to lower the IFP is to decrease the vasculature in tumor nodules. It has been 
recently shown by Gremonprez et al. [83] that the inhibition of VEGF by Bevacizumab enhances 
the penetration of chemotherapeutics into peritoneal tumors and inhibits tumor growth in mice 
bearing colorectal carcinomatosis. Whether the tumor penetration of nanomedicines would also 
improve upon inhibition of VEGF remains to be investigated. However, given the important role of 
VEGF in the angiogenesis and formation of ascites [8, 9] (see section 2.), VEGF inhibitors seem 
excellent candidates for the treatment of peritoneal metastatic cancer. Albendazole (ABZ) is a 
widely investigated anti-parasite drug for its ability to inhibit VEGF [84], as well as tumor growth 
via the inhibition of tubulin polymerization and G2 M phase of the cell cycle. Noorani et al. [85] 
formulated ABZ bovine serum albumin (BSA) NPs of respectively 7-10 nm and 200-250 nm for the 
sustained release of ABZ in the peritoneum. The anti-tumor efficacy of both formulations following 
IP injection was tested in vivo in OVCAR3 xenograft tumor model. The 10 nm ABZ BSA particles 
significantly suppressed the tumors at a much lower dose than the free drug, whereas non-
significant tumor inhibition compared with free drug was observed for the 200 nm ABZ BSA. Yet, 
both formulations significantly reduced the ascites volume and number of malignant ascites cells in 
the abdomen of the treated nude mice. The authors attributed the significant decrease in tumor 
burden between both formulations to the penetration of NPs into the tumor tissue, which is highly 
likely more pronounced for the 10 nm ABZ BSA. Therefore, it seems that smaller NPs are beneficial 
for optimal tumor penetration, in spite of the short residence time expected in the peritoneal 
cavity.  
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5. Strategies for IP delivery and sustained release of nanomedicines in 
the peritoneal cavity  
Possible strategies to enhance the biodistribution and residence time of nanomedicines in the 
peritoneal cavity are depicted in Table 2 and Figure 4. As mentioned above, for most NPs rapid 
clearance from the peritoneum to the systemic circulation takes place. Therefore, to overcome the 
obstacles associated with intraperitoneally injected nanomedicines as such (i.e. dispersed in 
solution), release of NPs in a sustained manner in the peritoneum seems an optimal solution 
(Figure 4B, 4E). Conceptually, controlled release of small doses of NPs loaded with anti-cancer 
therapeutics, nucleic acids or a combination of both from depot systems could attenuate lymphatic 
drainage of the NPs, prolong the retention time in the abdomen, increase the exposure time of the 
tumors with the drug, and as a result augment its efficacy (see Table 2). Aiming to increase the 
residence time of platinum (Pt) in the peritoneal cavity for the local treatment of ovarian cancer, 
Cho et al. encapsulated Pt within Hyaluronic acid (HA) NPs forming PtNPs [86]. These NPs were 
then loaded on a biocompatible and biodegradable in-situ crosslinkable HA gel (PtNP/gel). Both 
systems (PtNPs and PtNP/gel) showed in vitro sustained release kinetics of Pt, and in vivo drug 
release for the PtNP/gel depot system of less than 2 weeks in the peritoneal cavity. Unexpectedly, 
when these systems were IP instilled in the abdomen of mice bearing SKOV-3 tumors, no 
enhancement in anti-tumor efficacy was measured compared with a solution of the free drug (i.e. 
cisplatin solution) [86]. Therefore, these findings do not support the expected synergy between 
the residence time of the drug and its therapeutic effect. The same research group evaluated the 
efficacy of PTX nanocrystals and microparticulate PTX precipitates loaded on a similar crosslinkable 
HA hydrogel for the treatment of mice bearing SKOV-3 ovarian cancer tumors [87]. Contrary to 
outcomes obtained with the PtNP/gel, the PTX nanocrystals exhibited significant tumor suppression 
upon single IP administration compared with the commercially available Taxol®. The 
microparticulate PTX precipitates, did not, however, result in a significant tumor inhibition 
compared with Taxol®. Since both studies were performed with the same depot system (i.e. HA 
hydrogel) and cancer model, the differences in efficacy between the studies most probably arise 
from the PK properties of the drug encapsulated within the hydrogel. In particular, PTX, with a 
molecular weight of approximately 854 Da and a bulky structure, is probably cleared slowly from 
the peritoneal cavity [88], resulting in increased exposure to peritoneal tumors. Indeed, when 
compared with a lower molecular weight platinum-based compound, PTX exhibited the highest 
peritoneal-to-plasma area under curve (AUC) ratio [89]. Importantly, a high peritoneal-to-plasma 
AUC ratio is not always translated in enhanced antitumor activity, since drug penetration also 
plays an important role [90]. Fan et al. [91] did find that sustained release of NPs from a hydrogel 
may hold a promise for future clinical applications. A thermosensitive hydrogel (i.e. liquid at room 
temperature, gel at the body temperature) composed of polylactic acid and Pluronic L64, co-
encapsulating NPs loaded with the anti-cancer agent docetaxel and the anti-microbial tumor 
suppressing peptide LL37 (Figure 4B), significantly inhibited tumor growth in a mice model derived 
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from colorectal cancer HCT116 cells following IP administration. This significant inhibition was 
accompanied by an increase in the survival of the treated mice when compared with a solution 
containing both drugs and the hydrogel containing only docetaxel NPs. Similarly, Xu et al. [92] 
developed a thermosensitive hydrogel assembled by PTX NPs of amphiphilic copolymer, termed as 
PTX/PECTgel [93]. Upon IP administration of PTX/PECTgel in mice bearing CT26 colorectal PC model, 
the hydrogel degraded over 8 days in the peritoneal cavity and significantly decreased the tumor 
weight compared with the free PTX solution – Taxol®. Furthermore, the authors showed higher 
abdominal PTX concentration for the PTX/PECTgel compared with Taxol® for an extended period of 
time.  
Another possible interesting strategy to improve the biodistribution of nanomedicines in the 
peritoneal cavity is, similarly to the PIPAC method described in section 3.2., the aerosolization of 
nanomedicines in the peritoneum (Figure 4C). In theory, nanomedicines can be nebulized in the 
peritoneal cavity. Whether or not the nanomedicines’ structure or function is affected by the high 
pressure nebulization, however, remains to be elucidated.  
In contrast to PIPAC, NPs have already been used in the setting of (H)IPEC (Figure 4D). In a 
recent study by Nowacki et al.[94], HIPEC was performed in mice using a nano-sized drug delivery 
system based on carbon nanotubes (CNTs) [95]. Briefly, CNTs loaded with cisplatin were 
functionalized with the anti-CD133 antibody to reduce the resistance to chemotherapy, emerging 
from the CD133 antigen. When the CNTs functionalized with anti-CD133 were applied IP via the 
HIPEC procedure in the abdomen of mice bearing peritoneal B16 melanoma tumors, the best 
general survival (12.6 days) observed was for the functionalized CNTs, and the shortest general 
survival (8 days) was for the mice in which the HIPEC procedure was not carried-out [94]. 
Likewise, De Smet et al. [96] investigated the suitability of PTX nanosuspension stabilized by 
Pluronic F127® for HIPEC treatment in rats bearing SKOV-3 ovarian cancer. Compared with the 
commercially available PTX formulation - Taxol®, no significant tumor volume reduction was 
documented 7 days and 14 days after HIPEC treatment. A significant reduction in tumor volume 
was, however, observed when the PTX nanosuspension was compared with the non-treated group. 
Also, the rats treated with the PTX nanosuspension recovered faster following the HIPEC 
procedure.  
Overcoming the resistance of cancer cells remains one of the main hurdles in cancer therapy [97]. 
In many cancer patients, even after complete remission, a relapse can occur due to multi-drug 
resistant (MDR) tumors. One approach to limit drug resistance is to minimize the periods between 
drug doses. In addition to the localized delivery strategies aiming to enhance the exposure of 
tumors to chemotherapeutics, metronomic dosing represents a novel approach defined as the 
frequent and continuous administration of conventional chemotherapy drugs at low doses without 
drug-free breaks (Figure 4E) [98]. Goldberg and coworkers developed slow-release drug delivery 
systems based on dual layer surface coating of PLGA PEGylated NPs loaded with PTX for IP 
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treatment of mice bearing BR5FVB1-Akt drug resistant ovarian cancer tumors. Compared with free 
PTX, metronomic dosing obtained by sustained release of PTX in the peritoneum significantly 
prolonged the survival of the treated animals [99]. A synergy in anti-tumor activity was 
documented when metronomic dosing was achieved with PLGA-PRINT NPs encapsulating docetaxel 
in combination with the antiangiogenic complex of chitosan NPs loaded with the enhancer of zeste 
homolog 2 (mEZH2) siRNA in HeyA8 and SKOV3ip1 ovarian tumor models. The chemotherapeutic 
agent (i.e. PLGA-PRINT docetaxel) was IP administered, whereas the siRNA-NP complex was 
intravenously injected [100].  
 
Figure 4. Schematic illustration of the different therapies involving nanomedicines from left to right. (A) 
NPs loaded with chemotherapeutics or other macromolecules. (B) Sustained release of NPs loaded with anti-cancer 
drugs from a depot system (e.g. hydrogel). (C) Nebulization of NPs using PIPAC. (D) HIPEC of NPs. (E) Continuous 
administration of NPs loaded with chemotherapeutics at low doses without drug-free breaks known as metronomic 
therapy.  
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In addition to drug resistance, the lack of tumor specificity is a major obstacle in IP chemotherapy. 
Ideally, the nanomedicines should specifically accumulate at the target site, and leave healthy 
tissues unaffected. In general, this targeting can be accomplished by incorporating antibodies or 
targeting ligands at the NPs’ surface to enhance the interaction between the NPs and the tumor 
site. The folate receptor alpha (FR-alpha) has already been identified as a suitable target for 
cancer therapy and imaging [101]. Also, VEGF and Human Epidermal Growth Factor Receptor 2 
(HER2) targeted antibodies show potential for specific tumor targeting [102]. In these studies, the 
targeting moieties were coupled to fluorophores, to improve debulking in cytoreductive surgery 
after tumor-specific intraoperative fluorescence imaging. When a HER2 targeting antibody was 
coupled to PTX containing NPs, however, no difference in overall tumor accumulation between 
targeted and non-targeted NPs was seen [103]. It should be noted that due to the heterogeneous 
origin of primary tumors that can lead to PC, suitable targeting agents will greatly differ from 
patient to patient [104]. Therefore, a personalized medicine approach seems recommended, in 
which individual suitable tumor-specific targets can be identified and validated.    
Table 2. Investigated IP administered formulations to overcome the rapid clearance of nanomedicines in solution following 
IP injection     
Formulation 
Hydrodynamic 
diameter & 
surface 
charge (if 
available) 
Cancer model Outcome Reference 
Bovine serum albumin 
NPs encapsulating 
ABZ 
~ 10 nm 
~ 200 nm 
 
Nude mice 
bearing 
OVCAR3 
tumors 
Significant reduction in 
the ascites fluid 
volume, as well as in 
the VEGF expression 
[85] 
Pt solution, PtNPs and 
PtNPs loaded on HA 
hydrogel 
PtNP – 270 nm, 
negatively 
charged 
Balb/c mice 
bearing SKOV-
3 ovarian 
cancer tumors 
Pt solution was superior 
over the PtNPs and 
PtNP/gel in terms of 
tumor inhibition 
[86] 
PTX nanocrystals and 
microparticulate PTX 
loaded on HA hydrogel 
compared with the 
commercially available 
PTX formulation – 
Taxol® 
PTX 
nanocrystals – 
rods shaped ~ 
260nm and a 
surface charge 
of -6 mV, 
microparticulate 
PTX – needle 
shaped ~ 11.5 
µm in length 
and 2 µm in 
width, 
negatively 
charged (-3mV) 
Balb/c mice 
bearing SKOV-
3 ovarian 
cancer tumors 
PTX nanocrystals 
loaded on the HA 
hydrogel, but not the 
microparticulate PTX, 
significantly prolonged 
the survival of mice 
compared with the 
commercially available 
PTX formulation - 
Taxol®  
[87] 
PLA-L35-PLA NPs 
loaded with docetaxel 
and LL37 formulated 
into PLA-L64-PLA 
PLA-L35-PLA 
NPs ~ 130 nm, 
neutral NPs 
HCT116 PC 
model 
Sustained release of 
docetaxel and the 
suppressing peptide 
LL37 efficiently 
[91] 
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thermosensitive 
hydrogel 
suppressed the growth 
of PC in mice 
Thermosensitive 
hydrogel assembled 
with PTX nanoparticles 
(PTX/PECTgel) 
PTX/PECT NPs 
~120 nm 
Mice bearing  
CT 26 
colorectal PC 
model and 
ascites fluid  
IP administration of 
PTX/PECT hydrogel 
efficiently inhibited 
tumor growth and 
metastasis compared 
with Taxol® 
 [92] 
Carbon nanotubes 
(CNTs) loaded with 
cisplatin and 
functionalized with the 
CD-133 antibody 
NA 
IP B16 
melanoma 
tumors 
Longer survival (12.6 
days) was obtained for 
CNTs delivery systems 
after HIPEC compared 
to the situation where 
HIPEC was not carried-
out 
[94] 
Nanocrystalline PTX 
stabilized by Pluronic 
F127® 
~ 400 nm 
Rats bearing 
SKOV-3 
ovarian cancer 
tumors 
HIPEC treatment using 
the PTX 
nanosuspension 
resulted in a significant 
tumor suppression 
compared to the non-
treated group. No 
significant reduction in 
tumor growth was 
observed when the PTX 
formulation was 
compared to the 
commercially available 
Taxol® 
[96] 
Dual-layer surface 
PLGA PEGylated NPs 
loaded with PTX for 
metronomic dosing 
~150 nm, 
negatively 
charged 
mice bearing 
BR5FVB1-Akt 
drug resistant 
ovarian cancer 
tumors 
Significant increase in 
the survival of mice 
compared to the free 
drug 
[99] 
PLGA-PRINT docetaxel 
NPs (IP administered 
metronomic dosing) 
and chitosan NPs 
complexed with 
mEZH2 siRNA 
(administered IV) 
PLGA-PRINT 
docetaxel 
80 x 320 nm 
230 nm 
Negatively 
charged 
HeyA8 and 
SKOV3ip1 
ovarian tumors 
Significant anti-tumor 
activity in both cancer 
models 
[100] 
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6. Nanomedicine-based IP therapy – ongoing clinical trials 
Here, we focus on two NP formulations that were evaluated for IP therapy in humans (Table 3). A 
recent phase I study evaluated the toxicity, tolerability, and pharmacokinetics (PK) of 
intraperitoneally administered nanoparticulate Cremophor-free PTX (NanoTaX®) in 21 patients with 
peritoneal solid tumors malignancies, following CRS [105]. The selected patients received six 
escalating doses of NanoTaX® (50-275 mg/m2) every 28 days. Compared with the IV administered 
PTX, no additional increase in the toxicity was documented. Moreover, the treatment resulted in a 
favorable peritoneal PK profile, exhibited by peak concentrations of PTX in the peritoneal fluid that 
are 450-2900 folds higher than the peak concentrations of PTX in plasma 2 days following 
injection. Response was determined in 16 patients. Among those, four patients remained stable, 
while in twelve patients the tumors continued to grow (i.e. disease progression). Remarkably, five 
patients with advanced cancers survived more than 400 days after the beginning of the treatment. 
In summary, this study provided a clinical evidence in humans showing that NanoTax® 
administered via IP catheter exhibits lower systemic toxicity and higher levels of drugs in the 
peritoneal cavity compared with the IV administered PTX. This low toxicity and high peritoneal PTX 
retention is explained by the fact that NanoTax® is actually a 600-700 nm rod shaped reservoir 
which allows continuous release of PTX in the peritoneum. The study was completed in 2013 and it 
is unclear yet whether a subsequent phase II trial is planned.  
The second NP-based formulation under clinical investigation for IP therapy in humans is 
Abraxane®. Abraxane® is a Cremophor®-free, albumin-based NP with PTX (~130 nm), used in 
clinical oncology for the treatment of metastatic breast and pancreatic cancer, as well as 
neoplasms. The Food and Drug Administration (FDA) and the European Medicines Association 
(EMA) approved Abraxane® for IV administration [106]. Abraxane® has however not been 
approved yet for use in IP therapy. A recent phase I trial [107] aimed to examine the maximally 
tolerated dose (MTD), adverse effects and PK of dose-escalating intraperitoneally administered (via 
IP catheter) Abraxane®. 27 patients with advanced peritoneal malignancies showed high peritoneal 
exposure of Abraxane® compared to the plasma exposure (i.e. pharmacologic advantage) with a 
low inter – and intra-patient variability. 
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Table 3. Ongoing clinical trials using nanomedicines for the IP treatment of peritoneal tumors    
Formulation Diameter 
Clinical trial 
(phase/No. of 
patients) 
Outcome Reference 
NanoTax® - 
nanoparticulate  
reservoir of PTX 
Rod-shaped  
600-700 nm 
Phase 1 
included 21 
patients with 
peritoneal solid 
tumor 
malignancies 
after CRS 
IP administration of 
NanoTax® results in 
high PTX levels, 
minimal systemic 
exposure and reduced 
toxicity compared with 
the IV administration 
[105] 
Abraxane® - albumin 
based NPs bound to 
PTX 
~ 130 nm 
Phase 1 
included 27 
patients with 
advanced 
peritoneal 
malignancy 
Significant peritoneal 
exposure of Abraxane® 
compared to the 
plasma, low inter- and 
intra-patient variability 
[107] 
  
7. Conclusions and future perspectives 
IP therapy for the treatment of PC is a rapidly growing niche that is being explored through an 
intensive effort of clinicians, pharmacologists and material scientists. To date, IP therapy of PC has 
not become a standard of care. An important aspect to take into account when developing IP 
therapies is to retain anti-cancer agents as much as possible in the peritoneal cavity, to achieve 
maximal tumor exposure to the drug. NPs are being utilized to deliver drugs to the peritoneum, 
however, when administered as such in dispersion, rapid clearance to the systemic circulation 
hampers their biological activity. Therefore, to unravel the potential of nanomedicines for IP 
therapies, future research should focus on improving the biodistribution of nanomedicines in the 
peritoneum, and correlate it with tumor accumulation, penetration, and killing efficacy. The 
balance between these is not easy to achieve in the peritoneal cavity. On the one hand, the use of 
small nanomedicines (below 100 nm) would be very efficient for tumor penetration and 
maximizing drug efficacy. On the other hand, those small nanomedicines will highly likely be 
associated with a short residence time in the abdomen. In light of these limitations, it seems that 
injecting nanomedicines dispersed in a solvent will not be the optimal strategy for the treatment of 
PC. Nevertheless, to give a clear-cut answer whether the mission is possible with nanomedicines, 
in-depth investigation of the sustained release platforms described in this article, such as release 
of NPs from biodegradable hydrogels in the peritoneum and metronomic dosing is a prerequisite. 
Also, the identification and validation of tumor-specific targets will further help to develop 
targeting agents that increase tumor specificity of the nanomedicines. In addition, IP aerosol 
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delivery (PIPAC) of nanomedicines or (H)IPEC of NPs as an adjunct to surgery may hold promise in 
selected patients.  
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1. Introduction  
Peritoneal carcinomatosis (PC) is a secondary cancer in the peritoneal cavity that originates from 
gynaecological or non-gynaecological organs. Due to the late stage of discovery, these peritoneal 
metastasis are often widely spread in the peritoneal cavity and difficult to treat. Current treatment 
is based on cytoreductive surgery followed by intravenous (IV) administration of conventional 
chemotherapeutic agents. However, complete surgical removal is often not possible. Also, 
remaining tumor cells can spread and lead to the formation of new metastasis. Therefore, the 
majority of the patients unfortunately develop disease recurrence and relapse. Intraperitoneal (IP) 
administration has shown several advantages over the IV one, due to the ability to inject higher 
concentrations of anti-cancer agents into the site of action (i.e. the peritoneal cavity), with limited 
systemic side effects [1]. Also here, however, the IP administration of cytostatics suffers from the 
fact that the action of the currently used cytostatics is not tumor-specific and not long-lasting. 
The rapid progress that has been made during the last 20 years in medical sciences led to the 
development of new strategies in the treatment of cancer [2,3]. Gene therapy, for example, 
enables to specifically express or silence genes, thereby minimizing side effects which are often 
observed with the conventional chemotherapy. Given this, IP gene therapy is an attractive 
strategy to target tumors within the peritoneal cavity, taking advantage of the direct 
administration to the tumor site, and also the selectivity that could be achieved in gene targeting. 
Therefore, IP nucleic acid delivery could prove to be useful to specifically target the metastases in 
the peritoneum. In this chapter we will provide a brief introduction on the delivery of nucleic acids 
into tumor cells confined within the peritoneal cavity, with a focus on the mechanism of action of 
lipidic and polymeric carriers that have been administered intraperitoneally. It should be noted 
that none of these delivery systems has received FDA approval yet.  
2. Delivery of nucleic acids for the treatment of PC 
2.1 Plasmid DNA 
Plasmid DNA is a powerful tool to induce the expression of proteins, and offers great opportunities 
for cancer treatment. Plasmids are circular, double stranded DNA molecules that can be 
engineered to carry any gene of interest and can range between 1 to 1000 kilo base pair (kbp) in 
size. The rational beyond using DNA as a therapeutic agent is to take advantage of the body’s cell 
machinery to produce the encoded proteins at the site of action, thereby overcoming the need to 
produce and repeatedly administer highly purified proteins [4]. Generally speaking, the encoded 
proteins that result from the expression of a therapeutic gene can act either on intracellular 
targets, or extracellular when the formed proteins are released outside the cells and act on 
neighboring or distant cells [5]. In most applications using non-viral gene delivery, the resulting 
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gene expression is transient (e.g. limited in function of time). Alternatively, stable long-lasting 
gene expression can be obtained when a mutated gene is replaced with the wild type one.   
To ensure biological activity of DNA-based therapeutics, the genetic material should enter the 
nucleus of the target cell, and later on be transcribed into messenger RNA (mRNA) and translated 
into active protein. There are however several barriers for the delivery of DNA into cells, which will 
be discussed later in this chapter.  
2.1.1 DNA for cancer therapy 
The use of DNA for cancer therapy can be accomplished by targeting tumor cells directly or 
indirectly. Direct targeting includes the expression of tumor suppressors and the delivery of suicide 
genes. Tumor suppressor genes control the cell division rate of normal cells, preventing them to 
divide excessively and form tumor tissue. Cancer cells carrying mutated tumor suppression genes 
can be treated by the DNA induced expression of correct tumor suppressor genes, resulting in cell 
cycle arrest or death. The most common tumor suppressors are P53, PTEN, ARF and APC [6-9]. 
Also the delivery of suicide genes is being used to specifically kill cancer cells. Once delivered into 
the nucleus of cancer cells, suicide genes encode for enzymes that allow to metabolize a prodrug 
into a cytotoxin which is capable of diffusing into neighboring cells. Suicide genes can also directly 
encode for toxins, such as for example the diphtheria toxin A (DT-A), which inhibits protein 
synthesis thereby causing cell death. Indirect strategies include immunotherapy and 
chemoprotection. Chemoprotection is a process by which bone marrow cells are infected with 
viruses that protect them from the toxic effects of chemotherapy [10]. Immunotherapy aims to 
activate a local and systemic immune response against cancer cells, and is thought to be the least 
toxic approach in cancer therapy [11,12]. As an example for immunotherapy, genes encoding for 
anti-inflammatory cytokines can be incorporated into plasmid DNA (pDNA) and delivered into 
tumor microenvironment to enhance the immune response against cancer cells [13]. Alternatively, 
dendritic cells can be challenged with tumor specific antigens, after which they activate the 
immune system to specifically target the tumor cells where the antigens were derived from. 
Finally, plasmid DNA can also be used as a precursor to form short hairpin RNA (shRNAs) that can 
be processed by the cell to small interfering RNA (siRNA). Unlike pDNA, siRNA is used to 
downregulate the expression of the target proteins, in a process called RNA interference (RNAi) as 
will be discussed below.  
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2.2 RNAi  
In 1998, Fire and Mello reported the discovery of double-stranded RNA (dsRNA) which is capable 
to knockdown gene activity [14]. Small interfering RNA (siRNA) is a 21-23 nucleotide double 
stranded RNA that binds to a complementary mRNA sequence in the cytoplasm of cells, causing 
degradation of the desired mRNA, and consequently a decrease in the expression of the 
corresponding protein [15]. In principle, siRNA can be designed to be complementary for any 
mRNA sequence. For cancer applications, genes involved in apoptotic and proliferative pathways 
are subject to silencing in order to treat tumors that are resistant to chemotherapy or 
nonresectable tumors [16]. Currently, several RNAi-based drugs are in clinical trials, including 
treatments against solid tumors and advanced cancer [17]. As mentioned above, another type of 
RNAi uses shRNAs which are synthesized in living cells after the delivery of plasmids or viral or 
bacterial vectors into cells encoding for these shRNAs [18]. shRNAs consist of two complementary 
19-22 (bp) RNA sequences linked by a short loop, which is similar in structure to the natural 
microRNA (miRNA), and are processed intracellular into functional siRNA.   
2.2.1 RNAi for cancer therapy  
The last two decades have witnessed a revolution in genomics and proteomics during which tens of 
molecular pathways involved in proliferation of cancer cells were identified. These include immune 
evasion, angiogenesis, and metastasis. Theoretically, knockdown of every gene should be possible, 
however, for successful and specific gene knockdown it is important to screen targets that are 
over-expressed by cancer cells. As we will discuss later in section 4, RNAi opens the opportunity 
for designing personalized medicine [19], since it can influence the expression or knockdown of a 
specific gene in a particular cancer patient. To date, the most common RNAi targets related to 
cancer are the multidrug resistance (MDR) proteins [20]. MDR is a situation in which cancer cells 
develop resistance against anticancer drugs by several mechanisms such as decreased drug 
uptake, increased drug efflux, and induction of DNA repair mechanisms. For instance, P-
glycoprotein (P-gp) is a transporter protein encoded by the MDR-1 gene that pump drugs into the 
extracellular space before reaching the target. It has been shown that P-gp is over-expressed in 
several cancer types following chemotherapeutic treatment, making it an attractive target for RNAi 
[21]. Another common example of MDR encoded protein is survivin, a member of the inhibitor of 
apoptosis (IAP) protein family, since it is up-regulated in solid tumors and has been involved with 
drug resistance [22,23]. Recently, co-delivery of conventional anti-cancer chemotherapeutics and 
siRNA has received tremendous attention to overcome cancer resistance [24].   
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2.3 Mechanisms of DNA and RNAi  
The aim of DNA therapy is to bring wild type genes into the nucleus of cells or to correct mutated 
genes. The second requires a process called homologous recombination by which new exogenously 
administered DNA sequences can be introduced into the genome of a living cell [25]. Homologous 
recombination is considered a rare event, therefore most of the DNA therapies are based on 
transient delivery of the DNA sequence into the nucleus. Once in the nucleus, the DNA can be 
transcribed into mRNA, which relocates to the cytoplasm where it is translated into the 
corresponding proteins (Figure 1C, step 8). The extent by which the delivered gene is expressed 
depends on the number of DNA copies being transcribed. It has been suggested that the minimum 
number of copies required to measure gene expression ranges from 75 to 4000 [26,27]. For RNAi 
medicines, however, the site of action is the cytoplasm of the cell. Briefly, in the cytoplasm of the 
cell, a protein complex known as RNA-induced silencing complex (RISC) mediates the cleavage of 
one RNA strand, while the other guide-strand is involved in degrading the targeted mRNA (Figure 
1B, step 5, 6 and 7). Double stranded siRNAs can be produced endogenously (by cells) or 
chemically synthesized and applied. Exogenously administered RNA can either interact with the 
RISC complex immediately as double strand or after cleavage by an enzyme known as RNAse III 
Dicer [28]. The mechanism by which shRNA is processed within the cells is very similar to that of 
siRNA. Shortly, after its transcription in the nucleus, it is exported to the cytosol where it interacts 
with Dicer, which in turn converts shRNA into siRNA and binds to the RICS complex as described 
above [29].    
Naked nucleic acids suffer from instability and are prone to enzymatic degradation in the biological 
environment. Moreover, naked nucleic acids are rapidly excreted by kidney filtration, and are not 
able to interact with biological membranes due to their anionic charge. Hence, naked nucleic acids 
suffer from low transfection efficiency [30,31] and are complexed with viral or non-viral carriers to 
optimize their cellular delivery, as discussed below.  
2.4 Viral and non-viral vectors for nucleic acids delivery  
Viruses are infectious agents that can internalize into the host cell and take advantage of its 
cellular machinery to replicate its own genetic material and to infect other cells [32]. Different 
viruses have been exploited to deliver therapeutic DNA and siRNA into cells [33,34]. Importantly, 
viruses are genetically modified before their use in vivo, by removing the pathogenic part and 
replacing it with the desired therapeutic nucleic acid [35], without changing its structural 
properties and ability to infect other cells [32]. The non-pathogenic virus is then called a viral 
vector and can be used for in vivo transfection. Despite their high transfection efficiency [33], 
several limitations have been reported when viral vectors were used. First of all, acute immune 
response and toxicity continue to be a major concern for viral vectors [35]. Also, viral vectors are 
generally produced in small quantities and scaling up the process would come with a large cost 
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[36,37]. Finally, due to size limitations of the viral vectors, not all genes can be carried by the 
virus [35].  
The drawbacks of viral vectors made scientists think of other safer and possibly cheaper 
alternatives. Over the past decade, non-viral vectors have been widely investigated for DNA and 
siRNA delivery into cells both in vitro and in vivo. In this respect, non-viral vectors possess several 
advantages over their viral counterparts. They are relatively safe, and do not induce a strong 
immune response. Also, they can be more easily prepared in large quantities [38,39]. 
Nevertheless, the application of non-viral nucleic acid delivery systems is still limited due to low 
cellular uptake and poor transfection efficiency [36].  
Most non-viral nucleic acid delivery systems are based on polymeric or lipid nano-sized carriers. 
Nanotechnology in general and nano-based drug delivery in particular, have played a vital role in 
cancer therapy [40-42]. The ultimate goal for non-viral nucleic acid delivery systems is to obtain 
site-specific delivery of therapeutic nucleic acids, and release these nucleic acids in a controlled 
fashion, in order to maximize the treatment efficacy while minimizing side effects [43,44]. It has 
been shown that complexation or encapsulation of nucleic acids with lipid-based or polymer-based 
nanoparticles significantly enhances their uptake into tumor cells. In the majority of the cases, 
negatively charged nucleic acids are added to positively charged lipid or polymer particles, taking 
advantage of the electrostatic interactions to form liposome/nucleic acid complexes (LPXs) or 
polymer/nucleic acid complexes (polyplexes). These complexes generally have a positive charge 
and a size range between 80 – 600 nm.   
2.5 Barriers for IP DNA and siRNA delivery  
Clinical applications of non-viral DNA and siRNA carriers are still hampered by inefficient in vivo 
delivery. To obtain the desired therapeutic effect of nucleic acids, several extra- and intracellular 
barriers should be overcome, which will largely depend on the administration route of the 
complexes.    
For efficacious IP nucleic acid delivery, non-viral vectors should meet several requirements on both 
the extracellular (Figure 1A) and intracellular (Figure 1B and C) level. Following IP administration, 
non-viral vectors are present in the peritoneal fluid. Hence, they should remain stable in this IP 
fluid until the target cells are reached (Figure 1A, step 1). Non-viral vectors can however interact 
with components of the peritoneal fluid, especially proteins. This potentially leads to: (1) 
aggregation of the vectors (Figure 1A, step 3) and (2) pre-mature release of the cargo (i.e. nucleic 
acid) (Figure 1A, step 2), which results in the loss of transfection efficiency [45]. In this regard, 
the stability of different nano-sized particles should be studied in the extracellular fluids they will 
reside in, namely the peritoneal fluid in the case of IP delivery [45]. Also the ascites fluid is being 
investigated to understand and develop different clinical strategies for the treatment of peritoneal 
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cancer [46]. Ideally, non-viral vectors should protect nucleic acids from interaction with different 
molecules in the biological fluids without inducing immune responses [47]. Extracellular stability is 
a prerequisite to ensure interaction of the non-viral vectors with biological membranes of cells, 
which is essential towards reaching the site of action and to ensure good intracellular uptake. To 
enhance extracellular stability, carriers are often grafted with polyethylene glycol (PEG) chains to 
minimize binding of proteins, thereby preventing aggregation and recognition by the mononuclear 
phagocyte system (MPS). However, PEGylation has several disadvantages, especially on the 
intracellular level. It is known that the PEG chains can limit the interaction of carriers with 
intracellular organelles, such as the endosomal membrane. This on its turn prevents or seriously 
lowers endosomal escape of the carriers and thus the amount of nucleic acids that can be 
successfully delivered [48]. Also, we have shown that PEGylation may interfere with the 
electrostatic interactions formed between the negatively charged nucleic acid and the positively 
charged carrier, resulting in a more rapid pre-mature release of the cargo in the biological fluid 
[45]. It is therefore clear that a good balance should be reached between extracellular stability of 
the carriers and the ability to still efficiently deliver the nucleic acids in the intracellular 
environment. Also, carriers intended for IP delivery, should remain in the peritoneum for a 
sufficient long time, without relocation to the blood stream (Figure 1A, step 4). Which 
physicochemical properties are best to prevent leakage from the nanocarriers through the 
peritoneal/plasma barrier remains to be elucidated.   
Once a carrier has reached its target cell, it should enter the cells, which mostly occurs through 
endocytosis (Figure 1B and C step 1). Following uptake by cells via endocytosis, delivery vectors 
are present in the early endosome (Figure 1B and C, step 2), which mature to late endosome and 
eventually deliver their content to lysosomes. To avoid degradation in the lysosomal compartment 
(Figure 1B and C, step 3), the delivery vector needs to destabilize the endosomal membrane, 
leading to the release of the cargo into the cytoplasm of the cell, in a process which is known as 
endosomal escape (Figure 1B and C, step 4) [49]. It is often argued that endosomal escape is the 
most critical step in nucleic acid delivery. In the case of siRNA delivery, the cytoplasm is the 
intracellular site where the RISC machinery can be engaged (Figure 1B, step 5) and eventually, 
recognize the target mRNA leading to its degradation (Figure 1B, step 6 and 7). DNA vectors, 
however, have to efficiently migrate through the cytoplasm of the cell towards the nucleus in 
addition to the endosomal escape (Figure 1C, step 5). Then, crossing the nuclear membrane is 
required for DNA to be transcribed (Figure 1C, step 7) and translated (Figure 1C, step 8) into the 
encoded proteins [50,51]. It is generally accepted that the nuclear membrane is one of the most 
difficult intracellular barriers to overcome for DNA delivery. Also, degradation of DNA in the 
cytoplasm of the cells should be avoided (Figure 1C, step 6).     
Despite the progress that has been made over the last decade in overcoming the above-mentioned 
extracellular and intracellular challenges in non-viral nucleic acid delivery, their translation into 
clinical oncology is still premature. In the following section, we will review the non-viral DNA and 
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siRNA delivery systems that were investigated in vivo for their ability to target tumors confined 
within the peritoneal cavity following IP administration up to date.  
 
Figure 1. Schematic overview over the different barriers in non-viral nucleic acid delivery. (A) 
extracellular barriers. (B) and (C) intracellular barriers. 
3. Current in vivo use of plasmid DNA for PC   
Table 1 summarizes the current in vivo studies that have been performed with pDNA for the 
treatment of PC up to date. As mentioned above, pDNA aims to induce the expression of deficient 
proteins, suicide genes or proteins that stimulate the host immune system, with the goal to target 
tumor cells. Some studies also made use of reporter proteins such as luciferase, to explore the 
suitability of DNA carriers to reach tumor cells. For example Zhang et al. performed a proof of 
concept study of a delivery system for its ability to express luciferase in peritoneal tumors in vivo, 
without investigating its effect on tumor growth [53]. They studied ‘stabilized plasmid-lipid 
particles’ (SPLP) composed of DOPE, the cationic lipid dioleoydimethylammonium chloride 
(DODAC) and C8 Ceramide-PEG (C8 Cer-PEG) in an IP human melanoma B16 tumor model. C8 
Cer-PEG was chosen to PEGylate the lipid nanoparticles, because of its ability to diffuse out of the 
nanoparticles with a certain kinetic, ensuring good PEGylation in the extracellular biofluids, while 
the de-PEGylation over time restores the intracellular trafficking of the complexes. This in contrast 
to the commonly used DSPE-PEG which results in stable PEGylation that ensures good extracellular 
stability, but interferes on the level of cellular uptake and endosomal escape [52]. The authors 
reported high expression of luciferase in B16 tumors 24 h following IP injection [53]. In a study by 
Louis et al., the widely used linear polymer polyethylenimine (L-PEI) was used to deliver DNA 
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expressing luciferase in mice bearing SKOV-3 human ovarian cancer cells. Multiple IP injections of 
PEI/DNA complexes resulted in high transgene expression, without any toxicity signs [54].  
Immunotherapy is receiving increasing attention in the treatment of cancer. In this respect, 
several cytokines have been suggested to induce immune response, particularly IL-12 [55]. Fewell 
et al. synthesized PEG-PEI-cholesterol lipopolymers complexed with IL-12 plasmid and tested its 
ability to induce an anticancer immune response in mice bearing ovarian adenocarcinomas tumors. 
The authors reported a significant increase in murine IL-12 and interferon (IFN-γ) in ascites fluid 
and an increased survival of the animals. Additionally, a significant decrease was noted in vascular 
endothelial growth factor (VEGF), which plays an important role in ascites formation. As expected, 
when combined with chemotherapy, an additional increase in the survival of the treated mice was 
observed [56]. These successful in vivo experiments paved the way to clinical trials in humans. A 
phase I clinical trial was carried out on women diagnosed with chemotherapy-resistant ovarian 
cancer. In this study, 13 patients received four increasing doses of the formulated plasmid, namely 
0.6, 3, 12, or 24 mg*m-2, once every four weeks, via IP infusion. No major side effects were 
reported, except for fever and abdominal pain. High levels of IL-12 plasmid and (IFN-γ) were 
measured in the peritoneal fluid but not in serum during the treatment, suggesting that this IL-12 
delivery system is suitable for local delivery and the treatment of recurrent ovarian cancer [57]. 
Recently, the results of a phase II clinical trial addressing the toxicity and antitumor activity of the 
formulation in 20 platinum resistant patients were published [58]. Briefly, patients received a 
weekly IP infusion of the IL-12 plasmid containing lipopolymer at a dose of 24 mg*m-2. Common 
adverse effects were reported including fatigue, fever, chills, abdominal pain, nausea, vomiting, 
anemia, thrombocytopenia and leukopenia. No patients with partial or complete response were 
reported. In summary, seven patients had stable disease, nine had progressive disease, and six 
had survival progression-free survival (PFS) for six months. Therefore, the authors deduced that 
the treatment had insufficient and limited biological activity in platinum resistant ovarian cancer 
patients [58]. To this end, a phase I clinical trial is ongoing to evaluate the efficacy and toxicity of 
combined therapy of the IL-12 formulation (gene therapy) with a liposomal doxorubicin 
formulation (conventional chemotherapy) in ovarian cancer patients.  
Colon cancer is among the most common diseases in the world, with about 50,000 deaths yearly 
in the United States [59]. The difficulty in treating colon cancer is due to rapid spread and 
metastases. Vesicular stomatitis virus matrix protein (VSVMP) has been shown to inhibit host gene 
expression by interacting with the nucleoporin Nup 98, an important component of the nuclear 
core complex which is responsible for the transport of different molecules across the nuclear 
envelope, thereby blocking nuclear export and inducing apoptosis [60]. Guo et al. synthesized and 
investigated heparin-polyethyleneimine (HPEI) nanogels complexed with plasmids encoding for 
VSVMP (pVSVMP) for their ability to induce apoptosis in C-26 colon carcinoma cells. HPEI/pVSVMP 
nanogels efficiently inhibited peritoneal metastasis of C-26 colon carcinoma in mice following IP 
injection, and prolonged their survival [61]. Worth mentioning the fact that intravenous 
  
48 | Chapter 2 
 
administration of HPEI/pVSVMP nanogels resulted in rapid degradation of the complexes and their 
excretion through urine. Therefore, the data demonstrate a clear advantage of the IP route for the 
treatment of colon carcinoma when compared with the systemic one. In another study, the same 
research group used the same HPEI nanogels to deliver Filamin A interacting protein 1-like 
(FILIP1L). FILIP1L plays a role in regulating angiogenesis, apoptosis and proliferation of tumor 
cells. Interestingly, it has been proposed that FILIP1L is absent in ovarian cancer cell lines [62]. 
When tested in SKOV-3 IP ovarian carcinomatosis model, HPEI incorporating plasmids expressing 
FILIP1L suppressed tumor growth, and decreased tumor weight about 72% compared to the 
control group [63].  
As mentioned in section 2.5. , the use of PEG posts a challenge for the drug delivery community, 
especially within the field of nucleic acid delivery. It is becoming more common to coat different 
nanoparticles with PEG chains that can be detached upon trigger, or diffuse spontaneously out of 
the complexes in function of time [64]. Addressing this point, Kumagai et al. compared the toxicity 
and gene expression efficiency of two block copolymers that are able to form nano-sized micelles. 
The first is poly (ethylene glycol)-block-poly (PEG-P [Asp (DET)]) and the second is PEG-SS-P [Asp 
(DET)] containing a disulfide bond (S-S) between the cationic polymer and the PEG chains. The 
idea behind the disulfide bond is to trigger detachment of the PEG chains upon exposure to the 
intracellular reducing environment of the cells, and consequently facilitate interactions with 
intracellular organelles. When both polymers loaded with plasmid DNA encoding for human tumor 
necrosis factor α (hTNF-α) were IP injected in mice bearing a peritoneally disseminated cancer 
model, higher antitumor activity was observed for the polymer containing S-S bonds, without any 
differences in toxicity [65]. Similarly, in a study carried out by the same research group, a mixture 
of block/homo-mixed polymers were used to prepare micelles. More specifically, poly{N′-[N-(2-
aminoethyl)-2-aminoethyl]aspartamide} P[Asp(DET)] and (PEG)-b-P[Asp(DET)] was compared to 
(PEG)-b-P[Asp(DET)] alone for their ability to express luciferase in mice with peritoneal 
dissemination following IP administration. The mixture showed 12 folds higher luciferase 
expression 24 h after the injection. Additionally, antitumor activity of the mixed polymer loaded 
with granulocyte macrophage colony stimulating factor (GM-CSF) in mice as well as in cynomolgus 
monkeys was observed following IP injection via the activation of natural killer cells [66].   
Within the frame of gene therapy, delivery of suicide DNA to epithelial ovarian cancer cells has also 
been investigated. To date, several attempts have been reported. Langer and co-workers have 
developed a DNA construct that contains the diphtheria toxin A (DT-A) and a recombinase, to 
regulate gene expression on both the transcriptional and recombination level. This construct was 
delivered into ovarian cancer cells and inhibited tumor growth in mice [67]. Huang et al. showed 
that IP administration of cationic biodegradable poly(β-amino ester) to deliver DNA encoding for  
DT-A in mice bearing metastatic ovarian cancer tumors, not only inhibited tumor growth and 
prolonged the survival of mice, but also was more efficient in terms of tumor suppression than the 
conventional anticancer agents paclitaxel and cisplatin [68]. Taking advantage of the DT-A toxin, 
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Hine et al. proved that the fusion of the recombinase Rad51 promoter, which is overexpressed in 
many tumors, to the DT-A gene results in a specific killing of tumors, and thus is an attractive 
strategy for cancer treatment [69]. Later on, Hine et al. brought evidence for the efficiency of the 
system in vivo. In this study a Rad-51-luciferase construct was IP delivered using a cationic linear 
PEI, known as jetPEI, in mice bearing HeLa cells xenografts. Due to the luciferase expression it 
was possible to specifically detect tumors, with an in vivo bioluminescent camera, while no 
bioluminescence was detected in healthy mice. Furthermore, the treatment decreased tumor mass 
by fourfold, which was accompanied with a reduction in malignant ascites and a 90% increase in 
the life span of the treated mice compared to the control mice [70]. Finally, the study recommends 
to use pRad51-Luc-DT-A/jetPEI to image and treat different types of cancer.    
As explained above, plasmids can also be used to express short hairpin RNA (shRNA) that is 
further processed by the cell into siRNA. Therefore, plasmid delivery can also be used to 
downregulate specific proteins. Claudin-3 (CLDN3) is a tight junction, integral membrane protein 
that is overexpressed in ovarian tumors, but not in healthy ovarian tissue. CLDN3 overexpression 
eventually leads to invasion and survival of ovarian tumors [71,72]. Hence, downregulation of 
CLDN3 offers an attractive strategy for cancer treatment. Sun et al. developed a plasmid 
expressing shRNA against CLDN3 and encapsulated the plasmids within biodegradable poly (lactic-
co-glycolic acid) (PLGA) nanoparticles. Following 12 IP administrations to nude mice bearing 
SKOV-3 ovarian cancer, a significant reduction in the tumor weight of 67.4% compared to the 
control was measured [73].   
 
 
 
 
 
 
 
 
 
 
 
  
50 | Chapter 2 
 
Table 1. Summary of in vivo studies evaluating IP delivery of nanoparticles for cancer DNA therapy 
Gene type Carrier Cancer model Results Ref. 
Luciferase DNA 
(Reporter gene) 
Stabilized 
plasmid-lipid 
particles coated 
with diffusible 
Ceramide-
poly(ethylene-
glycol) 
B16BL-6 human 
melanoma cells 
were seeded in 
the peritoneal 
cavity of C57BL/6 
mice 
High luciferase 
expression in 
tumor tissue 
compared to 
healthy tissue 
[53] 
Luciferase DNA 
(Reporter gene) 
(L-PEI) Linear 
polyethylenimine 
SKOV-3 IP 
ovarian 
carcinomatosis 
Dose dependent 
significant level 
of transgene 
expression, 
preferentially in 
tumors compared 
to other organs, 
without toxicity 
[54] 
pmIL-12 
(Immunotherapy) 
Polyethylenimine 
covalently 
attached to 
methoxy 
polyethylene 
glycol and 
cholesteryl 
chloroformate 
In vivo: 
ID8 IP Ovarian 
cancer which 
lead to PC 
Phase I: 13 
women with 
chemotherapy-
resistant 
recurrent ovarian 
cancer 
Phase II: 20 
patients with 
platinum 
resistant 
recurrent ovarian 
cancer 
In vivo: 
Suppression of 
ascites 
accumulation, 
dramatic 
decrease in VEGF 
levels, no signs 
of toxicity 
Phase I: high 
levels of (IFN-γ) 
in PF but not in 
serum 
Phase II: seven 
patients had a 
stable disease, 
nine patients had 
progressive 
disease and six 
had a 
progression free 
survival for 6 
months 
[56-58] 
 
pVSVMP 
 
Heparin 
conjugated to 
polyethylenimine 
 
C-26 colon 
carcinoma 
 
The treatment 
prevented 
growth of 
abdominal 
metastasis and 
increased the life 
span of the 
treated mice 
 
[61] 
FILIP1LΔC103 
Heparin 
conjugated to 
polyethylenimine 
SKOV-3 IP 
ovarian 
carcinomatosis 
Significant 
inhibition of 
ovarian cancer, 
reduction in 
angiogenesis, 
decrease in cell 
[63] 
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proliferation and 
increase in tumor 
apoptosis 
hTNF-α 
PEG-SS-
P[Asp(DET)] 
SUIT-2 IP human 
pancreatic 
carcinoma 
High antitumor 
activity without 
renal and hepatic 
toxicity 
[65] 
(GM-CSF) 
(Immune therapy) 
(PEG)-b-
P[Asp(DET)] 
/P[Asp(DET)] 
SUIT-2 IP human 
pancreatic 
carcinoma 
Efficient uptake 
in tumor 
nodules, and 
prolongation of 
the survival rate 
in treated mice 
[66] 
Diphtheria toxin 
(DT-A) 
(Suicide therapy) 
cationic 
biodegradable 
poly(β-amino 
ester) 
Epithelial ovarian 
cancer 
Reduction in 
tumor mass, and 
increase in 
survival rate. 
Tumor 
suppression was 
superior over 
cisplatin and 
paclitaxel 
treatment 
[68] 
pRad51-DT-A 
(Suicide therapy) 
Linear 
polyethylenimine 
(jetPEI) 
IP HeLa tumor 
cells 
Efficient 
inhibition of 
malignant 
ascites, fourfold 
decrease in 
tumor mass, 
90% increase in 
the mean 
survival time of 
treated mice 
[70] 
 
Plasmid expressing 
shRNA-against 
Claudin-3 (CLDN3) 
(Short hairpin RNA) 
 
poly(lactic-co-
glycolic acid) PLGA 
 
SKOV-3 IP 
ovarian 
carcinomatosis 
 
Efficient 
downregulation 
of CLDN3, tumor 
suppression, 
reduction in 
tumor weight, 
and increase in 
tumor apoptosis 
 
[73] 
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4. Current in vivo use of RNAi for PC  
As mentioned earlier, since its discovery, siRNA has attracted remarkable attention for cancer 
applications. In general, RNAi aims to downregulate cancer-related proteins which are often 
overexpressed in cancer cells and contribute to their invasiveness and increased proliferation. 
Table 2 summarizes the siRNA based therapies that have been explored in vivo so far. In an 
attempt to downregulate the expression of focal adhesion kinase (FAK) which plays an important 
role in survival, migration and invasion of cancer cells [74], FAK siRNA complexed with 1,2-
dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) liposomes was IP injected in mice bearing an 
ovarian cancer model. This treatment reduced the mean tumor weight by 44% to 72% in three cell 
lines [75]. Similarly, the same research group employed the same ovarian cancer model in mice, 
evaluating the ability of Interleukin-8 (IL-8) siRNA-DOPC complexes to suppress IL-8 activity. IL-8 
is a proangiogenic cytokine that is overexpressed in many human cancers. The authors reported a 
significant reduction in the tumor weight that varies between 32%-52% in the tested cell lines, 
proposing that IL-8 gene silencing decreases tumor growth via an antiangiogenic mechanism [76].  
As mentioned above, the downregulation of Claudin-3 (CLDN3) offers possibilities for anti-cancer 
treatments. Huang et al. investigated whether the siRNA induced knockdown of CLDN3 prevented 
the growth of metastasis in a mice model derived from ovarian surface epithelial ID8 cells. 
Interestingly, IP injection of LPXs containing siRNA against CLDN3 to mice significantly decreased 
not only tumor growth, but also the development of ascites, indicating that suppression of 
metastasis occurred [77]. Likewise, Fujita et al. proposed an atelocollagen delivery system loaded 
with siRNA against NEDD1, a centrosomal protein that associates with the gamma-tubulin ring 
complex protein and plays an important role in regulating the metaphase of the cell cycle [78]. 
NEDD1 downregulation prolonged the survival of mice bearing a gastric and peritoneal metastasis 
model from ascites producing tumors [79]. In addition to CLDN3, IL-8 and FAK, inhibition of 
oncogenes is also an attractive strategy to suppress tumors. Briefly, oncogenes are genes that 
tend to cause cancer, and are mutated or overexpressed in tumor cells [80]. In a study by Ren et 
al., an inhibitor of DNA binding 4 (ID4) was characterized, and shown to be overexpressed on the 
surface of human ovarian cancer cells. In the same study, the authors demonstrate in vitro and in 
vivo silencing when nanocomplexes of cell-penetrating peptides containing siRNA against ID4 were 
injected IP to mice with disseminated intra-abdominal tumors, every 3 days for 30 days. The 
treatment remarkably increased the survival rate of 80% of the animals, with the ability to live 60 
days or even more, without inducing a strong immune response [81]. Recently, survivin, a 
member of the inhibitor of apoptosis (IAP) protein family, is receiving increased attention in cancer 
therapy, since it is up-regulated in solid tumors [80]. In an attempt to knockdown survivin 
expression in mice bearing a metastatic human pancreatic tumor model, Wang et al. investigated 
the ability of liposomes composed of 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-distearoyl-sn-glycero-3-
  
53 | Chapter 2 
 
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DSPE-PEG) complexed with siRNA 
against survivin. The study revealed that these complexes successfully decreased the expression 
of survivin, but only when they were co-administered with the conventional chemotherapeutic 
paclitaxel (PTX) [82]. The data presented in the study thus encourages the co-delivery of siRNA 
and other chemotherapeutic agents to tumors.  
 Other RNAi strategies are especially useful for personalized medicine purposes. BRCA1 is a tumor 
suppressor which is mutated in about 5% of the ovarian cancer population, leading to defects in 
the DNA repair process, such as mutations in chromosomal rearrangements [83,84]. On the 
contrary, Poly(ADP-ribose) polymerase-1 (PARP1) is involved in preventing DNA damage and 
genomic stability [85]. It has been postulated that orally administered PARP-1 inhibitors in 
patients with BRCA mutations resulted in antitumor activity [86]. When PARP-1 siRNA was IP 
delivered using lipid-like nanostructures called ‘lipidoids’ in mice bearing disseminated BRCA1-
deficient murine ovarian carcinoma allografts, a significant cell growth inhibition and extended 
survival of the treated mice was noticeable [87].   
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Table 2. Summary of in vivo studies evaluating IP delivery of nanoparticles for cancer RNAi therapy 
siRNA against Carrier Cancer model Results Ref. 
Focal adhesion 
kinase (FAK) 
DOPC liposomes 
Human ovarian 
cancer using 3 
cell lines SKOV-
3ip1, HeyA8 
(taxane 
sensitive), and 
HeyA8MDR 
(taxane 
resistant) in nude 
mice 
Reduction in 
tumor weight by 
44% to 72% 
depending on the 
cell line, 
Synergistic effect 
when siRNA was 
combined with 
docetaxel 
[75] 
IL-8 DOPC liposomes 
Human ovarian 
cancer cell lines 
SKOV-3ip1, 
HeyA8 (taxane 
sensitive), and 
SKOV-3ip2.TR 
(taxane 
resistant) in nude 
mice 
Reduction in 
tumor weight 
32% to 52% 
depending on the 
cell line, 
Synergistic effect 
when siRNA was 
combined with 
docetaxel 
[76] 
CLDN3 lipidoid 
ID8 IP Ovarian 
cancer 
Suppression of 
tumor growth, 
reduction in 
ascites, without 
any toxicity 
following multiple 
administrations 
[77] 
NEDD1 Atelocollagen 
HSC-60 IP gastric 
cancer in scid 
mice 
Significant 
increase in the 
life span of the 
treated mice 
[79] 
ID4 
Cell penetrating 
peptides (CPPs) 
OVCAR-8 IP 
tumors 
Remarkable 
prolongation in 
survival , 80% of 
the animals 
survived at least 
60 days without 
inducing immune 
response 
following one 
injection every 3 
days for 30 days 
[81] 
Survivin 
Liposomes 
composed of 
DOTAP DOPE PEG 
and cholesterol 
H766T IP 
pancreatic human 
metastatic 
xenograft 
Efficient 
knockdown of 
survivin was 
possible only 
when combined 
with paclitaxel 
[82] 
PARP-1 lipidoid 
Genetically 
defined murine 
ovarian cancer 
High specificity of 
the treatment, 
prolongation of 
the survival of 
mice 
[87] 
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5. Concluding remarks and future prospective 
In this chapter, we restricted our discussion on IP injection of non-viral vectors to deliver nucleic 
acids into tumors residing in the peritoneal space. IP delivery of nucleic acids is indeed an 
attractive approach to target PC. Although several non-viral gene delivery systems carrying 
plasmid DNA or siRNA have proven anti-tumor effect to some extent, none of the tested 
formulations have been approved for use in clinical oncology so far. Translation into the clinic still 
awaits a new class of formulations that can overcome both the intracellular and extracellular 
barriers as discussed above. The main problem in optimizing non-viral gene delivery systems 
remains the lack of knowledge on the relation between the physicochemical properties of delivery 
systems (e.g. charge and size) and their obtained therapeutic effect. Also, carrier properties which 
assure stability on the extracellular level (for example surface PEGylation) still often interfere with 
the intracellular performance of the same carrier. It should be noted that the efficiency of a 
delivery system can greatly depend on the extracellular barriers which are encountered, and thus 
on the administration route. It is crucial to evaluate and optimize gene delivery vehicles with the 
intended administration route in mind. For IP delivery, this implies that carrier properties should 
be studied in the peritoneal fluid. In an attempt to perform reliable measurements in more 
complex biological fluids, we have proven that advanced microscopy techniques such as 
fluorescence correlation spectroscopy (FCS) and single particle tracking (SPT) enable to monitor 
the disassembly and aggregation of non-viral vectors in undiluted biological fluids [45]. By 
employing these powerful techniques, we can simulate the in vivo situation, and screen for 
formulations that show minimal aggregation properties while keeping the maximal amount of their 
siRNA or pDNA load in the IP fluid. For local IP delivery, it should be noted that having colloidal 
stable particles in the peritoneal cavity is not the only requirement for optimal tumor targeting. It 
has been reported that nano-sized vectors are rapidly cleared from the peritoneal cavity following 
IP administration compared to microparticles [88] (Figure 1A, step 4). This rapid absorption from 
the peritoneal cavity to the systemic circulation, most likely seriously limits the amount of 
complexes that actually reach and enter the tumor target cells. The rapid clearance of 
nanoparticles from the peritoneal cavity has however also been exploited in some studies, where 
the IP route is being used for systemic gene delivery, to target systemic tumors. In a study by 
Aigner and co-workers, siRNA against c-erbB2/neu (HER-2) receptor complexed with PEI was 
injected IP into mice bearing subcutaneous SKOV-3 tumors and exhibited a remarkable reduction 
in tumor growth, whereas no reduction in tumor growth was observed following injection of naked 
siRNA [89]. In this case, the IP delivery is thus used as a depot system, from which systemic 
delivery of nanoparticles is aimed.     
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In the vast majority of the studies we reviewed, it is important to stress out the fact that long-
term biological activity by silencing or overexpressing genes was obtained only after multiple 
administrations of the formulations to the peritoneal cavity. Therefore, future strategies will most 
likely also depend on delivery systems that can increase the residence time of non-viral nucleic 
acid delivery systems in the peritoneal cavity, with limited distribution to the systemic circulation. 
In this respect, sustained release of non-viral vectors from an injectable depot system might be an 
advantage, due to the ability to maintain stable gene silencing or expression for a prolonged 
period of time. It is expected that the constantly increasing knowledge on possible gene targets in 
tumor cells will continue to fine-tune the use of plasmid DNA and siRNA delivery for the treatment 
of PC. Also, nucleic acid delivery will play a major role in personalized cancer treatments as 
screening methods allow more and more cancer associated genes to be identified on a person-to-
person basis. Finally, the combination of nucleic acids with conventional chemotherapeutics can 
also contribute to the translation of IP gene therapy to the clinic. 
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COLLOIDAL STABILITY OF NANO-SIZED 
PARTICLES IN THE PERITONEAL FLUID: TOWARDS 
OPTIMIZING DRUG DELIVERY SYSTEMS FOR 
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Abstract 
Intraperitoneal (IP) administration of nano-sized delivery vehicles containing small interfering RNA 
(siRNA) is recently gaining attention as an alternative route for the efficient treatment of peritoneal 
carcinomatosis (PC). The colloidal stability of nanomatter following IP administration has, however, 
not been thoroughly investigated yet. Here, enabled by advanced microscopy methods such as 
Single Particle Tracking (SPT) and Fluorescence Correlation Spectroscopy (FCS), we follow the 
aggregation and cargo release of nano-scaled systems directly in peritoneal fluids from healthy 
mice and ascites fluid from a patient diagnosed with PC. The colloidal stability in the peritoneal 
fluids was systematically studied in function of the charge (positive or negative) and Poly-Ethylene 
Glycol (PEG) degree of liposomes and polystyrene nanoparticles (NPs), and compared to human 
serum. Our data demonstrate strong aggregation of cationic and anionic NPs in the peritoneal 
fluids, while only slight aggregation was observed for the PEGylated ones. PEGylated liposomes, 
however, lead to a fast and premature release of siRNA cargo in the peritoneal fluids. Based on our 
observations, we reflect on how to tailor improved delivery systems for IP therapy.   
Keywords: Drug delivery, Aggregation, Peritoneal Carcinomatosis, Intraperitoneal administration, 
Release, siRNA 
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1. Introduction 
 Peritoneal metastases are one of the major causes of death in patients diagnosed with ovarian 
cancer [2]. Also in colorectal cancer, cancer cells often migrate to the abdomen where they spread 
and form PC [1]. The often late stage of discovery of peritoneal metastases, which can spread over 
the entire surface of the peritoneum (~2 m²), make the treatment very difficult. This fact is well-
demonstrated from clinical trials indicating the low median survival of patients diagnosed with PC 
[3].  
 Current treatment of PC involves removing the majority of peritoneal metastases 
(cytoreductive surgery) followed by intravenous (IV) administration of chemotherapeutic agents 
such as oxaliplatin in combination with 5-fluorouracil or leucovorin [4,5] to kill remaining tumor 
cells. Also platinum-based (i.e. oxaliplatin, cisplatin) chemotherapeutics in combination with 
paclitaxel [6,7] are used. Unfortunately, the majority of the patients develop disease recurrence 
[8,9]. Therefore, more efficient post-surgical strategies to kill remaining tumor cells are needed 
[10]. In this context, intraperitoneal (IP) administration of chemotherapeutics has shown to be 
superior over the IV route [11,12], particularly due to the ability to maintain high concentrations 
of cytotoxic agents in the peritoneal cavity [13]. Also, promising data have resulted from clinical 
trials evaluating hyperthermic intraperitoneal chemoperfusion (HIPEC) immediately after 
cytoreductive surgery [14,15]. HIPEC involves flushing the peritoneal cavity with 
chemotherapeutic agents at an elevated temperature of 41-42°C. It is hypothesized that HIPEC is 
more efficacious compared to conventional IP therapy since it not only takes advantage of the 
hyperthermic effect, but also enables distribution of the drug in all parts of the peritoneal cavity 
[16]. Nevertheless, the efficacy of HIPEC is still controversial as several studies claim that no 
synergistic effect exists between the anti-cancer agent and the hyperthermia [15,17].  
One strategy to improve the anticancer effect upon cytoreductive surgery is to use specialized 
drug delivery systems (DDSs) with the ability to reside in the peritoneal cavity for a prolonged 
period of time. Interestingly, recent in vivo data suggest that the IP administration of DDSs that 
release chemotherapeutics results in an enhanced body distribution in general, and on the 
intratumoral level in particular [18]. Also the delivery of small interfering RNA (siRNA) for the 
treatment of ovarian cancer and PC has recently attracted considerable attention [19]. siRNAs are 
small (20-21 nucleotides) double stranded RNA molecules that can downregulate specific protein 
production. siRNA has the benefit that it can target genes which are specific for tumor cells, 
leaving healthy, non-tumor tissue unaffected. Interestingly, carriers for combinatorial therapy of 
(specific) siRNA and conventional (non-specific) anti-cancer drugs (e.g. paclitaxel (PTX) or 
doxorubicin (DOX)) have been reported to result in some benefits compared to each one alone 
[20].  
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 In the past few years, different DDSs were evaluated for IP administration [21,22], Among 
them are targeted nanocarriers [23], NPs for IP gene delivery [24], micelles [25], microparticle 
(MP) [26,27] and hydrogels for sustained release in the peritoneal cavity [28-30]. For nanosized 
drug carriers, the state of aggregation and the release profile following IP administration may play 
a crucial role in their delivery performance. Indeed, the colloidal stability of nanocarriers influences 
e.g. the internalization of the cargo into cancer cells, and thus may alter the expected anti-tumor 
efficacy. Following administration, nano-carriers tend to bind/interact with various components 
that are present in biofluids [31], including proteins and enzymes forming the so called ‘protein 
corona’ [32,33]. For instance, recent reports suggest that the targeting capability of ligands 
conjugated to nanomaterials is lost by adsorption of a protein corona to their surface [34,35]. 
Increasing our knowledge on the relation between the physicochemical properties of delivery 
systems and their obtained therapeutic effect is crucial. Since the route of administration plays a 
major role in whether or not certain carriers will work, each carrier should be optimized for the in 
vivo situation where it is intended to be used, e.g. the peritoneal fluid in the case of IP delivery. 
Although several studies have addressed the colloidal stability of NPs in biofluids like blood, plasma 
and serum [36,37], the physicochemical behavior of delivery vehicles in terms of aggregation and 
release of cargo in peritoneal fluids has not been investigated yet.    
 The main objective of this study is to provide insight in the requirements for IP delivery 
systems in terms of charge and PEGylation degree, to be colloidally stable and to have an optimal 
release profile in the peritoneal fluid. Herein, for the first time, we study the aggregation of 
polystyrene (PS) NPs and liposomal formulations in peritoneal fluid from healthy mice 
(transsudate) and ascites fluid (exudate) from a patient diagnosed with PC. Additionally, we study 
the release profile of liposomal formulations carrying siRNA in the peritoneal fluids. For this 
purpose, we utilize state of the art fluorescence techniques that were previously developed in our 
laboratory, namely Single Particle Tracking (SPT) and Fluorescence Correlation Spectroscopy (FCS) 
to respectively gain information on the aggregation of NPs and the release of siRNA in undiluted 
biofluids [36,38]. The results are compared to measurements of the same NPs dispersed in human 
serum. 
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2. Materials and Methods 
2.1 Materials 
(2,3-Dioleoyloxy-propyl)-Trimethylammonium-chloride (DOTAP) and 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were purchased from Corden Pharma LLC (Liestal, Switzerland).  
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-
PEG) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). Chloroform, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), N-hydroxysulfosuccinimide (Sulfo-NHS), 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), Dimethylethylenediamine 
(DMEDA) and sodium chloride (NaCl) were purchased from Sigma Aldrich (Bornem, Belgium). 
Yellow-green fluorescent (λex= 505 nm, λem= 515 nm) carboxylated PS FluoSpheres (0.1 µm in 
size) and 1, 1’-dioctadecyl-3, 3, 3’, 3’-tetramethylindodicarbocyanine perchlorate (DID) (λex= 644 
nm, λem= 665 nm) were purchased from Invitrogen (Merelbeke, Belgium). Methoxy-polyethylene 
glycol-amine (mPEGa) 2 kDa was purchased from Creative PEGWorks (Winston Salem, USA). 
Alexa Fluor-488 Negative Control siRNA ((Eurogentec, Seraing, Belgium). 
2.2 Animals  
Mice, heterozygous for Foxn1 (nu/+) were purchased from Charles River (Sulzfeld, Germany) and 
maintained by the animal core facility. Animals were kept at 22°C in a humidified atmosphere with 
food and water ad libitum. 
2.3 Collection of biofluids 
To collect samples containing mouse peritoneal fluid, a lavage of the peritoneal cavity was 
performed. To this end, mice were euthanized by an overdose of the inhalation anesthetic 
isoflurane followed by cervical dislocation. The abdominal wall was opened immediately and the 
peritoneal cavity was washed with 1 mL of water. The lavage was taken and stored frozen until 
use. The procedure was approved and carried out in compliance with the guidelines for animal 
experiments of Leipzig University.  
Human serum was obtained from a healthy donor. Briefly, blood was collected at the Ghent 
University Hospital into Venosafe™ 6 mL tubes containing gel and clotting activator (Terumo 
Europe™, Leuven, Belgium). Then the tubes were centrifuged for 10 minutes at 4,000 × g and 
20°C. The supernatant (serum) was transferred into microvette® 500 Z-Gel (SARSTEDT, 
Numbrecht, Germany) and centrifuged for 5 min at 1,0000 × g and 20°C. The serum was 
portioned into 50 µl aliquots (to avoid freezing-thawing cycles) in sterile polypropylene tubes and 
stored in -20°C until use. Human ascites fluid was obtained from a patient diagnosed with PC at 
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the medical oncology department, Ghent University hospital. The experiments with the ascites fluid 
were approved by the ethics committee of the Ghent University hospital (# 2013/589). 
2.4 Protein analysis and capillary electrophoresis 
Total protein in human serum, human ascites fluid, and mice peritoneal fluid was assayed using a 
pyrogallol red-molybdate method on a Cobas 8000 analyzer (Roche, Mannheim, Germany) [39]. 
Human serum and human ascites fluid protein electrophoresis was performed using a Capillarys 
2™ CE system (Sebia, Paris, France) that is routinely employed in clinical 
laboratories [40,41]. Prior to the hydrodynamic injection (4”), 40 µl of serum is automatically 
diluted 5x in the running buffer (pH 10). Then, 7 kV is applied in the 8 silica-fused capillaries 
(effective length 15.5 cm; internal diameter 25 µm; optical cell 100 µm) for 4’ at 35.5°C (Peltier 
device). Proteins are detected at the cathode (deuterium lamp; 200 nm) as 5 fractions (γ-
globulins, β-globulins, α2-globulins, α1-globulins and albumin) that are automatically quantified as 
percentages of the total signal. 
For mice peritoneal fluid (characterized by low protein concentrations), agarose gel electrophoresis 
was carried out, followed by a sensitive staining using the Protur HiSi 100 system (Analis, Suarlée, 
Belgium).  
2.5 Viscosity measurements  
Viscosity measurements of human ascites fluid and human serum were performed using a micro-
Ubbelohde viscometer (53610/I) (Schott-Geräte (Mainz, Germany) at 22°C. 4 mL of each bio fluid 
were loaded on a capillary (ID number 100-002 with capillary constant K= 0.009671 mm2/s2) and 
the flow time (in seconds) was measured 3 times for each biofluid. The averaged flow time was 
used to calculate the kinematic viscosity according to the following equation:  
ν = K× (t-y) 
Where t is the averaged flow time, and y (in seconds) is the kinetic energy correction for the flow 
time provided by the manufacturer. For human serum, the calculated kinematic viscosity is 1.6 
mm2/s and for the human ascites fluid is 1.39 mm2/s. The dynamic viscosity η is defined using the 
following relation: 
η = ρ × ν 
Where ρ is the density of fluid (g/mL) and 1 cSt = 1 mm2/s. Since the density of human serum 
and human ascites fluid is very close to 1 g/mL [42], we assume all the densities of fluids used in 
this study are equal to 1, and thus in all Single Particle Tracking measurements the following 
values of dynamic viscosity were used: 1.39 cP for human ascites fluid, 1.6 cP for human serum, 
and 0.94 cP for mice IP fluid and HEPES buffer.  
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2.6 Functionalization of anionic polystyrene NPs  
Functionalization of 100 nm anionic NPs to PEGylated and positively charged ones was performed 
according to previously published procedures [43]. The charge and size of the NPs was measured 
using the Zetasizer Nano-ZS (Malvern, Worcestershire, UK). The average size of all the NPs in 
HEPES buffer (pH 7.4) was around 110 nm, and zeta-potential around 30 mV for the positively 
charged NPs, -13 mV for the PEGylated NPs, and around -33 mV for the anionic NPs.  
2.7 Preparation of liposomes 
DOTAP and DOPE lipids were dissolved in chloroform and mixed in a round bottomed flask. A lipid 
film was formed by rotary evaporation of the chloroform at 40°C. The dried lipid film was 
rehydrated with 20 mM HEPES buffer pH 7.4, resulting in a final concentration of 5 mM DOTAP and 
5 mM DOPE. Thereafter, liposomes were sonicated using a probe sonicator (Branson Ultrasonics 
Digital Sonifier®, Danbury, USA). For the preparation of PEGylated liposomes, the desired amounts 
of DSPE-PEG dissolved in chloroform (corresponding to 5 mol% or 10 mol% of the total lipids) 
were added to the lipids in the round bottomed flask before evaporation. For SPT experiments, 
liposomes were fluorescently labeled by incorporation of 1 mol% (of the total lipids) with DID. The 
average size and zeta potential of the liposomes was measured using Zetasizer Nano-ZS (Malvern, 
Worcestershire, UK). The average diameter of the liposomes was around 90 nm for the cationic 
liposomes and 100 nm for the PEGylated ones. The zeta potential around + 45 mV for the cationic 
liposomes, 15 mV for the 5 mol% PEGylated liposomes and 7 mV for the 10 mol% liposomes.  
2.8 Size and zeta-potential measurements  
The average size and the zeta potential of the liposomes and the PS NPs were measured using the 
Nano-ZS Zetasizer (Malvern, Worcestershire, UK) in 4 different biofluids: HEPES buffer, mice IP 
fluid, human ascites fluid, and human serum. Equal volumes of respectively cationic, 5% 
PEGylated and 10% PEGylated liposomes and biofluids were mixed and incubated for 1 h at 37°C. 
At the end of the incubation period, these mixtures were diluted with 20 mM HEPES buffer to a 
final concentration of 125 µM DOTAP (~2.5 vol% of biofluids). The size and ζ-potential 
measurements were performed at 25°C. The size and the zeta potential of the PS NPs were 
determined following the same procedure.  
2.9 Fluorescence single particle tracking (fSPT) 
Single particle tracking (SPT) is a fluorescence microscopy technique that uses wide-field laser 
illumination and a fast and sensitive CCD camera to record high speed movies of individual 
diffusing particles in biofluids. Thereafter, the movies are analyzed by a specific image processing 
algorithm to obtain the motion trajectories for all individual particles. The trajectories are then 
used to calculate the diffusion coefficient of each particle. After analyzing many particles, a 
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distribution of diffusion coefficients is obtained which is transformed into size distribution using the 
Stokes-Einstein equation and refined by the maximal entropy method (MEM), as previously 
described [36]. The conversion of diffusion coefficients to sizes requires knowledge of the viscosity 
of the biofluid and the temperature at which the experiment is performed.  
SPT measurements on different PS NPs (Anionic, PEGylated, Cationic) and DID labeled liposomes 
dispersed in biofluids were performed as follows. First, formulations were diluted 400 times in 
HEPES buffer. Then 5 µl was added to 45 µl of biofluid (e.g. 90 vol% of mice IP fluid, human 
ascites fluid and human serum), and incubated for 1 h at 37°C in a 96-well plate (Greiner bio-one, 
Frickenhausen, Germany). At the end of the incubation time, the sample was placed on the 
custom-built SPT set-up [36] and movies were recorded focused at about 5 μm above the bottom 
of the glassbottom 96-well plate. Videos were recorded at room temperature (22.5°C) with the 
NIS Elements software (Nikon) driving the EMCCD camera (Cascade II:512, Roper Scientific, AZ, 
USA) and a TE2000 inverted microscope equipped with a 100× NA1.4 oil immersion lens (Nikon). 
Analysis of the videos was performed using in-house developed software. During the incubation 
and measurements, the well plate was covered with Adhesive Plates Seals (Thermo Scientific, UK) 
to avoid evaporation of the sample and allow diffusion only.         
2.10 FCS on siRNA containing liposomes (lipoplexes)  
FCS is a microscopy-based technique that monitors the fluorescence intensity fluctuations of 
molecules diffusing in and out of the focal volume of a confocal microscope. Shortly, when free 
siRNA molecules are present in the focal volume, a fluorescence signal (baseline) is obtained which 
is proportional to the local siRNA concentration. When the siRNA is complexed with NPs, the 
concentration of free siRNA (e.g. the baseline) drops and peaks of high fluorescence intensity 
appear each time a nanocomplex containing many fluorescent siRNA molecules passes the 
detection volume. Vice versa, when siRNA dissociates from the complexes, the concentration of 
free siRNA increases again, resulting in an increase of the baseline. The drop/increase in the 
intensity of the baseline can be used to calculate the percentage of the complexed/released siRNA 
as was previously described by Buyens et al. [38]. Single color FCS measurements were 
performed on LPXs containing Alexa-488 siRNA Negative Control siRNA (Eurogentec, Seraing, 
Belgium). To follow the release of the complexed siRNA in function of time, LPXs with charge ratio 
of ±8 were prepared by adding appropriate amounts DOTAP DOPE liposomes to siRNA. The 
mixture was then incubated at room temperature for 30 minutes to allow formation of the LPXs. 
The size of the LPXs was measured using dynamic light scattering and was about 100 nm for 
cationic ones and 110 nm for the PEGylated. For FCS measurements, 5 µl of the LPXs were diluted 
in 45 µl of each biofluid (resulting in 90 vol% of mice IP fluid, human ascites fluid and human 
serum in the final samples) and the fluorescent signal was measured respectively immediately 
after mixing the LPXs with the biofluids and after one hour of incubation at 37°C. During the 
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incubation and the FCS measurements, the well plate was covered with Adhesive Plates Seals 
(Thermo Scientific, UK) to avoid evaporation of the sample and to minimize flow.  
FCS measurements were performed on C1si laser scanning confocal microscope (Nikon, Japan), 
equipped with a Time-Correlated Single Photon Counting (TCSPC) Data Acquisition module 
(Picoquant, Berlin, Germany). The laser beam was held stationary and was focused through a 
water immersion objective lens (Plan Apo 60×, NA 1.2, collar rim correction, Nikon, Japan), at 
about 50 μm above the bottom of the glassbottom 96-well plate (Grainer Bio-one, Frickenhausen, 
Germany), which contained the fluorescent samples (free Alexa488-siRNA and Alexa488-siRNA 
complexed to non-PEGylated, 5% PEGylated or 10% PEGylated liposomes (5 nM Alexa488-siRNA 
in all samples). The 488 nm laser beam of a krypton–argon laser (Bio-Rad, Cheshire, UK) was 
used and the green fluorescence intensity fluctuations were recorded using Symphotime 
(Picoquant, Berlin, Germany) during at least 60 seconds.   
3. Results  
3.1 Protein content of the biofluids   
The data in Table 1 depicts the total protein content in each biofluid. The highest protein content 
was determined in the human serum samples obtained from a healthy donor. Ascites fluid from the 
peritoneal cavity of a patient diagnosed with PC contained almost half the amount of proteins when 
compared to human serum. Peritoneal fluid extracted from mice was found to contain a rather low 
protein concentration. This most likely can be attributed to the collection procedure in which the 
peritoneal fluid of mouse was diluted between 10-50 times at least, unlike the human serum and 
ascites fluid, where the collection procedure did not involve any dilution. With regard to the type of 
proteins found in each sample, capillary electrophoresis of the human serum and ascites fluid 
reveals a very similar composition, with a major fraction of albumin (Figure 1A and 1B). Also 
mouse peritoneal fluid contains a major albumin fraction (68 KDa) and a prominent transferrin 
(Tfr) fraction (80 KDa) (Figure 1C). 
Table 1. Total protein of the studied biofluids 
Sample analyzed Total protein (mg/dl) 
Mice IP fluid 183.84 
Human ascites fluid 3296.4 
Human serum 6244 
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It should be noted that in the case of PC, the high protein content observed in the ascites fluid is 
attributed to the increased permeability of the peritoneal membrane induced mainly by vascular 
endothelial growth factor (VEGF) [44]. In patients with an earlier stage of PC, the total amount of 
proteins present in the peritoneal fluid is expected to be less. Nevertheless, a relative protein 
composition, similar as in Figure 1B is expected. 
 
  
Figure 1. Capillary electrophoresis of (A) ascites fluid, (B) human serum and (C) agarose gel electrophoresis of 
peritoneal fluid collected from mice.  
3.2 Colloidal stability of PS NPs and liposomes in diluted peritoneal fluids and serum 
The data in Figure 2 demonstrate the size and the zeta-potential of PS NPs measured by DLS 
following 1 h of incubation at 37°C in each of the studied biofluids. Samples were incubated in 50 
vol% of biofluids and further diluted to 2.5% biofluids for the actual measurements. As illustrated 
in Figure 2A (note the broken axis), cationic NPs (white bars) show pronounced aggregation in 
biofluids with a low protein concentration and less aggregation in biofluids with a high protein 
content. This aggregation is accompanied by a significant decrease in the zeta potential: the 
positively charged NPs (+ 28 mV) in HEPES buffer turn negative upon dispersing them in the 
biofluids (Figure 2B). Interestingly, an “opposite” aggregation pattern was observed with the 
anionic NPs (dark grey bars), whose state of aggregation seemed to be correlated with the protein 
content of the biofluids. Yet, when compared to cationic polystyrene NPs, this aggregation was less 
pronounced. Notably, the zeta potential of the anionic NPs increases from -33 mV in HEPES buffer 
to less negative NPs in the rest of the biofluids. The size of the PEGylated NPs (Figure 2A, grey 
bars) did not change upon incubation in the biofluids, indicating that the PEG-chains effectively 
inhibit aggregation.   
A B C 
Albumin (68 KDa) 
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Figure 2. (A) average size and (B) zeta-potential of cationic (white bars), PEGytlated (grey bars)and anionic (dark 
grey bars) PS NPs following 1 h incubation at 37°C with the different biofluids: HEPES buffer, mice IP fluid, ascites 
fluid and human serum (n=3). 
As liposomes are widely used in drug delivery and hold potential for siRNA delivery in the 
peritoneal cavity, it is of interest to have an insight on the aggregation profile of different 
liposomal formulations in IP fluid. Therefore, we investigated the colloidal stability upon incubating 
non-PEGylated, 5% PEGylated and 10% PEGylated liposomes in the biofluids. The data in Figure 3 
show the hydrodynamic diameter and the zeta potential of cationic and PEGylated liposomal 
formulations following 1 h of incubation in the biofluids. It can be seen that the extent of 
aggregation (Figure 3A, broken axis) is more severe in human serum > ascites fluid > mice IP 
fluid which correlates with the protein content of the biofluids (Table 1). In particular, the 
aggregation is the most pronounced for the cationic liposomes (white bars), while PEGylation 
significantly diminishes aggregation of cationic liposomes, indicating that the PEG chains improve 
the colloidal stability of the cationic liposomes. As can be seen from Figure 3B, a drop in the zeta 
potential was observed for all the liposomal formulations upon dispersing them in the biofluids 
(especially in human serum and ascites fluid). 
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Figure 3. (A) average size and (B) zeta-potential of cationic (white bars), 5% PEGytlated (grey bars) and 10% 
PEGylated (dark grey bars) DOTAP DOPE liposomes following 1 h incubation at 37°C with the different biofluids: 
HEPES buffer, mice IP fluid, ascites fluid and human serum (n=3). 
3.3 Aggregation of PS NPs and liposomes in undiluted biofluids 
Dynamic light scattering (DLS) is the most common technique to measure the average size of NPs 
in aqueous media. However, measuring the size of NPs in biofluids by DLS is challenging as 
proteins in the biofluids can scatter the light and interfere with the measurements. As an example 
size distributions of the biological fluids only diluted in HEPES buffer are shown in Supplemental 
Figure 1A and Figure 1B. Therefore, the DLS measurements in the previous sections were 
performed on highly diluted samples (only 2.5 vol% of biofluids in Figure 2 and Figure 3).  
 We have previously shown that SPT is a powerful technique to measure the size of NPs in 
undiluted biofluids such as serum and blood [36,45,46]. Here, we present for the first time the 
aggregation behavior of NPs in undiluted peritoneal fluids, and compared the aggregation profile 
with the one obtained in buffer and human serum. A particular benefit of SPT is that size 
measurements are performed on a per particle basis so that, contrary to DLS, there is no bias 
towards larger sizes. 
HEPES buffer Mice IP fluid Human ascites fluid Human serum
0
100
200
300
400
500
2000
4000
6000
8000
Z
- 
A
v
e
ra
g
e
 d
ia
m
e
te
r 
(n
m
)
 Cationic
 5% PEGylated
 10% PEGylated
HEPES buffer Mice IP fluid Human ascites fluid Human serum
-30
-20
-10
0
10
20
30
40
50
Z
e
ta
 p
o
te
n
ti
a
l 
(m
V
)
A 
B 
  
74 | Chapter 3 
 
 The size distributions of the PS NPs, as obtained by SPT in undiluted biofluids, are depicted 
in Figure 4 in line with the DLS data (Figure 2A), on average 100 nm size particles are observed in 
HEPES buffer. In the biological fluids, particles sizes increase to about 200 nm in human serum, 
300 nm in ascites fluid and even µm sized aggregates in mice IP fluid, again confirming the DLS 
results. For the anionic NPs (Figure 4B), a different aggregation pattern was observed: only a 
slight increase in size was noticed for the ascetic and mice IP fluid, while a broadened distribution 
was observed in human serum. In the case of PEGylated NPs (Figure 4C), the particles remained 
stable in mice and ascites IP fluid. Also, human serum resulted only in a very minor increase in 
size compared to the buffer sample. These findings are all consistent with the trends observed by 
DLS (Figure 2A).  
 
 
 
 
    
Figure 4. SPT sizing of (A) cationic, (B) anionic and (C) PEGylated PS NPs following 1 h incubation at 37°C with 
90 vol% of biofluids: HEPES buffer, mice IP fluid, ascites fluid and human serum.  
The aggregation behavior of the liposomes dispersed in the undiluted biofluids is shown in Figure 5 
and Figure 6. For the cationic liposomes, large non-diffusing aggregates (up to 2-3 µm) in size 
were observed at the bottom of the well following 1 h of incubation in mice IP fluid, ascites fluid 
and human serum (Figure 5). As these aggregates did not show Brownian motion, SPT data could 
not be obtained.  
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Figure 5. Snapshots of non-diffusing aggregates following 1 h incubation at 37°C of cationic DOTAP 
DOPE liposomes with 90 vol% of biofluids: HEPES buffer, mice IP fluid, ascites fluid and human serum. The 
scale bar corresponds to 10 µm. 
The size distributions of the 5% PEGylated liposomes (Figure 6A) confirm the outcome of the DLS 
data in Figure 3A, and show the profound aggregation of these liposomes in human serum. In the 
mice IP fluid and ascetic fluid, this aggregation is less prominent. Finally, the 10% PEGylated 
liposomes hardly aggregate in the peritoneal fluids. In human serum, at least a part of the 
liposomes did not aggregate as can be seen from the bimodal behavior. Note that the size 
distribution for the 10% PEGylated liposomes in HEPES buffer seems broader than the one for the 
5% PEGylated liposomes. Possibly, this is due to the structure the liposomes adopt with higher 
degrees of PEGylation, including small disks and large aggregates which contribute to the 
polydispersity of the sample [47]. 
 
 
 
 
 
 
 
Figure 6. SPT sizing of (A) 5% PEGylated liposomes and (B) 10% PEGylated DOTAP DOPE liposomes following 1 
h incubation at 37°C with 90 vol% of biofluids: HEPES buffer, mice IP fluid, ascites fluid and human serum.  
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3.4 Release of siRNA from liposomes in undiluted biofluids 
siRNA has the potential to treat peritoneal metastasis by preventing the growth and spread of 
circulating tumor cells. For siRNA to be biologically active, it needs to reach the cytoplasm of the 
tumor cells. Therefore, it is generally ‘complexed’ with cationic carriers such as polymers or 
liposomes, as ‘naked’ siRNA is not taken up by cells. In the next set of experiments, we aimed to 
determine the stability of siRNA-liposome complexes in peritoneal fluids, with respect to siRNA 
release from the formulations. When siRNA is prematurely released from the complexes in the 
biofluids, the biological activity will be lost. The percentage of free siRNA in HEPES buffer at the 
zero hour time point (Figure 7A, grey bars), shows the amount of siRNA that remained free (e.g. 
uncomplexed) when the siRNA/liposome complexes were formed. About 2%, 6% and 15% of 
siRNA is not encapsulated in respectively the cationic, 5% PEGylated and 10% PEGylated 
liposomes. This indicates that a higher PEGylation degree lowers the siRNA encapsulation 
efficiency. Following 1 h of incubation, the effect of PEGylation becomes even more pronounced: 
only the non-PEGylated liposomes retain the complexed siRNA. For the 5% and 10% PEGylated 
liposomes, respectively 30% and even 85% of siRNA is released into HEPES buffer. Next, the 
siRNA containing complexes were incubated with the undiluted biofluids. When compared to HEPES 
buffer (Figure 7A, grey bars), we observe an immediate release of siRNA at the zero time point 
upon dispersing the complexes in the biofluids (Figure 7, B-D, grey bars). This immediate release 
most likely corresponds to the release of surface-bound siRNA and increases with PEGylation 
degree. Further incubating the complexes in the biofluids for 1 h did not result in a substantial 
additional release of siRNA (Figure 7B-D, white bars), except for the 5% PEGylated complexes in 
human serum (Figure 7D, white bars). Overall, the siRNA release was limited to maximally 30% 
for the cationic liposomes, while for the 5% and 10% PEGylated liposomes, between 65-80% of 
siRNA was released into the peritoneal fluids and even close to 100% siRNA was released in 
human serum after 1 h. 
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Figure 7. Percentage of siRNA release of non-PEGylated and PEGylated AF-488 siRNA-liposome 
complexes (±8) determined by FCS analysis, in 90 vol% biofluids: of (A) HEPES buffer, (B) mice IP fluid, 
(C) ascites fluid and (D) human serum immediately after preparation (grey bars) and following 1 h incubation at 
37°C (white bars).  
4. Discussion 
Designing new delivery systems for targeting peritoneal cancer cells is a major challenge. Apart 
from the IV route of administration, IP delivery of NPs that target cancer cells over a prolonged 
period of time is being explored. Upon IP delivery, NPs are directly administered at the target site. 
Hence, interactions of the NPs with blood components that potentially induce immune responses or 
stability issues could be avoided [48]. The stability of NPs in the IP fluid is a major determinant for 
their efficacy. Indeed, either particle aggregation or premature release of cargo in the IP fluid 
could diminish the biological effect. The colloidal stability of NPs in IP fluids has, however, not been 
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studied in detail before. In this study, we employed advanced microscopy techniques to directly 
assess stability of NPs in terms of aggregation and cargo release, in undiluted biofluids such as 
mice IP fluid and ascites fluid from a patient diagnosed with PC and compared it to human serum.    
 4.1 Aggregation of model PS NPs and liposomes in peritoneal fluids 
Aggregation of different PS NPs and liposomal formulations in the peritoneal fluids was tested 
using DLS and SPT. Two main questions were addressed, namely: (1) does the physicochemical 
properties of the material (e.g. charge and PEGylation degree) influence aggregation and (2) does 
the concentration of the proteins in each of the biofluids correlate with the aggregation profiles?  
PS NPs were used in this study as an inert hydrophobic model system. Liposomes, on the 
other hand, are frequently used to deliver therapeutic agents to target cells. A summary of their 
aggregation profiles can be found in Table 2. It was already demonstrated before that serum 
induces quick aggregation of positively charged NPs [36]. This was confirmed in our study, 
especially for the positively charged liposomes. Also in mice and human IP fluid, severe 
aggregation of positively charged particles was observed. As seen in Figure 1, albumin is the major 
protein fraction in both mice and human IP fluid, as well as in human serum (~60%). Under 
physiological conditions (pH 7-7.4) albumin and other negatively charged proteins are capable of 
binding to cationic NPs, inducing the formation of micrometer sized protein-NP complexes [31]. It 
is thus most likely that albumin is the most abundant component in the protein corona around the 
positively charged NPs, as was observed before [49]. The formation of protein-nanoparticle 
complexes also explains the drop observed in the zeta potential in Figure 2A and 2B. It should be 
noted that negatively charged NPs tend to bind proteins with an isoelectric point greater than 5.5, 
such as IgG [50]. This explains why the zeta potential of the negatively charged polystyrene beads 
becomes less negative upon incubation with the biofluids.   
Table 2. Aggregation of the studied formulations in the different biofluids. / indicates no aggregation, +, ++ and +++ 
indicate aggregates up to respectively 200 nm, 500 nm and >1 µm. 
Formulation 
HEPES 
buffer 
Mice IP 
fluid 
Ascites 
fluid 
Human 
serum 
+ PS --- +++ + + 
- PS --- + + + 
PEG PS --- --- + + 
+ liposomes --- +++ +++ +++ 
5% PEG 
liposomes 
--- + + ++ 
10% PEG 
liposomes 
--- --- + + 
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The adsorption of proteins to the NPs described above is drastically diminished when the 
surface of the PS NPs and liposomes is decorated with PEG (Table 2). Despite the role of PEG in 
avoiding aggregation, the data presented in Figure 6B indicate that there is a limit to which extent 
the protein adsorption could be prevented. This finding is significant, suggesting that 10% 
PEGylated liposomes are very stable in the peritoneal fluids, but not in human serum where 
aggregation still takes place due to the high density of proteins bound on the surface of the PEG 
residues (Table 1). In general, it seems that PEGylation is necessary to avoid the formation of 
aggregation in peritoneal fluids. Both positively and negatively charged non-PEGylated NPs tend to 
form large aggregates upon incubation with peritoneal fluids or human serum. 
 Among all the studied formulations the aggregation tendency seemed proportional to the 
protein concentration of the incubation fluid, except for positively charged PS NPs, which show the 
greatest aggregation in mice IP fluid with lowest protein content. The exact reason for this is 
unclear. It should be noted, however, that the positively charged PS NPs become negatively 
charged upon incubation with the biofluids. The negatively charged PS NPs, on the other hand, 
become slightly less negative. Therefore, the actual proteins that bind to the NPs are expected to 
be different for cationic or anionic NPs, respectively, which might influence their aggregation 
behavior. Another observation is that the liposomes tend to aggregate more than PS NP in all 
biofluids. This most probably stems from the intrinsic properties of the building blocks. In 
particular, when collisions between two liposomes occur (especially non-PEGylated ones), 
hydrophobic interactions between lipids from both liposomes can take place, supporting the 
formation of aggregates. On the contrary, PS NP are ‘inert’ plastic particles that could ‘bounce’ 
upon collision and shown no additional attracting forces that would support the formation of 
aggregates.  
4.2 Release of siRNA from liposomes in the peritoneal fluids 
Apart from colloidal stability in terms of aggregation, the NPs should be able to bring their cargo to 
the target site. The release of siRNA from liposomal formulations in the peritoneal fluids was 
evaluated using Fluorescence Correlation Spectroscopy (FCS). As we previously demonstrated, FCS 
is an elegant technique to follow the complexation behavior of small nucleic acids to NPs, both in 
buffer and in living cells [38,51]. The data in Figure 7 clearly suggest better complexation and 
slower release of siRNA for the non-PEGylated LPXs over the PEGylated ones. The higher the 
PEGylation degree, the more rapid the siRNA molecules dissociate from the complexes, even in 
buffer conditions. This most likely stems from the proposed mechanism for LPX formation [52-54]. 
When cationic liposomes are added to negatively charged siRNA, strong electrostatic interactions 
occur, and the majority of the siRNA molecules attach to the surface of the liposomes. These 
siRNA-coated liposomes can subsequently fuse with other liposomes, so that siRNA is entrapped 
within the bilayer of the liposomes. In the case of PEGylated LPXs, the PEG chains prevent the 
fusion of different liposomes, resulting in LPXs in which siRNA is only bound to the outer surface 
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and not “sandwiched” in between the multilayers of the liposomes. Also, the lower surface charge 
leads to less complexation, resulting in an increasing amount of free siRNA at zero time with 
higher degree of PEGylation as seen in Figure 7.    
The release is also dependent on the composition of the biofluid in which the LPXs were incubated 
afterwards. For the PEGylated LPXs, the excess of albumin and other negatively charged proteins 
triggers the release of the surface bound siRNA from the complexes by competing for binding to 
the cationic lipids. In human serum, the release percentage of the siRNA is the highest when 
compared to other biofluids, as these samples contain the highest protein concentration. 
Interestingly, only small differences occur in the percentages of release of siRNA from non-
PEGylated LPXs in between zero time and 1 h of incubation in the different biofluids. This shows 
that negatively charged proteins in serum and IP fluids only compete with siRNA bound to the 
surface of the LPXs, leaving siRNA sandwiched in between the lipid bilayers unaffected.   
4.3 Tailoring delivery systems for IP therapy 
Nano-sized delivery vehicles for IP administration for the treatment PC should meet several 
efficacy and safety requirements: (1) long retention time in the peritoneal cavity to ensure 
maximal therapeutic efficiency, (2) limited leakage into the systemic circulation to avoid toxic side 
effects, (3) a specific targeting of tumor cells and (4) limited immune and inflammation responses. 
All these are still major challenges in IP delivery systems [22].  
 Figure 8 schematically represents the different steps and hurdles for NPs administered to 
the peritoneal cavity. In the case of siRNA, internalization of the carrier into the cells is needed, 
before knock down of proteins responsible for the proliferation of cancer cells can occur. The data 
presented in this study undoubtedly propose rapid aggregation of positively and negatively 
charged NPs in the peritoneal fluids. Large size aggregates, however, are not efficiently taken up 
by cells anymore. Therefore, the siRNA activity of these aggregates will be lost (Figure 8A, step 1). 
Also, premature release of siRNA from the carrier in the peritoneal fluid is not desired (Figure 8A, 
step 2) as free siRNA is not able to penetrate into the cytosol of the cancer cells. While reduced 
aggregation is achieved by PEGylation of NPs, the PEGylated liposomes suffered from a fast 
release of the complexed siRNA upon exposure to the IP fluids. Also, PEGylation has been 
associated with low transfection efficiency due to poor uptake and/or interaction with the 
endosomal membrane. Nevertheless, different PEGylation strategies can be exploited to prevent 
aggregation, while keeping the transfection efficiency [55]. An interesting strategy is the use of 
sheddable PEG-chains that protect the NPs from aggregation in the extracellular environment, but 
dissociate once the NPs enter certain intracellular compartments. Also, altering the formation 
procedure of liposomes is an option. By hydrating the lipid film with a solution of siRNA at least 
part of the loaded siRNA is entrapped inside the liposomal core, even when PEGylated liposomes 
are used [56]. Also post PEGylation of preformed siRNA/liposome formulations (in which all siRNA 
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is entrapped between lipid bilayers) is feasible. Apart from aggregation and premature cargo 
release, the clearance of NPs from the peritoneal cavity is an important parameter. Ideally, NPs 
should reside in the peritoneal cavity as long as possible, without leakage into the systemic 
circulation (Figure 8B, step 4). It has been suggested, however, that NPs are cleared from the 
peritoneal cavity within 2 days [57]. Therefore, for developing RNAi-based therapy for the 
treatment of peritoneal cancer (which preferentially makes use of nano-sized particles for 
optimized cell internalization), a future strategy could be to load NPs into a sustained release 
system. Taking into account the clearance rate of NPs from the peritoneal cavity, such a controlled 
release system can be tuned so that a constant amount of NPs is present in the peritoneal cavity. 
It should be noted that a good retention time in the peritoneal cavity was reported for 100 nm 
positively charged liposomes by Dadashzadeh et al. [58]. The size of the liposomes upon IP 
administration was however not continuously monitored. In our opinion, this slower clearance rate 
can be attributed to the aggregation of these NPs to micrometer sized particles in the IP fluid. As 
has been suggested, these MPs do indeed show a slower clearance rate from the peritoneal cavity 
when compared to NPs [59]. 
 
Figure 8. Schematic overview of the different pathways of siRNA complexes or NPs loaded with 
paclitaxel following IP injection.  
Unlike for siRNA, conventional anti-cancer agents such as paclitaxel and doxorubicin (DOX) do not 
need a carrier system to be taken up in cells. Therefore, the aggregation of NPs or premature 
cargo release might not be a major problem for these type of formulations (Figure 8B). 
Aggregation of NPs would however lead to large size aggregates which could lead to increasing 
difficulty of drug dissolution in the IP fluid (Figure 8B, step 1). Also, Kohane et al. concluded that 
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MPs do not appear to be good candidates for IP drug delivery due to the risk of adhesions [57]. 
Also, a disadvantage of the conventional cytostatics, is the non-specificity of the drugs which also 
affect healthy non-tumor cells and the fact that tumor cells can develop resistance after long-term 
treatment and exposure.    
  It should be noted that the environment of the peritoneal cavity seems to be less 
aggressive than the one of the systemic circulation: while 5% PEGylated liposomes remained 
stable in IP fluid, aggregation was still observed in the human serum. Therefore, one could argue 
that less colloidal stable NPs could still be used for IP administration. We have the opinion, 
however, that IP administered NPs should also be stable enough in the systemic circulation, since 
clearance of these particles from the peritoneal cavity to the systemic circulation is most likely 
inevitable (Figure 8, step 4). When a colloidal stable nanoparticle, once it leaves the peritoneal 
cavity, starts aggregating in the blood circulation, there is a risk of clogging blood capillaries, 
which should obviously be avoided.   
Finally, it is important to stress out that the outcomes from the stability testing in vitro in biofluids 
with the techniques used in this study (FCS and SPT) represent a good prediction of the stability 
for the in vivo situation. Therefore, formulations that are not stable enough in vitro should not be 
considered for in vivo applications. Rather, further in vitro optimization should take place to 
enhance the stability of NPs and to ensure that only stable formulations are used for further animal 
studies. It should be noted, however, that the in vivo situation is expected to be more complex 
than the in vitro one in biological fluids. Therefore, particles that showed good stability in the 
biofluids should always be further tested in vivo to determine their biological activity.  
5. Conclusions 
There is increasing interest from clinicians in treating carcinomatosis patients with some form of IP 
therapy. Unfortunately, none of the currently used drugs in this setting have been specifically 
designed or tested for IP application. In this study, for the first time, we investigate the 
aggregation and release of cargo from NPs in peritoneal fluids. Our data indicate fast aggregation 
of positively and negatively charged NPs in the peritoneal fluids, which can be prevented by 
decorating the surface with PEG. Conventional complexation of nucleic acids with our PEGylated 
liposomes results however in a rapid release of the nucleic acids in the peritoneal fluids, which is 
not preferred.  
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Supplementary Figure 1.  
 
 
DLS size distributions of (A) human serum and (B) ascites fluid diluted in HEPES buffer. 
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Abstract 
Small interfering RNA (siRNA) offers a great potential for the treatment of various diseases and 
disorders. Nevertheless, inefficient in vivo siRNA delivery hampers its translation into the clinic. 
While numerous successful in vitro siRNA delivery stories exist in reduced-protein conditions, most 
studies so far overlook the influence of the biological fluids present in the in vivo environment. In 
this study, we compared the transfection efficiency of liposomal formulations in Opti-MEM® (low 
protein content, routinely used for in vitro screening) and human undiluted ascites fluid obtained 
from a PC patient (high protein content, representing the in vivo situation). In Opti-MEM®, all 
formulations are biologically active. In ascites fluid, however, the biological activity of all lipoplexes 
(LPXs) is lost except for lipofectamine RNAiMAX. The drop in transfection efficiency was not 
correlated to the physicochemical properties of the nanoparticles (NPs), such as premature siRNA 
release and aggregation of the NPs in the human ascites fluid. Remarkably, however, all of the 
formulations except for lipofectamine RNAiMAX lost their ability to be taken up by cells following 
incubation in ascites fluid. To take into account the possible effects of a protein corona formed 
around the NPs, we recommend always using undiluted biological fluids for the in vitro 
optimization of nano-sized siRNA formulations next to conventional screening in low-protein 
content media. This should tighten the gap between in vitro and in vivo performance of NPs and 
ensure the optimal selection of NPs for further in vivo studies. 
Keywords: liposomes, siRNA delivery, ascites, protein corona, lipofectamine, peritoneal 
metastasis 
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1. Introduction 
Since the discovery of small interfering RNA (siRNA) [1,2] a lot of effort has been put into 
translating it into the clinic for the treatment of different diseases [3]. In vitro there are numerous 
options for successfully delivering siRNA to cells under “reduced serum conditions”. In more 
complex “protein-rich” biological fluids, however, the effect of the protein corona (being formed at 
the surface of the nanoparticles (NPs)) on the aggregation, release, uptake, intracellular 
trafficking, and transfection of NPs should not be underestimated [4-6]. Unfortunately, upon 
screening tens of papers that aim to optimize siRNA carriers for future in vivo use, the NPs are 
only evaluated in unrealistic protein-free conditions in spite of the fact that human biological fluids, 
e.g., blood, serum, plasma, ascites fluids, sputa, and synovial fluids, are easily accessible. As 
these undiluted biological fluids contain high concentration of proteins, they more closely resemble 
the in vivo situation. In vivo siRNA delivery is a complex process that includes both extracellular 
and intracellular barriers. Generally speaking, NPs are expected to keep the cargo (i.e., siRNA) in 
an intact form while circulating in the biological fluids of the body. Also, premature release of the 
siRNA from the NPs and aggregation of siRNA NPs in biological fluids are referred to as 
extracellular barriers for siRNA delivery [7]. While it is possible to determine the overall biological 
activity (i.e., gene knockdown) of siRNA formulations in vivo, it is impossible to monitor siRNA 
release, aggregation, and interaction of the formulations with biological membranes directly in 
vivo. Therefore, in vitro optimization of nanoparticle-based siRNA delivery is still needed, although 
it should be done under conditions that are as similar as possible to the in vivo situation in which 
the NPs are intended to be used. 
A better understanding of our failure to efficiently deliver siRNA in vivo [8] should arise from a 
stronger knowledge of the physicochemical and biophysical properties of siRNA delivery systems in 
the biofluids that are expected to be encountered. For patients diagnosed with PC, for example, 
the delivery of NPs in the peritoneal cavity is being considered as a promising future therapy. 
Locoregional anticancer therapy allows the targeting of the PC while at the same time limiting 
systemic toxicity. After locoregional administration, NPs come into contact with the peritoneal fluid 
present in the peritoneal cavity of these patients. Hence, understanding the influence of peritoneal 
fluid on the performance of the NPs is crucial. In the current study, we investigated the ability of 
different PEGylated and non-PEGylated cationic liposomes to induce siRNA-mediated knockdown in 
a human ovarian cancer cell line. We resembled the expected in vivo situation by incubating the 
NPs in undiluted ascites fluid isolated from a PC patient. Important parameters of the liposomal 
formulations that we studied were (i) the release of siRNA in the ascites fluid, (ii) the aggregation 
of the LPXs, and (iii) the effect of the biofluid on the cellular uptake of NPs. All parameters were 
correlated with the biological performance of the liposomal formulations. Our results indicate that 
there is a large discrepancy between the high transfection potential of the NPs seen under protein-
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free conditions and their performance that remains after exposing them to a protein-rich biofluid, 
such as human ascites fluid. 
 
2. Materials and methods 
2.1 Materials 
(2, 3-Dioleoyloxy-propyl)-Trimethylammonium-chloride (DOTAP), 1, 2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), and N-palmitoyl-sphingosine-1-{succinyl [methoxy (polyethylene 
glycol) 2000]} (C16 mPEG 2000 ceramide) were purchased from Avanti Polar Lipids (Alabaster, 
AL). Chloroform, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and sodium chloride (NaCl) were purchased 
from Sigma-Aldrich (Bornem, Belgium). Penicillin−streptomycin (5000 U/ml), lipofectamine 
RNAiMAX transfection reagent (LF), L-glutamine (200 mM), 0.25% trypsin−EDTA (1×) phenol red, 
McCoy’s 5A (modified), Opti-MEM®, and 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine perchlorate (DID) (λex = 644 nm, λem = 665 nm) were purchased 
from Invitrogen (Merelbeke, Belgium). Luciferase assay substrate was purchased from Promega 
(Madison, WI). Fetal bovine serum (FBS) was purchased from HyClone Thermo Scientific 
(Cramlington, UK). Passive lysis buffer and luciferase assay kits were purchased from Promega 
(Leiden, Netherlands). Negative-control siRNA (siNEG) and luciferase siRNA (siLuc) were 
purchased from Eurogentec (Searing, Belgium). 
2.2 Preparation and characterization of the LPXs 
Liposomes corresponding to 5 mM of DOTAP and 5 mM of DOPE lipids were prepared by mixing the 
appropriate amount of lipids in a round bottomed flask before evaporation. PEGylated liposomes 
were prepared by adding the desired amounts of C16 Cer-PEG dissolved in chloroform 
(corresponding to 5 mol %) to the lipids before evaporation. A lipid film was formed by rotary 
evaporation of the chloroform at 40 °C. Liposomes were prepared by rehydrating the lipid film with 
HEPES buffer (20 mM, pH 7.4), followed by sonication using a probe sonicator (Branson 
Ultrasonics Digital Sonifier, Danbury, USA). LPXs with a charge ratio of ±8 were prepared by 
adding the appropriate amounts of liposomes to siRNA. The mixture was incubated at room 
temperature to allow the formation of the LPXs. Lipofectamine RNAiMAX LPXs were prepared as 
described by the manufacturer. Briefly, the appropriate volume of lipofectamine RNAiMAX was 
added to a solution of siNEG, siLuc, or fluorescently labeled siRNA, respectively, and incubated at 
room temperature for 15 min before use. Throughout the manuscript, lipofectamine RNAiMAX LPXs 
will be termed LF-LPXs. 
The average size and ζ-potential of all formulations were measured by a Zetasizer Nano-ZS 
(Malvern, Worcestershire, UK). 
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2.3 Cell Culture 
The human ovarian cancer cell line SKOV-3, which stably expresses firefly luciferase, was used for 
in vitro experiments. Cells were cultured in McCoy’s 5A medium supplemented with FBS and 
penicillin−streptomycin. Cells were cultured until 80% to 90% confluency and detached from 
tissue-culture dishes with 0.25% trypsin. Cells were maintained in an incubator at 37 °C in a 
humidified atmosphere with 5% CO2. 
 
2.4 Transfection efficiency 
SKOV-3 cells were cultured overnight on 24 well plates (35 000 cells per well) in 500 μL of 
medium containing 10% FBS. Cells were then washed and incubated with the LPXs and 
LF-LPXs in Opti-MEM® for 4 h. After 4 h of incubation, the transfection medium was replaced by 
culture medium, and cells were returned to the incubator for 24 h. The siLuc concentration in the 
wells equaled 25 nM. LF-LPXs, prepared as recommended by the manufacturer, were used as the 
positive control. Each LPX containing siLuc was compared with its own control (e.g., siNEG). After 
overnight incubation, cells were lysed with passive lysis buffer and analyzed for firefly luciferase 
expression using the luciferase assay kit (Promega). The bioluminescence (relative light units, 
RLU) was measured using a GloMax luminometer (Promega). The percentage of luciferase 
downregulation was determined by the following equation: 
 
% transfection = 100 − (100 × RLULuc/RLUNEG) 
 
Where RLUNEG and RLULuc are the mean bioluminescence as measured for siNEG and siLuc, 
respectively. The data shown in Figure 1 are based on three experiments performed on three 
different days. For transfections in the ascites fluid, 300 μL LPXs (of each formulation) were first 
added to 700 μL ascites fluid and incubated for 1 h. Then, 300 μL of this mixture was added to 700 
μL of Opti-MEM® in each well of a 24 well-plate. Thereafter, the medium was replaced with growth 
medium and cells were returned to the incubator for 24 h as described above. So-named “upside-
down transfections” were performed as follows: 300 μL of LF-LPXs was incubated for 1 and 3 h at 
37°C in 700 μL of human ascites fluid. SKOV-3 cells were cultured (during 24 h) on 12 mm 
coverslips. Subsequently, the cells (on the coverslips) were mounted upside-down on plastic tubes 
(diameter of 1.3 cm and height of 0.9 cm) filled with 700 μL of Opti-MEM®. A total of 300 μL of 
LFLPXs was then added to these tubes as such or after incubation in the ascites fluid. After 4 h of 
exposure of the LF-LPXs to the cells, the coverslips were placed in the wells of a 24 well plate and 
kept in the incubator for 24 h after adding growth medium to the cells. Subsequently, the cells 
were lysed, and the percentage of luciferase inhibition was calculated as mentioned above. It 
should be noted that in this upside-down transfection mode, the precipitation of LF-LPXs on the 
cells due to gravity is avoided. 
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Statistical analysis (shown in Figure 1) was performed using GraphPad Prism 6. Statistically 
significant differences were calculated by using an analysis of variance (ANOVA) at a 0.05 
significance level, followed by Sidak’s post-test. For each formulation, transfection experiments 
carried out in Opti-MEM® were compared to those in ascites. 
 
2.5 Fluorescence Correlation Spectroscopy on LPXs 
Fluorescence correlation spectroscopy (FCS) is a microscopy-based technique that monitors the 
fluorescence intensity fluctuations of (fluorescent) molecules diffusing in and out of the focal 
volume of a confocal microscope.[7,10] Single-color FCS measurements were performed on LPXs 
containing 30% Cy5 siRNA and having a charge ratio of ±8. A total of 5 μL of such LPXs was 
diluted to a final volume of 45 μL HEPES buffer or 45 μL of ascites fluid (∼90 vol % of biofluid); the 
samples were analyzed by FCS immediately, 1 and 24 h after incubation in the biofluids at 37 °C. 
During the incubation and FCS measurements, the well plate was covered with adhesive plates 
seals (Thermo Scientific, UK) to avoid evaporation of the sample and to minimize flow. FCS 
measurements were performed on the experimental setup described before [7]. 
2.6 Fluorescence Single-Particle Tracking 
Fluorescence single particle tracking (fSPT) is a fluorescence microscopy technique that is 
very well-suited for the determination of diffusion and aggregation of NPs in undiluted biological 
fluids, as was previously shown [11]. fSPT measurements were performed on LPXs (cationic, 5% 
C16 Cer-PEG, and LF-LPXs), labeled with DID or containing Alexa-Fluor 488 (AF-488)-labeled 
siRNA. LPXs were dispersed in biofluids as follows. First, formulations were diluted 400 times in 
HEPES buffer. Then, 5 μL was added to 45 μL of human ascites fluid (∼90 vol % of biofluid) and 
incubated for 1, 2, and 3 h, respectively, at 37°C in a 96 well plate (Greiner Bio-One, 
Frickenhausen, Germany). At the end of the incubation time, the samples were placed on a 
custom-built fSPT setup [11], and movies were recorded at about 5 μm above the bottom of the 
96 well plate. Videos were analyzed as was previously explained using the following values of 
viscosity at room temperature: 1.39 cP for the ascites fluid and 0.94 cP for the HEPES buffer [7]. 
Human ascites fluid was obtained from a patient diagnosed with PC at the Medical Oncology 
Department of Ghent University Hospital (approved by the Ethics Committee of the Ghent 
University Hospital (no. 2013/589)). 
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2.7 Internalization of siRNA into SKOV-3 cells 
SKOV-3 cells were plated on 24 well plates (35 000 cells in each well) and allowed to grow in an 
incubator for 24 h. For uptake experiments, cells were incubated in Opti-MEM® with fluorescent 
LPXs containing 10% of AF-488 siRNA for 4 h at 37 and 4°C. At the end of the incubation, cells 
were washed extensively with warm growth medium and PBS, then detached using trypsin and 
analyzed by FACS (FACSCalibur flow cytometer, BD Biosciences). Uptake experiments were 
performed with LPXs as such (directly after preparation) or after incubation of the LPXs with ∼70% 
ascites fluid for 1 h before adding them to the cells, as described above under transfection 
efficiency. 
 
3. Results 
3.1 Characterization of the liposomes and LPXs in HEPES buffer 
As depicted in Table 1, all the formulations resulted in nano-sized vesicles, as determined by 
dynamic light scattering (DLS). Despite the fact that the average size of the LF-based liposomes 
(LF-LP) and LF-LPXs were in the same range as the other formulations, the polydispersity of the 
LF-LP and LF-LPXs was higher (polydispersity index (PDI) >0.5). The size increased for all 
formulations upon complexation of the liposomes with siRNA (except for LF-LPXs). The cationic 
liposomes and LPXs showed the highest positive surface charge (as reflected from their ζ 
potential). As expected, PEGylation lowered the surface charge of the liposomes and the LPXs. LF-
LP and LF-LPXs showed an intermediate surface charge. 
Table 1. Z-Average diameter and ζ-Potential of the different formulations used in this study 
 
Formulation 
Z-average 
diameter ± SD 
(nm) 
Polydispersity 
index (PDI) 
ζ-potential 
(mV) (mean 
±SD) 
Abbreviation 
Cationic 
liposomes 
85 ± 1 0.2 56 ± 1 Cationic LP 
Cationic LPX 107 ± 1 0.2 53 ± 1 Cationic LPXs 
5% C16 Cer-PEG 
liposomes 
115 ± 2 0.2 6 ± 1 5% C16 Cer-LP 
5% C16 Cer-PEG 
LPX 
151 ± 2 0.2 5 ± 1 5% C16 Cer-LPXs 
Lipofectamine 
RNAiMAX 
liposomes 
137 ± 12 0.6 26 ± 2 LF-LP 
Lipofectamine 
RNAiMAX LPX 
106 ± 3 0.6 22 ± 3 LF-LPXs 
 
 
 
  
96 | Chapter 4 
 
 
3.2 Transfection efficiency of the LPXs in reduced serum conditions and protein-rich 
conditions 
To evaluate the ability of the LPXs to knock down the expression of a specific gene, we incubated 
SKOV-3 cells stably expressing luciferase with the LPXs containing siRNA against luciferase (siLuc). 
To verify the knockdown specificity, we used formulations loaded with a scrambled sequence 
(siNEG) as well. Figure 1 (dark gray bars) demonstrates the transfection efficiency of the LPXs 
following incubation in Opti-MEM®. All of the formulations efficiently downregulated luciferase 
expression. Considering the fact that NPs for in vivo IP gene therapy will come into contact with 
peritoneal fluids, we were interested to see whether incubation of the LPXs in the ascites fluid 
obtained from a human PC patient would influence their transfection efficiency. The white bars in 
Figure 1 show a dramatic significant decrease in the transfection efficiency for the cationic LPXs 
and 5% C16 Cer-LPXs while the LF-LPXs remain active. This raised the question as to why the 
LPXs and 5% C16 Cer-LPXs significantly lost their biological activity upon exposure to human 
ascites fluid. 
 
 
 
 
 
 
 
 
 
Figure 1. Inhibition of luciferase in SKOV-3 cells by the LPXs in Opti-MEM® (dark gray bars) following 
incubation of the LPXs for 1 h in ascites fluid (70 vol %) (white bars). The values in the graph represent the average 
from at least three experiments that were performed on different days. 
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3.3 Release of siRNA from LPXs in undiluted human ascites fluid  
A possible reason why LPXs are less efficient in human ascites fluid could be a premature release 
of siRNA from the formulations. Indeed, the more siRNA is released from the carriers, the less 
siRNA remains available for uptake in cells. As demonstrated previously by us, FCS is a suitable 
method for determining the amount of siRNA that is present in nanocarriers [9,10]. Likewise, FCS 
can be used to follow the release of siRNA from NPs upon incubating them in buffer and biological 
fluids [7]. Figure 2 shows the percentage of siRNA that is associated with the different 
formulations in HEPES buffer immediately following preparation (e.g., complexation efficiency) and 
after incubation for 1 and 24 h in human ascites fluid (90% vol). In HEPES buffer (gray bars), 
cationic LPXs show the highest complexation efficiency, with more than 90% of the siRNA 
associated with the cationic liposomes. PEGylation of the cationic liposomes seems to reduce the 
complexation efficiency because only 75% of the siRNA is bound to the 5% C16-Cer LPXs. LF-LPXs 
have the lowest loading efficiency, with 65% of siRNA complexed. Following 1 h of incubation in 
human ascites fluid (white bars), all formulations release a substantial amount of the initially 
complexed siRNA, leaving only 50%, 40%, and 40% of siRNA complexed in cationic LPX, 5% C16-
Cer LPXs, and LF-LPXs, respectively. Following 24 h of incubation in human ascites fluid, the 
release of siRNA continues, resulting in less than 20% of siRNA remaining complexed in all of the 
formulations (dark gray bars). Taken together, human ascites fluid induces a massive release of 
siRNA from all liposomal formulations, reducing the amount of complexed siRNA that remains 
available for biological activity to about 20%. The substantial loss of siRNA following incubation in 
ascites fluid could explain the lower transfection efficiency of the cationic LPXs and 5% C16 Cer-
LPXs in Figure 1. Nevertheless, LF-LPXs retain only 20% of complexed siRNA while maintaining 
their biological activity. In a next step, we evaluated the aggregation of the complexes in the 
undiluted human ascites fluids and whether or not this aggregation influences the biological 
activity of the complexes. 
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Figure 2. Complexation efficiency of liposomes immediately following preparation in HEPES buffer (gray bars) 
and percentage of siRNA still complexed after incubation of the lipoplexes in 90 vol% of human ascites fluid during 1 
h (white bars) and 24 h (dark gray bars), respectively. 
3.4 Aggregation of the LPXs in undiluted human ascites fluid  
In our previous study [7], we have shown that dynamic light scattering (DLS) is not an ideal 
technique for quantifying the extent of aggregation of nanocarriers in (undiluted) ascites fluids, 
simply due to light scattering that results from the high amount of proteins in such samples. In our 
hands, fSPT has proven to be superior over DLS to study the aggregation of NPs in biological fluids 
[7,11-13]. Figure 3A shows the size distributions of the cationic LPXs incubated in undiluted 
human ascites fluid (∼90 vol % of biofluid) during 1, 2, and 3 h. In HEPES buffer, the average 
diameter of the cationic LPXs is about 200 nm. In ascites fluid, aggregation in time clearly occurs 
with the formation of 1−2 μm sized aggregates. The 5% C16 Cer-LPXs have an average size of 
150 nm in HEPES buffer (Figure 3B, black curve). Following 1 h of incubation in ascites fluid, the 
size distribution is (very) slightly shifted toward the right, showing the aggregation of a specific 
population of particles, particularly those that were initially smaller than 100 nm (Figure 3B, red 
curve). After 2 h of incubation, aggregation seems to become more prominent, with an average 
diameter of 200 nm (Figure 3B, blue curve). No further aggregation was observed following 3 h of 
incubation (Figure 3B, green curve). Figure 3B confirms our previous results, showing that 
PEGylation protects liposomes from aggregation in undiluted human ascites fluid [7]. LF-LPXs 
showed a high polydispersity in HEPES buffer, with particles ranging from tens of nanometers up 
to 1 μm in size (Figure 3C, black curve). Following incubation in ascites fluid, we observed a slight 
aggregation after 1 h of incubation (Figure 3C, red curve), followed by a pronounced aggregation 
after 2 and 3 h (Figure 3C, green and blue curve), with the presence of micron-sized particles. On 
the basis of the data in Figure 3C, it is clear that very severe aggregation occurs in ascites fluids 
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for LF-LPXs. Figure 1 demonstrates that LF-LPXs exposed to ascites fluids show the highest 
transfection efficiency, while the (more) colloidally stable cationic LPXs and 5% C16 Cer-LPXs lose 
their biological activity in ascites fluid (Figure 1, white bars). One possible reason for these 
observations could be that the larger LF-LPXs aggregates rapidly sediment onto the cells during 
transfection, leading to a forced increased uptake and transfection efficiency. To test this 
hypothesis, we evaluated the cell uptake of the LPXs before and after incubation of the 
formulations in ascites fluid. 
 
 
 
 
 
 
Figure 3. fSPT size distributions of the different lipoplexes following incubation in 90 vol % human 
ascites fluid at 37°C. (A) Cationic LPXs, (B) 5% C16 Cer-LPXs, and (C) LF-LPXs. The dotted pink line 
corresponds to aggregates of 5 μm in size. The Y-axis refers to the fraction (f) of NPs that appear with the 
corresponding size on the X-axis. 
3.5 Influence of ascites fluid on the cellular uptake of the LPXs by SKOV-3 cells  
To test the extent of LPX uptake in cells after incubation with ascites fluid, we exposed SKOV-3 
cells to LPXs loaded with fluorescently labeled AF-488 siRNA and quantified their uptake by flow 
cytometry. Figure 4A indicates that in Opti-MEM® (and at 37°C), the various types of LPXs carried 
the fluorescent siRNA into SKOV-3 cells. At 4°C, intracellular AF-488 fluorescence was minimal 
(data not shown), indicating that at 37°C, the LPXs were indeed internalized and did not just 
attach at the surface of the cells. When the same experiment was performed with LPXs that were 
incubated in ascites fluid for 1 h, the cationic LPXs and the 5% C16 Cer-LPXs completely lost their 
ability to carry the fluorescent siRNA into the cells, as depicted in Figure 4B. Only LF-LPXs were 
still efficiently internalized into SKOV-3 cells.  
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Figure 4. Uptake of AF-488 siRNA-labeled LPXs by SKOV-3 cells. LPXs were prepared in HEPES buffer and 
added to the cells in Opti-MEM® following preparation as such (A) or after incubation of the LPXs for 1 h in human 
ascites fluid before adding them on the cells (B). 
 
3.6 Aggregation: not the sole determinant of in vitro transfection efficiency  
Because Figure 3C demonstrates that mainly LF-LPXs form large aggregates in ascites fluid, which 
may easily sediment on the cells, we wondered whether those severe aggregates explain why LF-
LPXs keep transfecting the cells. Therefore, we tested the ability of LF-LPXs to transfect SKOV-3 
cells in an “upside-down transfection mode” where cells are positioned at the top surface of the 
LPXs dispersions, thus avoiding the spontaneous sedimentation of aggregates on the cells. Upside-
down transfections were performed with LF-LPXs in Opti-MEM® and with LF-LPXs that were 
incubated in ascites fluid during 1 or 3 h. As depicted in Figure 5, in Opti-MEM® luciferase down 
regulation remained 80%, which is similar to the “normal transfection mode” (see Figure 1). This 
demonstrates that in Opti-MEM®, LF-LPXs can transfect equally well cells that are below (Figure 1) 
or on top (Figure 5) of the LF-LPX solution, thereby ruling out the possibility that only aggregates 
contribute to the transfection efficiency. Following the incubation of LF-LPXs for 1 and 3 h in the 
ascites fluid, the transfection efficiency decreased to 40% in the upside-down transfection mode 
(Figure 5), while this decrease was not observed in the “normal transfection mode” (see Figure 1). 
Our data suggest that in the “upside-down transfection mode”’, the non-aggregated fraction of the 
LF-LPXs can reach 40% of the cells, while in the “normal transfection mode” an additional 40% of 
cells are transfected by LF-LPXs aggregates that are formed in ascites fluid and sediment onto the 
cells. Therefore, aggregates can indeed contribute to the transfection efficiency, though they are 
not solely responsible for the observed biological activity. 
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Figure 5. Luciferase inhibition, following upside-down transfections by LF-LPXs, respectively, in Opti-MEM® 
and following incubation of the complexes for 1 and 3 h in ascites fluid. The values in the graph represent the 
average from at least three experiments that were performed on different days. 
 
4. Discussion 
siRNA-mediated downregulation of disease-related proteins is a very promising therapeutic 
application. Although numerous efficient NPs have been identified for successful siRNA delivery in 
vitro, the actual number of formulations that withstand the harsh in vivo conditions is extremely 
disappointing. In vivo, NPs face additional barriers such as protein-rich biofluids that are not 
present in the widely used protein-low conditions when screening NPs in vitro. Hence, the influence 
of extracellular fluids on the nanoparticle performance after administration to the human body is 
often overlooked. In this study, we evaluated the potential of non PEGylated and PEGylated 
liposomal formulations to successfully deliver siRNA to a human ovarian cancer cell line. 
Considering the potential use of locoregional administration of lipid-based siRNA carriers to treat 
peritoneal metastasis, NPs in this study were tested in human ascites fluid obtained from a PC 
patient. Additionally, biological activity was determined in the widely used low protein content 
medium Opti-MEM®. Importantly, solely on the basis of the transfections in this low-protein 
medium, all formulations performed to expectations. Unfortunately, when incubating the 
formulations in a high-protein-content medium (i.e., ascites fluid in this study), only LF-LPXs were 
able to keep their original efficiency. To explain the drop in transfection efficiency, we evaluated 
three important properties of the NPs, namely premature siRNA release, nanoparticle aggregation, 
and cellular uptake in the presence of human ascites fluid. The complexation of siRNA to (cationic) 
carriers is necessary to enhance the cellular uptake of these negatively charged nucleic acids. 
Hence, the premature release of siRNA from the nanocarriers in the biofluids before cellular uptake 
has taken place will result in a lower amount of siRNA that is able to reach the cytoplasm of the 
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cells. Using FCS, we found that all tested formulations showed the release of siRNA in the presence 
of ascites fluid. This siRNA release most likely results from competition between siRNA and the 
abundantly present negatively charged proteins in the human ascites fluid for binding to the 
positively charged liposomes. Although testing the release of siRNA in protein-rich conditions can 
tell us something about the fraction of siRNA that is lost, it is important to note that the absolute 
values of complexed siRNA were not predictive for the expected biological activity. Indeed, all of 
the formulations end up with almost the same amount of remaining siRNA following 24 h of 
incubation (Figure 2), while clear differences in transfection efficiency exist (Figure 1). Because the 
uptake of NPs is both charge and size dependent, the aggregation of NPs can potentially influence 
the uptake profile and subsequent transfection efficiency [14]. Therefore, we evaluated whether 
the aggregation of the NPs was related to the obtained biological activity. Contrary to the release 
profile, the differences in aggregation between the formulations are much more pronounced. 
Aggregation is most pronounced in the case of the cationic LPXs, while in the case of C16 Cer-
LPXs, the PEG chains protect the LPXs from aggregation. One could argue that the formation of 
large aggregates could be the reason why lipofectamine RNAiMAX is still efficiently transfecting 
cells after incubation in ascites fluid. Indeed, aggregates are expected to sediment onto cells and, 
in this way, a larger amount of NPs (and thus concentration of siRNA) comes into contact with cells 
during the 4 h incubation period. When we ruled out this sedimentation with an upside-down 
transfection setup, however, LF-LPXs still retained 50% of their transfection efficiency, 
demonstrating that aggregation alone cannot be the sole reason for the better transfection 
efficiency of LF-LPXs. Aggregation of particles remains, however, extremely important for the in 
vivo situation because large aggregates can cause severe toxicity, such as blocking the blood 
capillaries. Therefore, aggregation studies remain predictive of the suitability of NPs for the in vivo 
situation, and one should keep in mind that strongly aggregated NPs have no future for in vivo 
use, even when high in vitro transfection efficiencies were obtained. Cellular uptake is a first 
important step of the intracellular journey of NPs. Importantly, the drop in the transfection of the 
cationic and PEGylated LPXs does correspond with the observation that the complexes are no 
longer internalized into cells after incubation in ascites fluid (Figure 4B). Because we measured the 
uptake based on fluorescent siRNA, a premature release of siRNA in the ascites fluid would lower 
the amount of complexed siRNA that can enter the cells and be detected. The amount of released 
siRNA in ascites fluid is, however, comparable for the three formulations studied (Figure 2). 
Because all formulations contained at least 40% of complexed siRNA, the possible internalization 
of the complexes should be detectable. The fact that only LF-LPXs are still taken up in the cells 
after pre-incubation in ascites fluid could in theory also be ascribed to the sedimentation of a 
larger amount of particles onto the cells. As described above, however, LF-LPXs also transfect (and 
thus are taken up) in an upside-down transfection setup to which larger aggregates do not 
contribute. When NPs are dispersed in extracellular fluids, proteins in these biofluids may bind at 
the surface of the NPs, forming a so-called protein corona. It has been shown that the protein 
corona formed around transferrin functionalized NPs impairs their ability to bind transferrin 
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receptors on the cell surface following incubation in fetal bovine serum and human serum [15,16]. 
Also, the protein corona can alter the intracellular processing of particles, increasing the fraction 
that accumulates in the lysosomes [17]. Both the protein composition of the biofluid and the 
surface properties of the NPs will determine the composition of the protein corona that is 
eventually formed. We have previously shown that the protein concentration in human ascites fluid 
is half the concentration of proteins present in human serum, while the protein composition of 
human ascites fluid is very similar to that of human serum, with albumin as main fraction (62%) 
[7]. We hypothesize that the poor uptake observed following the incubation of cationic LPXs and 
PEGylated LPXs in the ascites fluid results from the surface coating of these formulations with 
negatively charged proteins [5]. It is worth mentioning that this is not the first study showing that 
NPs lose their ability to interact with biological membranes following incubation with a protein rich 
biological environment. Interestingly, very recently, Hadjidemetriou et al. also reported that bare 
and PEGylated liposomes significantly lost their ability to internalize into cells following incubation 
in undiluted plasma [18]. This points out that the detrimental effect of human ascites fluid on the 
internalization of NPs could be a common problem for many nanoparticle formulations exposed to 
various biological fluids. As for nucleic acid delivery, uptake is necessary for biological activity, and 
testing the uptake of gene delivery systems following incubation in undiluted biological fluids is 
extremely important and should become a routine test before performing in vivo studies. Taken 
together, the “protein corona field” is rapidly growing with new findings that are extremely 
important for translating the in vitro to the in vivo situation but is still not getting enough attention 
among scientists in the RNAi-delivery community.  
 
5. Conclusion 
Importantly, we found that good complexation and transfection properties in reduced serum 
conditions like Opti-MEM® are not predictive of the actual performance of NPs after being exposed 
to more complex biological fluids, such as human ascites fluid. On the basis of our results, we 
determined that the most important factor that eventually determines the biological activity is the 
biological fluid in which the particles are incubated with prior to adding them onto cells. The 
composition of the biological fluid may substantially influence the extent of release, aggregation, 
uptake, and biological activity of nano-sized siRNA formulations. Therefore, we strongly 
recommend performing in vitro optimization of nano-sized siRNA formulations in undiluted 
biological fluids, taking into account the route of administration regardless of the type of the 
formulation (lipid-based or polymer-based), before assessing the transfection efficiency of NPs in 
vivo. Because most biofluids, such as peritoneal fluid in the case of IP gene delivery and serum or 
blood in the case of intravenous (IV) delivery, are relatively easily accessible, testing NPs in these 
more complex biological environments is very feasible and far more representative for the in vivo 
situation.  
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On the basis of assays performed in protein free (Opti-MEM®) conditions only, we determined that 
one runs the risk of selecting NPs that are able to cross an empty street, hoping they will also 
survive the busy traffic conditions in vivo. Just like earning a driving license, however, NPs should 
be tested in realistic in vitro conditions so that in vivo animal testing can be restricted to only 
those particles that passed the relevant screening conditions. 
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Abstract 
Delivery of small interfering RNA (siRNA) is recently gaining tremendous attention for the 
treatment of ovarian cancer. The present study investigated the potential of different liposomal 
formulations composed of (2,3-Dioleoyloxy-propyl)-trimethylammonium (DOTAP) and 1,2-
Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) encapsulating siRNA (hydration method) for 
their ability to knockdown luciferase (Luc) activity in human ovarian cancer SKOV-3 cells. 
Fluorescence Single Particle Tracking (fSPT) and fluorescence correlation spectroscopy (FCS) in 
human undiluted ascites fluid obtained from a PC patient revealed that cationic hydra-lipoplexes 
(HYDRA-LPXs) and HYDRA-LPXs decorated with stable DSPE-PEG (DSPE HYDRA-LPXs) showed high 
stability during at least 24 h. HYDRA-LPXs decorated with sheddable C8 and C16 PEG-Ceramides 
(Cer HYDRA-LPXs) resulted in rapid and premature release of siRNA already in the first hours. 
Despite their role in preventing aggregation, liposomes decorated with stable PEG residues 
resulted in a poor transfection compared to the ones decorated with sheddable PEG residues in 
reduced serum conditions. Yet, the transfection efficiency of both Cer HYDRA-LPXs significantly 
decreased following 1 hour of incubation in ascites fluid due to a drastic drop in the cellular uptake, 
while DSPE HYDRA-LPXs are still taken up by cells, but too stable to induce efficient gene silencing.  
Keywords: siRNA delivery, siRNA encapsulation, peritoneal metastasis, sheddable PEG, ascites  
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1. Introduction 
Small interfering RNA (siRNA) therapeutics hold great potential for the treatment of different 
diseases, such as neurodegenerative pathologies, genetic and metabolic disorders and cancer [1, 
2]. To ensure their therapeutic activity, siRNA-based medicines should be delivered into the 
cytoplasm of the target cell where the natural RNAi machinery could be engaged. Towards this 
goal, complexation or encapsulation of siRNA within nano-sized particles is being utilized to protect 
the siRNA from blood nucleases and other extracellular components with the aim to increase the 
fraction that enters into cells following administration. Apart from protection of the siRNA against 
nucleases , these nano-carriers should also (i) be resistant to the formation of large aggregates 
while circulating in the extracellular biofluids, (ii) prevent premature release of the siRNA before 
reaching the target cell [3], and (iii) (sufficiently) interact extracellularly with the plasma 
membrane and intracelluarly with the endosomal membrane, an interaction which is essential for 
therapeutic activity of siRNA [3, 4]. 
Over the last decade, both polymeric and lipid nanoparticles (LNPs) were employed for 
siRNA delivery [2, 5]. Due to the negative charge of the siRNA, cationic lipid-based and polymeric 
NPs are widely used to obtain spontaneous electrostatic interactions and protect the siRNA from 
degradation [6-8]. The most important difference between the lipid-based and polymeric vehicles 
is that the majority of the cationic polymers do not contain a hydrophobic tail, and thus are 
completely soluble in water. Also, cationic polymers can be synthesized in different molecular 
weights and shapes (linear versus branched) and can be more easily tuned with functional groups, 
to influence, for example, the intracellular trafficking of the vehicles and their biological activity [8, 
9]. Generally speaking, LNPs contain a lipid bilayer-disrupting lipids that are activated by low 
endosomal pH, whereas polymers are very easy to modify and control their structure in a way that 
they become positively charged in acidic endosomes in order to enhance endosomal escape of 
siRNA [10].     
Lipid nanoparticles (LNPs) have been extensively investigated as candidates for siRNA 
delivery in cancer therapy [11]. Currently, LNPs represent the most promising platform for 
systemic delivery of siRNAs, with lipid-based formulations in clinical trials for the treatment of 
different diseases [2, 5]. Despite major advances with LNPs for siRNA delivery, the main challenge 
remains their colloidal stability within the fluids of the body. In this context, grafting LNPs with 
polyethylene glycol (PEG) is the most common strategy to prevent aggregation and prolong their 
half-life in the circulation [12]. PEGylation, however, has been associated with poor biological 
activity of siRNA [12]. It is speculated that PEG chains significantly decrease the uptake of LNPs by 
cells and disrupt their interaction with the endosomal membrane [4, 13]. For instance, increasing 
the PEGylation of siRNA-lipoplexes (siRNA-LPXs) from 2 to 5 mol% dramatically diminished the 
siRNA gene silencing in vivo [14]. Furthermore, it has been postulated that multiple administration 
of stabilized PEGylated lipid particles (SPLP), induced a strong immune response against PEG, 
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resulting in accelerated blood clearance [15-17]. Worth mentioning also is that PEG residues 
interfere with the electrostatic interactions between negatively charged siRNA and positively 
charged lipids resulting in a low complexation/encapsulation efficiency. Also, we observed that 
PEGylation leads to the rapid premature release of the siRNA from the surface of the liposomes in 
different biological fluids [18-20]. Therefore, when tailoring LNPs for in vivo siRNA delivery, a 
delicate balance between avoiding (i) aggregation, (ii) premature release, (iii) immune responses 
and realizing efficient intracellular release of siRNA in the cytoplasm of cells should be installed to 
overcome PEG-associated problems. In this respect, an interesting approach could be the use of 
‘exchangeable’ PEG-derivatized lipids, also called “sheddable PEG”, which diffuse out of LPXs upon 
contact with biological membranes, depending on the length of the acyl chain of the lipid anchor. 
Among the most used sheddable PEG-lipids are ceramides (Cer-PEG) and diacylglycerols (PEG-S-
DAGs) [21, 22]. 
Ovarian cancer leads to more than 140,000 deaths annually in women around the world 
[23]. In the majority of the cases, ovarian cancer often migrates to the peritoneal cavity forming 
fatal PC. Interestingly, IP administration of different drugs has recently shown some advantages to 
treat peritoneal tumors when compared to intravenous administration, mainly due to high 
concentrations of drug at the tumor site following IP administration [24-26]. Also, the delivery of 
siRNA to ovarian cancer cells using different nano-sized carriers is recently gaining increasing 
attention in cancer therapy [27-30]. It has been reported that the co-delivery of chemotherapeutic 
agents with siRNA is an efficient strategy to enhance tumor killing effect and overcome resistance 
of cancer cells when compared to delivery systems carrying either siRNA or chemotherapeutics 
alone [31-33]. First of all, siRNAs can specifically silence cancer associated genes, causing less 
side effects in non-cancer cells. Moreover, siRNA is not limited to target receptors that are 
expressed on the surface of cancer cells, but can also silence genes associated with intracellular 
targets [34]. 
In this study, we investigate the suitability of different liposomes (cationic, PEGylated and 
grafted with diffusible Cer-PEG) composed of DOTAP and DOPE (as lipids) encapsulating siRNA 
within the aqueous core (prepared by the hydration method) [18, 35] to knockdown luciferase in 
the human ovarian cancer cell line SKOV-3. Initially we employ advanced fluorescence microscopy 
techniques, such as fluorescence correlation spectroscopy (FCS) and fluorescence single particle 
tracking (fSPT) [36, 37] to follow the release and aggregation of the LPXs in ascites fluid obtained 
from a PC patient. Additionally, we test the uptake, toxicity and silencing efficiency of all the 
formulations. We hypothesized that liposomes encapsulating siRNA and decorated with diffusible 
Cer-PEG may be an attractive strategy to target tumors confined within the peritoneal cavity 
following IP adminstration, as they represent a fine balance between PEGylation and de-PEGylation 
[38].   
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2. Materials and methods 
2.1 Materials 
(2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride (DOTAP) and 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were purchased from Corden Pharma LLC (Liestal, Switzerland). 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-
PEG), N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene-glycol)2000]} (C16 mPEG 2000 
Ceramide), N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]} (C8 mPEG 
2000 Ceramide) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Chloroform, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) and sodium chloride (NaCl) were purchased from Sigma 
Aldrich (Bornem, Belgium).  
Penicillin-Streptomycin (5000 U/ml), L-Glutamine (200 mM), 0.25% Trypsin-EDTA (1X) Phenol 
Red, McCoy's 5A (Modified), Opti-MEM® and 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine perchlorate (DID) (λex= 644 nm, λem= 665 nm) were purchased 
from Invitrogen (Merelbeke, Belgium). Luciferase Assay Substrate was purchased Promega 
(Madison, WI, USA). Fetal Bovine Serum (FBS) was purchased from HyClone® Thermo Scientific 
(Cramlington, UK). Passive Lysis Buffer and Luciferase Assay Kit were purchased from (Promega, 
Leiden, Netherlands).  
2.2 Preparation and characterization of the HYDRA LPXs  
Liposomes corresponding to 5 mM of DOTAP and 5 mM of DOPE lipids were prepared by mixing the 
appropriate amount of each lipid in a round bottomed flask before evaporation. PEGylated 
liposomes were prepared by adding the desired amounts of DSPE-PEG, or C8 Cer-PEG or C16 Cer-
PEG dissolved in chloroform (corresponding to 5 mol% the total lipids) to the lipids before 
evaporation. A lipid film was formed by rotary evaporation of the chloroform at 40°C.  
To obtain the so named ‘HYDRA LPXs’, the dried lipid film was hydrated with a siRNA solution in 
HEPES buffer (20 mM, pH 7.4) resulting in LPXs with a charge ratio of ± 8. Finally, the obtained 
solution was sonicated using a probe sonicator (Branson Ultrasonics Digital 
Sonifier®,Danbury,USA).We showed previously that this method results in the encapsulation of 
50% of the complexed siRNA inside the liposomes and 50% bound to the outer surface of the 
liposomes [35]. The average size and zeta potential of all formulations were measured using 
Zetasizer Nano-ZS (Malvern, Worcestershire, UK). 
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2.3 Fluorescence Single Particle Tracking (fSPT) 
Fluorescence Single particle tracking (fSPT) is a fluorescence microscopy technique which is used 
to characterize the diffusion of nanoparticles. Briefly, fSPT makes use of a fast CCD camera and 
wide-field laser illumination to obtain movies of single, fluorescently labeled particles in biological 
media. The movies are then analyzed by using in-house image processing software [36], where 
the motion trajectories and subsequently the diffusion coefficient of each individual particle is 
calculated. Based on the trajectories of all the particles, it is possible to make a distribution of 
diffusion coefficients, which is then converted into size distribution using the Stokes-Einstein 
equation given the viscosity of the biofluid at which the experiment was performed is known. 
Finally, the distribution is refined by the maximal entropy method [36]. We have previously shown 
that fSPT is ideally suited to characterize the size (and thus the extent of aggregation) of 
nanoparticles in biological fluids like human serum, ascites fluid, human plasma, and blood [3, 20, 
36]. The main advantage of fSPT over the widely used sizing techniques such as Dynamic Light 
Scattering (DLS), is the ability to perform sizing measurements in undiluted biological fluids, 
without the influence of the proteins present in these fluids [3].  
fSPT measurements were performed on the HYDRA-LPXs (Cationic, 5% DSPE-PEG, 5% C8 Cer-
PEG, 5% C16 Cer-PEG) labeled with the lipophilic dye DID, that labels the lipid bilayer of the 
liposomes). LPXs were dispersed in biofluids as follows. First, formulations were diluted 400 times 
in HEPES buffer. Then 5 µl was added to 45 µl of biofluid (~90 vol% of ascites fluid), and 
incubated for 1, 2 and 3 h at 37°C in a 96-well plate (Greiner bio-one, Frickenhausen, Germany). 
fSPT-videos of the different formulations in the biofluids were recorded with the NIS Elements 
software (Nikon) driving the EMCCD camera (Cascade II:512, Roper Scientific, AZ, USA) and a 
TE2000 inverted microscope equipped with a 100_ NA1.4 oil immersion lens (Nikon) as previously 
described [3, 20] using the following values of viscosity at room temperature: 1.39 cP for human 
ascites fluid and 0.94 for HEPES buffer [3]. Human ascites fluid was obtained from a patient 
diagnosed with PC at the Medical Oncology Department of Ghent University Hospital (approved by 
the Ethics Committee of the Ghent University Hospital (no. 2013/589). 
2.4 Fluorescence Correlation Spectroscopy (FCS) on HYDRA LPXs  
FCS is a microscopy-based technique that monitors the fluorescence intensity fluctuations of 
molecules diffusing in and out of the focal volume of a confocal microscope [3]. When free 
fluorescently labeled siRNA molecules pass through the focal volume, a fluorescence baseline with 
an intensity that corresponds to the concentration of the free labeled siRNA molecules is obtained. 
When the siRNA is complexed/encapsulated within a carrier, the concentration of free siRNA drops 
and subsequently, a drop in the baseline intensity of the fluorescence signal occurs, accompanied 
with fluorescence fluctuations (i.e. peaks) each time a complex passes the focal volume. Release 
of siRNA, on its turn, results in an increase in the fluorescence baseline. An important advantage 
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of FCS is the low volume of samples needed to perform the experiments (~50 µl). Our group 
showed before that FCS is ideally suited to measure the amount of siRNA that is 
released/associated from/with nano-sized carriers in various types of biofluids [3,4,15].  
FCS measurements were carried-out on HYDRA-LPXs containing 30% Cy-5 siRNA and 70% non-
labeled siRNA, with a charge ratio of ± 8. 5 µl of LPXs were diluted to a final volume of 50 µl in 
respectively HEPES buffer or ascites fluid (~ 90 vol%) and FCS measurements were done (i) 
immediately after diluting the LPXs (in HEPES or ascites fluid), (ii) 1 h and (iii) 24 h after 
incubation with the biofluids at 37°C. FCS measurements were performed on a C1si laser scanning 
confocal microscope (Nikon, Japan), equipped with a time-correlated single photon counting 
(TCSPC) data acquisition module (Picoquant, Berlin, Germany). The laser beam was held 
stationary and focused through a water immersion objective lens (Plan Apo 60, NA 1.2, collar rim 
correction, Nikon, Japan) at ~ 50 µm above the bottom of the glass-bottom 96-well plate (Grainer 
Bioone, Frickenhausen, Germany), which contained the fluorescent LPXs. The 633 nm laser beam 
was used to record fluorescence intensity fluctuations using SymPhoTime (Picoquant, Berlin, 
Germany).  
2.5 Cell culture 
The human ovarian cancer cell line SKOV-3 which stably expresses firefly luciferase was used for in 
vitro experiments. Cells were cultured in McCoy's 5A medium supplemented with FBS, Penicillin-
Streptomycin and L-Glutamine. Cells were cultured until 80% to 90% confluency and detached 
from tissue culture dishes with 0.25% trypsin. Cells were maintained in an incubator at 37°C in a 
humidified atmosphere with 5% CO2.   
2.6 Cell viability assay  
The MTT assay was used as a measure of cell viability following incubation of the studied 
formulations with a final negative control siRNA concentration of 10, 15 and 20 nM. SKOV-3 cells 
were cultured on 24-well tissue culture plates (35,000 cells per well). On the next day, cells were 
incubated for 4 h with 500 µl Opti-MEM® containing the LPXs of interest or 30% of ethanol as 
positive control. Then, cells were washed and incubated with McCoy's 5A medium for an additional 
24 h. Thereafter, 100 µl of MTT stock solution (5 mg/ml MTT in PBS) in McCoy's 5A was added to 
each well and incubated for 3 h. After aspirating the medium, 500 µl of DMSO was added to each 
well in order to dissolve the formazan crystals. The plates were covered with aluminum foil, placed 
on an orbital shaker for 10 min and the absorbance of the formed formazan crystals was 
determined at 590 nm with reference at 690 nm using a Wallac EnvisionTM multilabel reader 
(PerkinElmer, Zaventem, Belgium). Percentages of cell viability for each sample were calculated as 
follows: (absorbance of the sample / absorbance of the negative control) x 100%.   
 
 
  
114 | Chapter 5 
 
2.7 Internalization of siRNA into SKOV-3 cells 
SKOV-3 cells were plated on 24-well plates (35,000 cells in each well) and allowed to grow in an 
incubator for 24 h. Cells were incubated with the formulations containing 10% Alexa Fluor-488 
siRNA at a final siRNA concentration of 15 nM for 4 h at 37°C. At the end of the incubation, cells 
were washed extensively with warm growth medium and PBS, then detached using trypsin and 
analyzed by FACS (FACSCalibur Flow Cytometer, BD Biosciences, USA). Uptake experiments were 
done with LPXs administered in Opti-MEM® or with LPXs which were first incubated for 1 h in 
human ascites fluid, as previously described [20]. Uptake experiments in the ascites fluid were 
performed by incubating 300 µl of each of the studied formulations with 700 µl of ascites fluid for 1 
h at 37°C. Then, 300 µl of the mixture were added in triplicates to 700 µl of Opti-MEM® in each 
well of a 24 well-plate. After 4 h of incubation at 37°C, cells were washed, detached and analyzed 
as described above.  
 
2.8 Transfection efficiency 
SKOV-3 cells were cultured on 24-well plates (35,000 cells/well) in 500 µl of medium containing 
10% FBS 24 h prior to the transfection. Cells were incubated with HYDRA-LPXs at a final siRNA 
concentration of 15 nM respectively in Opti-MEM® or following 1 h of pre-incubation in ascites fluid 
as previously explained [20]. After 4 h incubation, the transfection medium was replaced by 
culture medium and cells were returned to the incubator for 24 h. Then, cells were lysed with 
Passive Lysis Buffer and analyzed for firefly luciferase expression using the luciferase assay kit 
(Promega). The bioluminescence (Relative Light Units, RLU) was measured using a GloMax 
Luminometer (Promega). The percentage of luciferase downregulation was determined by the 
following equation:  
% transfection = 100 – (100 x RLUluc/RLUctrl), where RLUctrl is the mean for control siRNA and 
RLUluc is the mean for luciferase siRNA. Transfection experiments were performed in triplicates on 
three different days. For transfections in the ascites fluid, 300 µl of each HYDRA-LPX (of each 
formulation) were incubated with 700 µl ascites fluid and incubated for 1 h at 37°C. Thereafter, 
300 µl of the mixture was added to 700 µl of Opti-MEM® in each well of a 24 well-plate. Then, the 
medium was replaced with growth medium and cells were returned to the incubator for 24 h, as 
described above.  
 
2.9 Statistical analysis 
Statistical analysis on the transfection data (Figure 5) was performed using GraphPad Prism 6. 
Data are presented as means ± SD. Statistically significant differences were calculated by using an 
analysis of variance (ANOVA) at a 0.05 significance level, followed by Sidak’s post-test. For each 
formulation, transfection experiments carried out in Opti-MEM® were compared to these in ascites 
fluid. 
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3. Results 
3.1 Characterization of the studied LPXs 
Table 1 shows the size and zeta potential of the different used formulations. In the 
hydration method, formulations were prepared by hydrating the lipid film with siRNA directly. This 
results in liposomes in which the siRNA is also encapsulated inside the aqueous core of the 
resulting LPXs, as well as being complexed to the outer surface of the liposomal formulations. As 
depicted in Table 1, all the studied formulations resulted in nano-sized vesicles, as determined by 
dynamic light scattering (DLS). When compared to empty liposomes, the size increased for all 
formulations when LPXs were formed, except for the 5% C16 Cer HYDRA-LPXs. 
As expected, both PEGylation and the addition of siRNA influenced the charge of the 
liposomes. Introducing PEG chains on the surface of the liposomes results in shielding of the 
positive charge from about 56 mV for the cationic liposomes to about 17-20 mV for the PEGylated 
ones. Encapsulation of siRNA resulted in a further decrease of the charge, except for the 5% C16 
Cer HYDRA-LPXs.   
 
Table 1. Hydrodynamic diameter and ζ-Potential of the liposomes only or loaded with siRNA at pH 7.4.  
Formulation 
Z-average 
diameter ± SD 
(nm) 
Polydispersity 
index (PDI) 
ζ-potential 
(mV) (mean 
±SD) 
Abbreviation 
Cationic 
liposomes 
86 ± 1 0.2 56 ± 1 Cationic LP 
HYDRA-LPX 135 ± 3 0.25 46 ± 1 HYDRA- LPXs 
5% DSPE-PEG LP 93 ± 1 0.2 17 ± 1 DSPE-LP 
5% DSPE-PEG 
LPX 
129 ± 3 0.25 14 ± 1 DSPE HYDRA-LPX 
5% C8 Cer-PEG  93 ± 1 0.33 18 ± 1 5% C8 Cer-LP 
5% C8 Cer-PEG 
LPX 
106 ± 1 0.24 13 ± 1 
5% C8 Cer 
HYDRA-LPX 
5% C16 Cer-PEG 
LP 
115 ± 2 0.24 6 ± 1 5% C16 Cer-LP 
5% C16 Cer-PEG 
LPX 
115 ± 1 0.25 6 ± 1 
5% C16 Cer 
HYDRA-LPX 
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3.2 Aggregation of the formulations in undiluted ascites fluid 
In our previous study we have shown that DLS is not an ideal technique for characterizing 
aggregation of nanoparticles in biological fluids, simply due to scattering that results from e.g. the 
proteins in the biofluids [3]. fSPT has proven to be superior over DLS for this purpose [3, 36]. 
Figure 1A shows the size distributions of the HYDRA-LPXs as measured by fSPT. In agreement with 
the DLS outcomes in Table 1, HYDRA-LPXs have an average size around 100 nm when measured in 
HEPES buffer (Figure 1A, black curve). Following 1 h of incubation in ascites fluid, the size 
distribution is shifted to the right (red curve), with a peak diameter around 200 nm. Upon longer 
times in ascites fluids, aggregation of the HYDRA-LPXs seemed somehow to continue, resulting in 
HYDRA-LPXs with a peak diameter of 300 nm (Figure 1A, blue curve). After 3 h of incubation, the 
size distributions did not further change, indicating the aggregation reached an equilibrium already 
after 2 h (Figure 1A, green curve).  
Next, we were interested if PEGylation would further inhibit the aggregation of HYDRA-LPXs. Two 
types of PEGylation were tested, namely the incorporation of respectively stable, non-
exchangeable DSPE-PEG chains, and exchangeable PEG-Ceramides. In the case of the DSPE-PEG 
HYDRA-LPXs (Figure 1B), initially a minor aggregation was observed following incubation in ascites 
fluid when compared to the distribution in HEPES buffer (~ 150 nm). Then, the PEGylated 
complexes remained stable, resulting in particles of about 250 nm in diameter. For the 5% C8 Cer 
HYDRA-LPXs, the size in HEPES buffer was around 100 nm (Figure 1C) and increased to 200 nm 
after 1 h of incubation in ascites fluid. Surprisingly, further incubation in ascites fluid for 2 and 3 h 
resulted again in smaller 5% C8 Cer HYDRA-LPXs of 150 nm and less. The SPT data in Figure 1D 
for the C16 Cer HYDRA-LPXs exhibit a similar behavior to the C8 Cer HYDRA-LPXs, with an 
equilibrium reached after 1 h of incubation in ascites fluid, and a peak diameter of about ~250 nm. 
Taken together, all the formulations seemed sufficiently stable in the ascites fluid: no micrometer-
sized aggregates were observed and the size of all LPXs remained sufficiently small to allow 
endocytosis by cells.   
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Figure 1. fSPT size distributions of the different formulations following incubation in 90 vol % human 
ascites fluid at 37 °C. (A) HYDRA-LPX, (B) DSPE HYDRA-LPX, (C) 5% C8 Cer HYDRA-LPX and (D) 5% C16 Cer 
HYDRA-LPX.  
 
3.3 Release of siRNA from the formulations in undiluted ascites fluid 
As demonstrated previously, FCS is a suitable method to follow the release of siRNA from different 
types of formulations in undiluted biological fluids [3, 19, 20]. Figure 2 displays the complexation 
efficiency of the studied formulations. HYDRA-LPXs show a high complexation efficiency with about 
80% of the siRNA complexed with the liposomes immediately after preparation in HEPES buffer 
(Figure 2, white bars) and during 24 h (grey and green bars). Following 1 h of incubation (Figure 
2, blue bars), a burst release was observed leading to about 40% complexed siRNA (60% of free 
siRNA). This release is highly likely ascribed to the siRNA which is bound on the surface of the 
liposomes and not actually encapsulated inside. No substantial further release was noted after 24 
h of incubation in ascites fluid, demonstrating that eventually about 35% of the siRNA was 
encapsulated within the aqueous core of the liposomes (magenta bars). PEGylation clearly 
influenced the complexation efficiency and release profile of the studied formulations. For DSPE 
HYDRA-LPXs, only 50% of the siRNA is complexed immediately after preparation, suggesting that 
PEGylation lowers the siRNA complexation efficiency (white bars). This 50% of siRNA, however, 
can be retained in the DSPE HYDRA-LPXs for the complete 24 h incubation period and is therefore 
most likely encapsulated inside the liposomes (Figure 2, magenta bars). For the Cer HYDRA-LPXs, 
the effect of PEGylation was even more pronounced, with 70% and 75% of free siRNA (e.g. 
uncomplexed) as such in HEPES buffer for the 5% C8 Cer and 5% C16 Cer HYDRA-LPXs 
respectively. Following 24 h of incubation in ascites fluid, both Cer HYDRA-LPXs resulted in around 
90% of free siRNA (Figure 2, magenta bars). 
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Figure 2. Complexation efficiency of the studied formulations immediately following preparation (white bars), 
1 h (grey bars) and 24 h (green bars) following incubation in HEPES buffer, and percentage of complexed siRNA 
after incubation of the formulations in 90 vol % of human ascites fluid during 1 h (blue bars) and 24 h (magenta 
bars). 
3.4 Cytotoxicity of the studied formulations 
The toxicity of the formulations was assessed on SKOV-3 human ovarian cancer cells using 
a MTT assay. As can be seen in Figure 3, the formulations did not exhibit any severe decrease in 
the metabolic activity of the cells, with maximum 20% mortality for the highest siRNA 
concentrations of 20 nM. A decrease in the cell viability was observed with increasing siRNA 
concentrations. To stay within the non-toxic range of concentrations, we decided to perform 
uptake and transfection experiments with a final concentration of 15 nM.  
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Figure 3. Outcomes of the cell viability assay (MTT). For each formulation the toxicity of the liposomes and 
LPXs was evaluated using 3 different concentrations, 10 nM (dark grey bars), 15 nM (white bars) and 20 nM (grey 
bars), respectively. Results are expressed as mean ± SE.  
3.5 Cellular uptake and transfection efficiency of the formulations by SKOV-3 cells 
To evaluate the ability of the different formulations to knockdown the expression of a specific 
gene, SKOV-3 cells stably expressing luciferase were incubated with the formulations containing 
siRNA against luciferase (luc siRNA). To verify the knockdown specificity, luc siRNA formulations 
were compared to the same formulations loaded with a scrambled negative control siRNA.  
We have recently proven the importance of performing uptake experiments of formulations 
carrying siRNA in the relevant biofluid [20]. Uptake is a key feature in siRNA delivery, since naked 
siRNA cannot internalize into cells due to its negative charge and hydrophilicity. To test whether 
the formulations are capable of delivering siRNA into cells, we incubated SKOV-3 cells with 
fluorescently labeled LPXs and followed their uptake with flow cytometry. The outcomes of the 
uptake experiments shown in Figure 4 indicate that all the formulations are internalized into SKOV-
3 cells at 37°C when incubated in serum reduced media (i.e. Opti-MEM®), represented by high 
percentage of positive cells (Figure 4, white bars). Following 1 h of incubation in ascites fluid 
(Figure 4, grey bars), however, all the formulations significantly lose their ability to be taken up by 
cells, except for the DSPE-HYDRA LPXs where cellular uptake still occurs. 
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Figure 4. Uptake of AF-488 siRNA-labeled formulations by SKOV-3 cells. The studied formulations were 
prepared in HEPES buffer and added to the cells in Opti-MEM® following preparation as such (white bars) or after 
incubation for 1 h in human ascites fluid before adding them on the cells (grey bars). 
Figure 5 depicts the transfection efficiency of the studied formulations in Opti-MEM® (white bars) 
and following 1 h of incubation in ascites fluid (grey bars). In Opti-MEM®, it can be seen that only 
DSPE HYDRA-LPXs resulted in a very poor transfection efficiency (37%). All other formulations 
demonstrated high and significant downregulation of 70% for the HYDRA-LPXs, 73% for the 5% 
C8 Cer HYDRA-LPXs and 80% for the 5% C16 Cer HYDRA-LPXs. Following incubation in ascites 
fluid, however, all the formulations lost their ability to silence luciferase, when compared with the 
situation in Opti-MEM®. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Inhibition of luciferase in SKOV-3 cells by the formulations in Opti-MEM® (white bars) and 
following incubation of the LPXs for 1 h in ascites fluid (70 vol %) (grey bars). The values in the graph represent the 
average from at least three experiments that were performed on different days. 
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4. Discussion  
4.1 Choice of the study  
The final goal of this study is to assess the suitability of liposomal-based formulations 
loaded with siRNA via the hydration method and possessing different surface modifications in 
undiluted ascites fluid obtained from a PC patient for siRNA delivery. As a follow-up of our previous 
study [3] and towards enhancing the stability of LPXs and maximizing their biological activity, we 
focused on two main aspects: 1) the siRNA loading method and 2) the PEGylation strategy. On the 
level of loading, we used the hydration method [18, 35], while on the level of PEGylation we 
decided to evaluate the stable DSPE-PEG, diffusible C8 and C16 Cer-PEG. The different PEG-chains 
were chosen to understand whether Cer-PEGylation can still play a role in preventing aggregation 
in the extracellular IP fluid, while the diffusion of the PEG-chains out of the liposomal formulations 
upon interaction with biological membranes would enhance the cellular uptake and endosomal 
escape on the intracellular level. In this context, Cer-PEG with shorter C8 acyl chain lipids (C8) 
seems to be best candidates for local IP delivery, due to the rapid exchange rate of the Cer-PEG 
from the surface of the liposomes, compared to the longer acyl chains (C20) [39]. Additionally, C8 
Cer-PEG were successfully exploited to deliver plasmid DNA for regional gene therapy [40].  
 
4.2 Influence of PEGylation on encapsulation efficiency  
It is of interest to point out the differences between the hydration technique used in this 
study and the widely used complexation technique. With the conventional complexation technique, 
liposomes are prepared by hydrating the lipid film with a buffer solution. Then, LPXs are prepared 
by the simple mixing of siRNA and the preformed liposomes, taking advantage of the electrostatic 
interactions between the negatively charged siRNA and the cationic liposomes. In this case the 
siRNA binds on the surface of the liposomes, and is not encapsulated into the aqueous core. We 
have previously demonstrated, however, that the surface bound siRNA in this classic complexation 
protocol is easily displaced when the liposomes are dispersed in biofluids such as human serum or 
ascites fluid, especially when PEGylated liposomes are used [3].  
We hypothesized that when using the hydration protocol [35], which ensures an even 
distribution of the negatively charged siRNA over the inner and outer core of a cationic lipid, the 
premature release of siRNA in the ascites fluid could be overcome [35]. Indeed, only the surface 
bound siRNA is expected to be released from the LPXs in the biofluids, while the siRNA 
encapsulated in the aqueous core is protected from premature release. Figure 2 demonstrated that 
this hypothesis was valid to some extent. We have previously shown that 5% DSPE-PEG LPXs 
prepared with the classic complexation method, release the majority of the complexed siRNA 
immediately after incubation with ascites fluid [3]. For DSPE HYDRA-LPXs, however, 50% of the 
siRNA is still encapsulated within the liposomes following 24 h of incubation in ascites fluid (Figure 
2). This agrees with our assumption that with the hydration method, the siRNA within the aqueous 
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core of the liposomes is protected from the external environment, and thus the negatively charged 
proteins (mainly albumin) which compete for binding to the liposomes. Also the non-PEGylated 
HYDRA-LPXs retain about 35-40% of the complexed siRNA within the aqueous core after 24 h of 
incubation in ascites fluid, following the initial burst release of the siRNA which is complexed on the 
surface of the liposomes and exposed to the proteins in the ascites fluid. Unfortunately, the high 
stability of the HYDRA-LPXs and DSPE HYDRA-LPXs was not observed for the formulations 
containing C8 and C16 Cer-PEG chains. Both formulations resulted in the formation of complexes 
with a low complexation efficiency of siRNA. Also, the majority of siRNA that was complexed, is 
released almost immediately following incubation in ascites fluid. This rapid and premature release 
most likely stems from a re-organization on the level of the lipid bilayer upon introducing the C8 
and C16 Cer-PEG chains within the lipid bilayer, resulting in a smaller aqueous core and 
consequently lower complexation efficiency where most of the siRNA is free or attached to the 
surface of the complexes.  
 
4.3 Influence of stability on biological activity  
While extracellular stability is one of the major concerns when designing siRNA delivery systems, 
the internalization and intracellular interactions with the different organelles are key factors to 
ensure maximal biological activity. The size and the charge of the studied formulations (Table 1) 
suggest that these complexes can cross biological membranes and deliver the siRNA into cells 
(Figure 4). Also, all PEGylated formulations used in this study succeeded in preventing the 
aggregation of the liposomal formulations for at least 3 hours when incubated in ascites fluid 
(Figure 1). Therefore, each PEGylation strategy seems suitable to stabilize the formulations and to 
assure the presence of nano-sized formulations for a sufficiently long time to warrant cellular 
uptake. Following internalization, endosomal escape is essential to ensure delivery of siRNA in the 
cytoplasm and to induce efficient silencing of the target gene [4]. For the HYDRA-LPXs and Cer 
HYDRA-LPXs, substantial luciferase inhibition was observed when the incubation took place in Opti-
MEM® (Figure 5, white bars), except for the DSPE HYDRA-LPXs formulation. In the case of the 
HYDRA-LPXs, the cationic charge facilitates the interaction and destabilization of the endosomes, 
leading to fusion and eventually release of the siRNA into the cytosol. The fusion is further 
enhanced when a fusogenic “helper lipid” is incorporated within the liposomal formulation, such as 
DOPE in this case. It has been shown that upon acidification of the endosomal compartment DOPE 
triggers a conformational change from the stable lamellar phase into the highly unstable inverted 
hexagonal phase, which is thought to destabilize the endosomal membrane and release the cargo 
into the cytosol [41] . This conformational transition is not possible in the DSPE HYDRA-LPXs [42]. 
This explains the relatively low transfection efficiency of this formulation when compared with 
other formulations (Figure 5).  
When PEGylation is performed with sheddable Cer-PEG instead of stable DSPE-PEG chains, it can 
be seen that both Cer-PEG HYDRA-LPXs result in high transfection efficiency. The transfection 
efficiency of the Cer-PEG formulations is highly likely ascribed to the “de-PEGylation” that occurs 
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upon interaction of the Cer-PEG formulations with the cell membrane [42], and consequently, 
similar interaction with the endosomes as the one described above for the HYDRA-LPXs is 
expected.  
Since the final goal of this study is to determine the biological activity of the studied formulations 
in a relevant undiluted biofluid, we tested the transfection efficiency of all the formulations 
following incubation in ascites fluid obtained from a PC patient (Figure 5, grey bars). We are 
convinced that undiluted ascites fluids better resembles the in vivo peritoneal situation, not only in 
terms of stability, but also biological activity [20]. The drop in the transfection efficiency observed 
upon incubation in ascites fluid can be discussed on two levels: 1) cellular uptake of the studied 
formulations and 2) intracellular trafficking of the DSPE HYDRA-LPXs specifically following 
internalization. In particular, the HYDRA-LPXs and Cer HYDRA-LPXs are not internalized into SKOV-
3 cells following 1 h of incubation in ascites fluid (Figure 4). Consequently, the cargo (i.e. siRNA) is 
not delivered into the cytoplasm of the cell where it should be further processed by the RNAi 
machinery, leading eventually to the absence of biological activity depicted in Figure 5.  
Based on the stability data in Figure 1 and Figure 2, DSPE HYDRA-LPXs are protected from 
aggregation in the presence of ascites fluid and are able to keep the siRNA encapsulated for a 
sufficient long time to allow internalization into the cells. Therefore, the poor transfection efficiency 
observed for the DSPE HYDRA-LPXs is mainly due to the poor interaction with the endosomes, as 
also observed for the transfections in Opti-MEM®. The poor transfection efficiency of the DSPE-PEG 
formulation stands in line with recently published data, where DOTAP/cholesterol pDNA LPXs with 
2% DSPE-PEG diminished the transfection compared to the non-PEGylated LPXs in vitro [43]. 
Additionally, DOTAP DOPE LPXs loaded with survivin siRNA and grafted with 1% DSPE-PEG 
successfully downregulated the activity of survivin in cultured cells, but lost its activity in 
peritoneal tumors in vivo [33].  
Taken together, the findings of this study provide an evidence of the sensitive interplay that exists 
between extracellular stability, cellular uptake and biological activity when developing nano-sized 
siRNA formulations in protein-rich biological fluids. An optimal formulation designated for in vivo 
applications should fulfill all the requirements of colloidal stability, interaction with biological 
barriers, and intracellular trafficking in the relevant biofluid. One should keep in mind that 
formulations that show good stability and transfection characteristics in protein-free conditions 
such as Opti-MEM®, do not necessarily translate in potent formulations when transfections are 
being performed in the relevant biological fluids. For the formulations tested in this study, cellular 
uptake was the bottleneck for obtaining efficient gene knockdown, whereas poor intracellular 
processing was most probably the reason for the low gene knockdown observed with the only 
formulation taken up by the cells following incubation in undiluted ascites fluid (i.e. DSPE HYDRA-
LPX).The cellular uptake in this case was not a problem, since this formulation exhibited low 
transfection efficiency (Figure 5) even in protein-free conditions (i.e. Opti-MEM®), where efficient 
internalization occurred.  
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5. Conclusions  
In this study we tested the stability of different liposomal formulations for IP siRNA delivery based 
on the hydration technique and different types of PEGylation in human undiluted ascites fluid, as 
well as, the transfection efficiency in the SKOV-3 ovarian cancer cell line. We hypothesized that 
liposomes encapsulating siRNA and grafted with Cer-PEG chains would be an ideal platform for IP 
siRNA delivery. Nonetheless, our findings revealed that these carriers are not taken up by SKOV-3 
cells in protein-rich conditions (i.e. ascites fluid). On the contrary, liposomes encapsulating siRNA 
and coated with stable DSPE-PEG are endocytosed by SKOV-3 cells in protein-rich conditions, but 
are associated with poor biological activity highly likely due to insufficient intracellular processing.   
 
 
Acknowledgments 
GD is a doctoral fellow of the Flemish Government (Vlaamse overheid). WC is a senior clinical 
investigator of the Fund for Scientific Research – Flanders (FWO). The research was supported by 
the Research Foundation-Flanders (research project G006714N). We thank Senne Corneils for his 
help with the experiments.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
125 | Chapter 5 
 
References 
[1] M.R. Lares, J.J. Rossi, D.L. Ouellet, RNAi and small interfering RNAs in human disease therapeutic 
applications, Trends Biotechnol, 28 (2010) 570-579. 
[2] A. Wittrup, J. Lieberman, Knocking down disease: a progress report on siRNA therapeutics, Nat Rev 
Genet, 16 (2015) 543-552. 
[3] G.R. Dakwar, E. Zagato, J. Delanghe, S. Hobel, A. Aigner, H. Denys, K. Braeckmans, W. Ceelen, S.C. De 
Smedt, K. Remaut, Colloidal stability of nano-sized particles in the peritoneal fluid: towards optimizing drug 
delivery systems for intraperitoneal therapy, Acta Biomater, 10 (2014) 2965-2975. 
[4] T.F. Martens, K. Remaut, J. Demeester, S.C. De Smedt, K. Braeckmans, Intracellular delivery of 
nanomaterials: How to catch endosomal escape in the act, Nano Today, 9 (2014) 344-364. 
[5] R. Kanasty, J.R. Dorkin, A. Vegas, D. Anderson, Delivery materials for siRNA therapeutics, Nature 
Materials, 12 (2013) 967-977. 
[6] C.K. Chen, C.H. Jones, P. Mistriotis, Y. Yu, X.N. Ma, A. Ravikrishnan, M. Jiang, S.T. Andreadis, B.A. 
Pfeifer, C. Cheng, Poly(ethylene glycol)-block-cationic polylactide nanocomplexes of differing charge density 
for gene delivery, Biomaterials, 34 (2013) 9688-9699. 
[7] D.C. Forbes, N.A. Peppas, Polycationic Nanoparticles for siRNA Delivery: Comparing ARGET ATRP and UV-
Initiated Formulations, Acs Nano, 8 (2014) 2908-2917. 
[8] C.H. Jones, C.K. Chen, A. Ravikrishnan, S. Rane, B.A. Pfeifer, Overcoming Nonviral Gene Delivery 
Barriers: Perspective and Future, Mol Pharmaceut, 10 (2013) 4082-4098. 
[9] A. Elouahabi, J.M. Ruysschaert, Formation and intracellular trafficking of lipoplexes and polyplexes, Mol 
Ther, 11 (2005) 336-347. 
[10] S.K. Samal, M. Dash, S. Van Vlierberghe, D.L. Kaplan, E. Chiellini, C. van Blitterswijk, L. Moroni, P. 
Dubruel, Cationic polymers and their therapeutic potential, Chem Soc Rev, 41 (2012) 7147-7194. 
[11] C. Wan, T.M. Allen, P.R. Cullis, Lipid nanoparticle delivery systems for siRNA-based therapeutics, Drug 
Delivery and Translational Research, 4 (2014) 74-83. 
[12] L.C. Gomes-da-Silva, N.A. Fonseca, V. Moura, M.C.P. de Lima, S. Simoes, J.N. Moreira, Lipid-Based 
Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges, Accounts of Chemical 
Research, 45 (2012) 1163-1171. 
[13] S. Mishra, P. Webster, M.E. Davis, PEGylation significantly affects cellular uptake and intracellular 
trafficking of non-viral gene delivery particles, European Journal of Cell Biology, 83 (2004) 97-111. 
[14] A. Santel, M. Aleku, O. Keil, J. Endruschat, V. Esche, G. Fisch, S. Dames, K. Loffler, M. Fechtner, W. 
Arnold, K. Giese, A. Klippel, J. Kaufmann, A novel siRNA-lipoplex technology for RNA interference in the 
mouse vascular endothelium, Gene Therapy, 13 (2006) 1222-1234. 
[15] A. Judge, K. McClintock, J.R. Phelps, I. MacLachlan, Hypersensitivity and loss of disease site targeting 
caused by antibody responses to PEGylated liposomes, Mol Ther, 13 (2006) 328-337. 
[16] T. Tagami, K. Nakamura, T. Shimizu, T. Ishida, H. Kiwada, Effect of siRNA in PEG-coated siRNA-lipoplex 
on anti-PEG IgM production, Journal of Controlled Release, 137 (2009) 234-240. 
[17] T. Tagami, K. Nakamura, T. Shimizu, T. Ishida, H. Kiwada, Effect of siRNA in PEG-Coated siRNA-Lipoplex 
on the Anti-PEG IgM Production as Induced by the PEG-Coated siRNA-Lipoplex, Mol Ther, 17 (2009) S253-
S253. 
[18] K. Buyens, S.C. De Smedt, K. Braeckmans, J. Demeester, L. Peeters, L.A. van Grunsven, X.D. du Jeu, R. 
Sawant, V. Torchilin, K. Farkasova, M. Ogris, N.N. Sanders, Liposome based systems for systemic siRNA 
delivery: Stability in blood sets the requirements for optimal carrier design, Journal of Controlled Release, 158 
(2012) 362-370. 
[19] K. Buyens, B. Lucas, K. Raemdonck, K. Braeckmans, J. Vercammen, J. Hendrix, Y. Engelborghs, S.C. De 
Smedt, N.N. Sanders, A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in 
full human serum, Journal of Controlled Release, 126 (2008) 67-76. 
[20] G.R. Dakwar, K. Braeckmans, J. Demeester, W. Ceelen, S.C. De Smedt, K. Remaut, Disregarded Effect 
of Biological Fluids in siRNA Delivery: Human Ascites Fluid Severely Restricts Cellular Uptake of Nanoparticles, 
ACS Applied Materials & Interfaces, 7 (2015) 24322-24329. 
[21] E. Ambegia, S. Ansell, P. Cullis, J. Heyes, L. Palmer, I. MacLachlan, Stabilized plasmid-lipid particles 
containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression, 
Biochimica Et Biophysica Acta-Biomembranes, 1669 (2005) 155-163. 
[22] M.S. Webb, D. Saxon, F.M.P. Wong, H.J. Lim, Z. Wang, M.B. Bally, L.S.L. Choi, P.R. Cullis, L.D. Mayer, 
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the 
pharmacokinetics of liposomal vincristine, Biochimica Et Biophysica Acta-Biomembranes, 1372 (1998) 272-
282. 
[23] J. Hunn, G.C. Rodriguez, Ovarian Cancer: Etiology, Risk Factors, and Epidemiology, Clinical Obstetrics 
and Gynecology, 55 (2012) 3-23. 
[24] W.P. Ceelen, M.F. Flessner, Intraperitoneal therapy for peritoneal tumors: biophysics and clinical 
evidence, Nature Reviews Clinical Oncology, 7 (2010) 108-115. 
  
126 | Chapter 5 
 
[25] P. Zahedi, J. Stewart, R. De Souza, M. Piquette-Miller, C. Allen, An injectable depot system for sustained 
intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, 
peritoneal and intratumoral levels, Journal of Controlled Release, 158 (2012) 379-385. 
[26] G.R. Dakwar, M. Shariati, W. Willaert, W. Ceelen, S.C. De Smedt, K. Remaut, Nanomedicine-based 
intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible?, Adv Drug Deliv 
Rev, (2016). 
[27] R.D. George, S.C.D.S. Stefaan, R. Katrien, Intraperitoneal nonviral nucleic acid delivery in the treatment 
of peritoneal cancer, Intraperitoneal Cancer Therapy, CRC Press2015, pp. 359-371. 
[28] M.S. Goldberg, siRNA Delivery for the treatment of ovarian cancer, Methods, 63 (2013) 95-100. 
[29] H.J. Kim, A. Kim, K. Miyata, K. Kataoka, Recent progress in development of siRNA delivery vehicles for 
cancer therapy, Adv Drug Deliv Rev, 104 (2016) 61-77. 
[30] S.J. Lee, M.J. Kim, I.C. Kwon, T.M. Roberts, Delivery strategies and potential targets for siRNA in major 
cancer types, Adv Drug Deliv Rev, 104 (2016) 2-15. 
[31] M. Creixell, N.A. Peppas, Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome 
cancer resistance, Nano Today, 7 (2012) 367-379. 
[32] M. Saraswathy, S.Q. Gong, Recent developments in the co-delivery of siRNA and small molecule 
anticancer drugs for cancer treatment, Mater Today, 17 (2014) 298-306. 
[33] J. Wang, Z. Lu, B.Z. Yeung, M.G. Wientjes, D.J. Cole, J.L.S. Au, Tumor priming enhances siRNA delivery 
and transfection in intraperitoneal tumors, Journal of Controlled Release, 178 (2014) 79-85. 
[34] D. Bumcrot, M. Manoharan, V. Koteliansky, D.W.Y. Sah, RNAi therapeutics: a potential new class of 
pharmaceutical drugs, Nature Chemical Biology, 2 (2006) 711-719. 
[35] K. Buyens, J. Demeester, S.C. De Smedt, N.N. Sanders, Elucidating the Encapsulation of Short 
Interfering RNA in PEGylated Cationic Liposomes, Langmuir, 25 (2009) 4886-4891. 
[36] K. Braeckmans, K. Buyens, W. Bouquet, C. Vervaet, P. Joye, F. De Vos, L. Plawinski, L. Doeuvre, E. 
Angles-Cano, N.N. Sanders, J. Demeester, S.C. De Smedt, Sizing Nanomatter in Biological Fluids by 
Fluorescence Single Particle Tracking, Nano Letters, 10 (2010) 4435-4442. 
[37] K. Braeckmans, K. Buyens, B. Naeye, D. Vercauteren, H. Deschout, K. Raemdonck, K. Remaut, N.N. 
Sanders, J. Demeester, S.C. De Smedt, Advanced fluorescence microscopy methods illuminate the 
transfection pathway of nucleic acid nanoparticles, Journal of Controlled Release, 148 (2010) 69-74. 
[38] S.D. Li, L. Huang, Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting, 
Journal of Controlled Release, 145 (2010) 178-181. 
[39] J.J. Wheeler, L. Palmer, M. Ossanlou, I. MacLachlan, R.W. Graham, Y.P. Zhang, M.J. Hope, P. Scherrer, 
P.R. Cullis, Stabilized plasmid-lipid particles: construction and characterization, Gene Therapy, 6 (1999) 271-
281. 
[40] Y.P. Zhang, L. Sekirov, E.G. Saravolac, J.J. Wheeler, P. Tardi, K. Clow, E. Leng, R. Sun, P.R. Cullis, P. 
Scherrer, Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties, 
Gene Therapy, 6 (1999) 1438-1447. 
[41] I.S. Zuhorn, U. Bakowsky, E. Polushkin, W.H. Visser, M.C.A. Stuart, J.B.F.N. Engberts, D. Hoekstra, 
Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and 
transfection efficiency, Mol Ther, 11 (2005) 801-810. 
[42] F.X. Shi, L. Wasungu, A. Nomden, M.C.A. Stuart, E. Polushkin, J.B.F.N. Engberts, D. Hoekstra, 
Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; 
role of lipid exchangeability and non-lamellar transitions, Biochemical Journal, 366 (2002) 333-341. 
[43] J.L. Betker, J. Gomez, T.J. Anchordoquy, The effects of lipoplex formulation variables on the protein 
corona and comparisons with in vitro transfection efficiency, Journal of Controlled Release, 171 (2013) 261-
268. 
 
  
 
  
 
 
 
 
 
 
 
  
128 | Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter is in preparation:  
George R. Dakwar1, Artur Ghazaryan2, Kevin Braeckmans1,3, Wim Ceelen4, Volker Mailänder2, 
Stefaan C. De Smedt1, Katrien Remaut1, Nanoparticles’ incubation in fetal bovine serum is not 
representative for protein corona formation in undiluted biological fluids.  
 
1 Ghent Research Group on Nanomedicines, Faculty of Pharmaceutical Sciences, Laboratory for General Biochemistry and 
Physical Pharmacy, Ghent University, Ghent, Belgium 
2 Max Planck Institute for Polymer Research, Mainz, Germany  
3 Center for Nano- and Biophotonics, Ghent University, Ghent, Belgium  
4 Department of Surgery, Laboratory of Experimental Surgery, Ghent University Hospital, Ghent, Belgium
 
 
6 
NANOPARTCLES’ INCUBATION IN FETAL BOVINE 
SERUM IS NOT REPRESENTATIVE FOR PROTEIN 
CORONA FORMATION IN UNDILUTED BIOLOGICAL 
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Abstract  
Upon exposure of nanomedicines to protein-rich biofluids, a layer of proteins termed as « protein 
corona » is formed around the particles. It has become increasingly clear that the protein corona 
might affect the cellular uptake, intracellular trafficking and eventually the biological activity of 
nanomedicines. In an attempt to predict the influence of the protein corona on their stability and 
performance, nanomedicines are often incubated with fetal bovine serum (FBS). Here, we 
investigate if incubation in FBS is representative for the protein corona formed in undiluted 
biofluids such as human serum and ascites fluid obtained from a carcinomatosis patient. As 
nanomedicines, small interfering RNA (siRNA) containing lipoplexes (LPXs) were prepared from 
different molar ratios of the cationic lipid DOTAP and cholesterol (CHOL). All LPXs were taken up 
and were biologically active in Opti-MEM®. In FBS, nanoparticles’ uptake was not altered, but the 
biological activity severely decreased. In human serum and ascites fluid, nanomedicines lost their 
activity mainly due to impaired cellular uptake. As demonstrated by qualitative SDS-PAGE and 
quantitative LC-MS analysis, increasing amounts of cholesterol in the LPXs diminished the amount 
of proteins bound, whereas the type of biofluid determined the composition of proteins present. 
We conclude that incubation in FBS is not representative for the protein corona formed in undiluted 
biofluids. Therefore, we suggest to always incubate nanoparticles in the representative biofluid and 
not FBS to predict the formation of a protein corona around nanomedicines, especially when 
mechanistic studies on the transfection pathway are being considered.      
Keywords: Protein Corona, siRNA delivery, Undiluted biofluids, Cellular uptake, Gene 
downregulation, FBS 
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1. Introduction  
The fate of nano-sized nucleic acid delivery systems, both in vitro and in vivo, depends on their 
behavior in biological milieu. To date, in vitro optimization of nucleic acid delivery systems is 
routinely performed in reduced serum conditions (Opti-MEM®) or in fetal bovine serum (FBS), 
before performing in vivo experiments. Unfortunately, such optimization does not take into 
account the composition and high concentration of proteins that exist in undiluted biological fluids, 
which in fact better resemble the in vivo situation. The protein corona might influence the uptake, 
intracellular trafficking, targeting ability and eventually the biological activity of nanomedicines [1-
6]. Therefore, evaluating nanomedicines upon exposure to different biofluids is key to enhance the 
in vitro in vivo correlations. 
When small interfering RNA (siRNA) is used as cargo, siRNA should be delivered to the cytoplasm 
of the cells. Different steps in the transfection pathway include interaction of the delivery vehicle 
with the plasma membrane of cells, cellular uptake and intracellular release of the siRNA. Nano-
sized delivery systems should protect the siRNA from the proteins present in the biological 
environment and avoid the extracellular release of siRNA. Also, aggregation of nanomedicines in 
the extracellular fluid should be prevented to avoid clogging of capillaries and maintain sufficient 
cellular uptake [7, 8].  
We have previously shown that lipid-based delivery vehicles are good candidates for siRNA 
delivery. A wide variety of lipids is available for the formation of liposomes. Often, the cationic lipid 
DOTAP is used to bind the negatively charged siRNA and enhance interaction with the negatively 
charged cell membrane. Also, PEGylated lipids are often included as Poly-Ethylene-Glycol (PEG) 
prevents aggregation of the liposomal formulations [8, 9]. A number of research groups have 
demonstrated the ability of cholesterol (CHOL) to resist serum aggregation, thereby functioning as 
an alternative for the widely used PEG. Also, DNA lipoplexes (LPXs) containing high mol% of CHOL 
resulted in a high transfection efficiency following exposure to FBS or fetal calf serum (FCS) [10-
13]. In our previous study, we showed the importance of performing in vitro optimization of siRNA 
delivery systems in undiluted biological fluids [7]. Furthermore, we provided an experimental 
evidence that cellular uptake is a key parameter that eventually dictates the biological activity of 
siRNA LPXs in undiluted ascites fluid obtained from a PC patient [7]. 
To gain a mechanistic insight on the effect of different protein coronas formed around siRNA LPXs 
upon exposure to different biofluids, we prepared siRNA LPXs composed of the positively charged 
lipid DOTAP, supplemented with different molar ratios of cholesterol (CHOL). The cellular uptake 
and downregulation efficiency in SKOV-3 human ovarian cancer cells following incubation of the 
LPXs in Opti-MEM® and culture medium containing 10% and 50% FBS was compared to the 
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efficiency of LPXs incubated with undiluted ascites fluid from a PC patient and human serum. 
Additionally, we investigate the colloidal stability (i.e. aggregation and siRNA release) of the LPXs 
by fluorescence single particle tracking (fSPT) and fluorescence correlation spectroscopy (FCS) in 
the ascites fluid. Finally, the composition of the protein corona surrounding the different LPXs was 
analyzed qualitatively and quantitatively by SDS-PAGE and liquid-chromatography mass 
spectroscopy (LC-MS) respectively. With this set of experiments, we aimed to investigate whether 
the protein corona is mainly determined by the nature of the nanoparticles or by the respective 
biofluids in which these nanoparticles where dispersed. We observed that increasing amounts of 
cholesterol in the LPXs diminished the amount of proteins bound, whereas the type of biofluid 
determined the composition of proteins present. Importantly, the protein corona formed around 
the LPXs following incubation in FBS was not representative of the protein corona formed in the 
undiluted biofluids from human origin. 
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2. Materials and methods 
2.1 Materials 
(2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride (DOTAP), cholesterol (CHOL), were 
purchased from Avanti Polar Lipids (Alabaster, AL). Chloroform, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Sodium Dodecyl Sulfate (SDS), 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and sodium chloride(NaCl) were purchased 
from Sigma-Aldrich (Bornem, Belgium). Penicillin−streptomycin (5000 U/ml), L-glutamine (200 
mM), 0.25% trypsin−EDTA (1×) phenol red, McCoy’s 5A (modified), Opti-MEM®, and 1,1-
dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine perchlorate (DID) (λex = 644 nm, λem = 665 
nm) were purchased from Invitrogen (Merelbeke, Belgium). Luciferase assay substrate was 
purchased from Promega (Madison, WI). Fetal bovine serum (FBS) was purchased from HyClone 
Thermo Scientific (Cramlington, UK). Passive lysis buffer and luciferase assay kits were purchased 
from Promega (Leiden,Netherlands). Negative-control siRNA (siNEG), luciferase siRNA (siLuc) and 
5’ Cy® siRNA (Cy5 siRNA) were purchased from Eurogentec (Searing, Belgium). 
2.2 Preparation and characterization of the lipoplexes (LPXs) 
 
Liposomes composed of DOTAP and CHOL were prepared by mixing the appropriate amount of 
lipids in a round bottomed flask before evaporation to obtain a 50:50 or 20:80 molar ratio of 
DOTAP:CHOL. A lipid film was formed by rotary evaporation of the chloroform. Liposomes were 
prepared by rehydrating the lipid film with HEPES buffer (20 mM, pH 7.4), followed by sonication 
using a probe sonicator (Branson Ultrasonics Digital Sonifier®,Danbury,USA). LPXs were prepared 
with a charge ratio of ±8 by adding the appropriate amounts of liposomes to siRNA. The mixture 
was incubated at room temperature to allow the formation of the LPXs. The average size and zeta 
potential of all formulations, was measured in HEPES buffer by a Zetasizer Nano-ZS (Malvern, 
Worcestershire, UK). Throughout the manuscript, siRNA-liposome complexes composed of DOTAP 
CHOL 50:50 and DOTAP CHOL 20:80 will be termed DOTAP CHOL 50:50 LPXs and DOTAP CHOL 
20:80 LPXs respectively.  
2.3 Cell culture 
The human ovarian cancer cell line SKOV-3, which stably expresses firefly luciferase was used for 
in vitro toxicity, uptake and transfection experiments. Cells were grown and cultured in McCoy's 5A 
medium supplemented with 10% FBS, and Penicillin-Streptomycin. Cells were cultured until 80% 
to 90% confluency and detached from tissue-culture dishes using 0.25% trypsin. Cells were 
maintained in an incubator at 37°C and humidified atmosphere of 5% CO2 as previously described.  
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2.4 Internalization of siRNA into SKOV-3 cells 
SKOV-3 cells were seeded on 24-well plates (35,000 cells in each well) and allowed to grow in an 
incubator for 24 h. For uptake experiments, cells were incubated in different biological media with 
fluorescent LPXs containing 10% of Alexa-Fluor-488 siRNA for 4 h. At the end of the incubation, 
cells were washed with Phosphate Buffered Saline (PBS) and growth medium and, then detached 
using trypsin and analyzed by FACS (FACSCalibur Flow Cytometer, BD Biosciences, USA). Uptake 
experiments were performed with LPXs at 4°C, Opti-MEM®, medium containing 10% or 50% FBS, 
and finally after incubation of the LPXs in ~70% ascites fluid or human serum for 1 h before 
adding them to the cells, as described previously [7]. LPXs were incubated with SKOV-3 cells at a 
final siRNA concentration of 15 nM, which shows limited toxicity as determined by an MTT assay 
(Supplementary Figure 1.).  
Human ascites fluid was obtained from a patient diagnosed with PC at the medical oncology 
department of Ghent University hospital (approved by the ethical committee of the Ghent 
University hospital (# 2013/589)). 
 
2.5 Transfection Efficiency  
SKOV-3 cells were cultured overnight on 24 well plates (35, 000 cells per well) in 500 μL of growth 
medium containing 10% FBS. Cells were then incubated with the LPXs in Opti-MEM®, medium 
containing 10% FBS and medium containing 50% FBS for 4 h. After 4 h of incubation, the 
transfection medium was replaced by culture medium, and cells were returned to the incubator for 
24 h. Each LPX containing siRNA against luciferase (siLuc) was compared with the same 
formulation containing control siRNA (siNEG). After overnight incubation, cells were lysed with 
passive lysis buffer and analyzed for firefly luciferase expression using the luciferase assay kit 
(Promega). The bioluminescence (relative light units, RLU) was measured using a GloMax 
luminometer (Promega). The percentage of luciferase downregulation was determined by the 
following equation: 
% transfection = 100 − (100 × RLULuc/RLUNEG) where RLUNEG and RLULuc are the mean 
bioluminescence as measured for siNEG and siLuc, respectively. The data shown in Figure 1B is 
based on three experiments performed on three different days. For transfections in the ascites 
fluid and human serum, 300 μL LPXs (of each formulation) were first added to 700 μL ascites fluid 
or human serum and incubated for 1 h. Then, 300 μL of this mixture was added to 700 μL of Opti-
MEM® in each well of a 24 well-plate and incubated for 4 h. Thereafter, the medium was replaced 
with growth medium and cells were returned to the incubator for at least 18 h. 
Statistical analysis (shown in Figure 1B) was performed using GraphPad Prism 6. Statistically 
significant differences were calculated by using an analysis of variance (ANOVA) at a 0.05 
significance level, followed by Sidak’s post test. For each formulation, transfection experiments 
carried out in Opti-MEM® were compared to the other biological fluids.  
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2.6 Fluorescence Correlation Spectroscopy on LPXs  
Fluorescence Correlation Spectroscopy (FCS) is a microscopy-based technique that enables to 
follow the fluorescence intensity fluctuations of (fluorescent) molecules diffusing in and out of the 
focal volume of a confocal microscope. Eventually, FCS allows to quantify the fraction of 
complexed/released siRNA from the LPXs at different time points following incubation in undiluted 
biological fluids [14]. Single color FCS measurements were performed on LPXs containing 30% Cy5 
siRNA. 5 µl of each LPXs was diluted to a final volume of respectively 50 µl HEPES buffer or 50 µl 
ascites fluid (~ 90 vol% of biofluid). The samples were analyzed by FCS respectively immediately, 
1 h and 24 h after incubation in the biofluids at 37°C. During the incubation and FCS 
measurements, the well plate was covered with Adhesive Plates Seals (Thermo Scientific, UK) to 
avoid evaporation of the sample. FCS measurements were performed on the experimental set-up 
described before [7, 8]. 
2.7 Fluorescence single particle tracking  
Fluorescence single particle tracking (fSPT) is a fluorescence microscopy technique which is used 
for the determination of diffusion and size of nanoparticles in undiluted biological media, as was 
previously shown [9]. 
 fSPT measurements were performed on LPXs labeled with DID. LPXs were first diluted 400 times 
in HEPES buffer. Then, 1 µl of this dilution was added to 49 µl of human ascites fluid (~ 98 vol% of 
biofluid), and incubated for respectively 1, 2 and 3 h at 37°C. Movies were recorded using the 
same set-up as was previously described [7, 8]. Videos were analyzed as was previously explained 
using the following values of viscosity at room temperature: 1.39 cP for the ascites fluid and 0.94 
cP for HEPES buffer [8].  
2.8 Protein corona preparation 
DOTAP CHOL 50:50 LPXs and DOTAP CHOL 20:80 LPXs were prepared in fresh HEPES buffer as 
described above. Subsequently, 200 µl of LPXs were incubated with 200 µl of FBS, human ascites 
fluid or human serum in triplicates for 1 h at 37°C. The incubation time of 1 h is sufficient to obtain 
a stable protein corona as has been demonstrated by Walcyzk et al. [15]. Also, this is the same 
time frame as was used when LPXs were preincubated with undiluted biological fluids for the 
uptake and transfection experiments. The ratio between the LPXs (100 µl) and each of the 
biological fluids (100 µl) was kept constant for all the samples.  
The LPXs were separated from the biological fluid (i.e. supernatant) by centrifugation at 15000g 
for 15 minutes. The obtained pellet was resuspended in HEPES buffer and washed by two more 
centrifugation steps at 15000g for 15 minutes. Thereafter, the supernatant was discarded and the 
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obtained pellet was resuspended in 100 µl of freshly prepared SDS-Tris buffer (2% (w/v) SDS, 
62.5 mM Tris-HCl solution) and incubated at 95°C for 5 minutes followed by centrifugation at 
15000 g and 4°C for 15 minutes.  
Quantification of the total protein concentration in each sample was performed using the Pierce 
660 nm protein assay (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
Bovine Serum Albumin (BSA) was used as a standard.   
 2.9 SDS polyacrylamide gel electrophoresis  
16.25 μL protein sample, equivalent to 1 µg, was mixed with 6.25 μL NuPAGE LDS Sample Buffer 
and 2.5 μL NuPAGE Sample Reducing Agent, heated at 70°C for 10 min and loaded onto a NuPAGE 
10% Bis-Tris Protein Gel (Novex, Thermo Fisher Scientific). The electrophoretic run was carried out 
in NuPAGE MES SDS Running Buffer at 150V for 2 h using SeeBlue Plus2 Pre-Stained Standard as 
a molecular marker (Invitrogen). The gel was then silver-stained using SilverQuest Silver Staining 
Kit (Thermo Fischer Scientific).  
 2.10 Protein in-solution digestion and Liquid-chromatography mass-spectrometry (LC-
MS) analysis 
The digestion of corona proteins and subsequent LC-MS analysis was carried out following the 
protocol described in Schöttler et al. [6] with subtle modifications. 25 μg of each protein was 
precipitated and digested by Trypsin with an enzyme-to-protein ratio of 1:50. For LC-MS analysis, 
the digested samples were diluted 4-fold with aqueous 0.1% formic acid and spiked with Hi3 E.coli 
Standard (final concentration of 20 fmol/µL) (Waters Corporation) for absolute quantification. 2 µL 
sample was injected into the LC-MS. 
Quantitative analysis of protein samples was performed using a nanoACQUITY UPLC system 
coupled with a Synapt G2-Si mass spectrometer (Waters Corporation). Tryptic-digested peptides 
were separated on the nanoACQUITY system equipped with a C18 nanoACQUITY Trap Column (5 
μm, 180 μm x 20 mm, Waters Corporation) and a C18 analytical reversed-phase column (1.7 μm, 
75 μm x 150 mm, Waters Corporation). Samples were processed with mobile phase A consisting of 
0.1% (v/v) formic acid in water and mobile phase B consisting of acetonitrile with 0.1% (v/v) 
formic acid. The separation was performed at a sample flow rate of 0.3 μL/min using a gradient of 
2-40% mobile phase B for 65 minutes. As a lock-mass reference compound 150 fmol/μL Glu-
Fibrinopeptide was infused at a flow rate of 0.8 μL/min. Data-independent acquisition (MSE) 
experiments were performed on the Synapt G2-Si operated in resolution mode. Electrospray 
Ionization was performed in positive ion mode using a NanoLockSpray source. Data was acquired 
over a range of m/z 50-2000 Da with a scan time of 0.5s and a total acquisition time of 80 min. All 
samples were analysed in two technical replicates and averaged. Data acquisition and processing 
was carried out using MassLynx v4.1, and Progenesis QI for Proteomics v2.0 software was used to 
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process data and identification of proteins. The generated peptide masses were searched against a 
reviewed human or bovine protein sequence databases downloaded from UniProt. 
3. Results  
3.1 Characterization of the LPXs 
Table 1 depicts the average size and surface charge of the liposomes and LPXs used in this study. 
All the formulations show an increase in their average diameter following complexation with siRNA, 
with the largest hydrodynamic diameter for the DOTAP CHOL 20:80, most likely due to the 
formation of cholesterol domains when the molar ratio of CHOL in the formulation exceeds 66 
mol% [12]. The zeta-potential of the LPXs was positive due to the presence of the positively 
charge lipid DOTAP in the formulation. Taken together, both the surface charge and the size of the 
LPXs should enable interaction with biological membranes and subsequently, cellular uptake. 
Table 1. Characterization of the studied LPXs 
Formulation 
Z-Average diameter ± 
SD 
(nm) 
Polydispersity 
index (PDI) 
ζ-potential 
(mV) 
(mean ± SD) 
DOTAP CHOL 
50:50 
Liposomes 76.6 ± 0.6 0.22 46.8 ± 2.2 
LPXs 137.9± 2.9 0.24 51.7 ± 0.4 
DOTAP CHOL 
20:80 
Liposomes 103.2 ± 1.1 0.36 49.9.7 ± 1.6 
LPXs 202.2 ± 1.2 0.23 51.8 ± 2.2 
 
3.2 Internalization and biological activity of the LPXs in SKOV-3 cells 
To test whether the LPXs are capable to deliver the siRNA into SKOV-3 cells, we carried-out uptake 
experiments in different biofluids. The rationale behind such an experiment is to understand 
whether there are alterations in the interaction between the LPXs and the cellular membranes (and 
subsequent internalization) following the formation of a protein corona around the surface of the 
LPXs [16].  
Figure 1A shows the uptake of the complexes in different conditions. As control, LPXs carrying 
fluorescently labeled AF-488 siRNA were incubated with the cells for 4 h at 4°C, to block the 
temperature dependent internalization of the LPXs. The amount of complexes binding to the 
outside of the cells without being internalized is negligible (Figure 1A, black bars). In Opti-MEM®, 
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both LPXs are taken up by SKOV-3 cells, although the uptake of the DOTAP CHOL 20:80 LPXs was 
lower when compared with DOTAP CHOL 50:50 LPXs (Figure 1A, white bars). In the presence of 
10% FBS (Figure 1A, red bars) however, the cellular uptake of DOTAP CHOL 20:80 LPXs increased 
and became comparable to the level of uptake for the DOTAP CHOL 50:50 LPXs. This indicates that 
LPXs containing a high molar ratio of CHOL (above 66 mol%) have a better interaction with the 
cell membrane in the presence of FBS, as was observed before [11,12]. Further increasing the FBS 
content of the cell medium to 50% slightly decreased the percentage of positive cells of both LPXs 
(Figure 1A, blue bars). After pre-incubation of the complexes with human serum, however, only 
the DOTAP CHOL 50:50 LPXs were still taken up in more than 70% of the SKOV-3 cells (Figure 1A, 
magenta bars), while no uptake was observed for DOTAP CHOL 20:80 LPXs. Following exposure to 
the ascites fluid (Figure 1A, cyan bars) both LPXs lost their ability to carry the fluorescently labeled 
siRNA into SKOV-3 cells.  
Also on the level of the biological activity of the DOTAP CHOL LPXs, the influence of the different 
tested biofluids became clear (Figure 1B). The LPXs were only able to downregulate luciferase 
expression in the SKOV-3 cells when incubated in the low protein containing Opti-MEM®, resulting 
in 65% and 50% of luciferase downregulation for DOTAP CHOL 50:50 LPXs and DOTAP CHOL 
20:80 LPXs, respectively. Unfortunately, a significant decrease in luciferase inhibition occurred for 
both LPXs in all the tested biological fluids (Figure 1B). It should be noted the lack of transfection 
efficiency is expected for the formulations that are not taken up, as the siRNA needs to be 
delivered intracellularly. Some LPXs, however, clearly had a good intracellular uptake profile in the 
SKOV-3 cells, yet did not result in a productive siRNA delivery at the intracellular level.   
 
 
Figure 1. Uptake and transfection efficiency of the DOTAP CHOL LPXs. LPXs were prepared in HEPES buffer and 
added on the cells in Opti-MEM®, 10% FBS and 50% FBS or after incubation for 1 h in human ascites fluid or human 
serum before adding them on the cells. (A) Uptake of Af-488 siRNA labeled LPXs by SKOV-3 cells and (B) inhibition 
of luciferase in SKOV-3 cells by the LPXs. The values represent the average from at least three experiments that 
were performed on 3 different days.  
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3.3 Colloidal stability of the LPXs in undiluted ascites fluid   
As the ascites fluid had such a drastic effect on the cellular uptake of the LPXs, we tested the 
stability of the LPXs in the undiluted ascites fluid. Figure 2A shows the fraction of siRNA complexed 
with the LPXs immediately following preparation in HEPES buffer (black bars). DOTAP CHOL 50:50 
LPXs complex around 60% of siRNA, whereas about 80% of the siRNA is complexed in the case of 
DOTAP CHOL 20:80 LPXs. Following 1 h of incubation in the ascites fluid (Figure 2A, red bars), a 
fraction of the siRNA is released from the LPXs, resulting in about 45% of siRNA that remains 
complexed for both formulations. After 24h incubation in ascites fluid, almost all complexed siRNA 
has been released from the formulations, showing the poor long term stability of these complexes 
in a protein rich environment. As the uptake experiments above were performed following 1 h 
incubation in ascites fluid, however, the pre-mature release of siRNA at the 1 h time point cannot 
be responsible for the drastic decrease in cellular uptake following exposure to the ascites fluid. 
Next, we tested if aggregation of the LPXs could be responsible for the lack of cellular 
internalization. Therefore, we carried-out fSPT to obtain size distributions of the LPXs following 
incubation in full ascites fluid. Both formulations showed good stability in the ascites fluid, with the 
higher molar fraction of CHOL in the formulations preventing aggregation in undiluted ascites fluid 
the most. The size distributions of DOTAP CHOL 50:50 following 1, 2, and 3 h of incubation in 
ascites fluid (Figure 2B) are slightly shifted towards higher sizes, when compared to HEPES buffer 
(black curve). For the DOTAP CHOL 20:80 LPXs (Figure 2C), however, the peak diameter of the 
size distribution in HEPES buffer (black curve) overlaps with the size distributions following 1, 2, 
and 3 h of incubation in ascites fluid. Taken together, both the release and aggregation data point 
out to the fact that the LPXs are sufficiently colloidally stable following 1 h of incubation in ascites 
fluid, both in terms of the amount of siRNA that they carry as for the size range of the complexes 
that should enable crossing biological membranes.  
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Figure 2. Colloidal stability of the LPXs in human ascites fluid. (A) Complexation efficiency of the LPXs 
immediately following preparation in HEPES buffer (black bars), and after incubation in 90 vol % of ascites fluid 
during 1 h (red bars) and 24 h (blue bars), respectively. (B) fSPT size distributions of the DOTAP CHOL 50:50 LPXs 
and (C) DOTAP CHOL 20:80 LPXs in 98 vol % of ascites fluid.  
3.4 Protein corona of the LPXs  
In a next set of experiments, we aimed to evaluate whether the differences in cellular uptake and 
biological activity could stem from different protein coronas that are formed upon incubation of the 
LPXs in the different biofluids. It should be noted that the centrifugation and washing steps for the 
separation of the LPXs from the biofluids results in the removal of proteins that are loosely bound 
to the surface of the LPXs – known as the ‘soft’ protein corona. Therefore, the obtained data 
represent the ‘hard’ protein corona which is more strongly bound to the LPXs [17]. First, we 
quantified the amount of adsorbed proteins on the surface of the LPXs following 1 h of incubation 
with each of the biological fluids. Figure 3A shows that the amount of CHOL in the formulations 
clearly influences the amount of proteins that bind to the LPXs. Specifically, the DOTAP CHOL 
50:50 LPXs exhibit protein binding which is 22, 47 and 6 fold higher than the one measured for the 
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DOTAP CHOL 20:80 LPXs in respectively FBS, ascites fluid and human serum. For the DOTAP CHOL 
20:80 LPXs, the highest protein adsorption was measured in human serum. For DOTAP CHOL 
50:50 LPXs, both ascites fluid and human serum resulted in a higher amount of absorbed proteins 
when compared to FBS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Protein adsorption to the surface of DOTAP CHOL 20:80 and DOTAP CHOL 50:50 LPXs following 
incubation in the different biological fluids. The formulations were incubated with FBS, ascites fluid 
obtained from a peritoneal carcinomatosis patient and human serum (HS). (A) Quantification of the 
concentration of adsorbed proteins with Pierce 660 nm assay. Values are expressed mean ± SD of three biological 
replicates. (B) SDS-PAGE was performed to qualitatively determine the composition of the protein corona formed 
around the LPXs following incubation in the different biological environments.  
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Apart from the amount of proteins, a clear difference was also observed in the protein pattern as 
seen with SDS-PAGE (Figure 3B). For all formulations, a band is detected around 62 kDa, 
representing albumin. The DOTAP CHOL 20:80 LPXs incubated with human serum show additional 
bands around 14 and 38 kDa, which are not observed for FBS and ascites fluid. Also for the DOTAP 
CHOL 50:50 LPXs, additional bands are observed around 14 kDa, 17 kDa, 38 kDa and 200 kDa for 
ascites fluid and human serum, but not for the LPXs incubated with FBS.  
The SDS-PAGE provides a qualitative insight on the composition of the protein corona. To identify 
the specific proteins involved in each of the coronas formed around the LPXs and to quantify their 
abundance, quantitative LC-MS analysis was carried out. Unfortunately, the low amount of proteins 
bound to the DOTAP CHOL 20:80 LPXs in FBS and ascites fluid didn’t enable us to perform LC-MS 
analysis on these samples. Therefore, only the 4 formulations that exhibited the highest amount of 
proteins bound were used, namely DOTAP CHOL 20:80 LPXs in human serum and all DOTAP CHOL 
50:50 LPXs. Table 2 highlights the most abundant proteins in the composition of each of the 
coronas formed following incubation of the LPXs with different biofluids. For the DOTAP CHOL 
50:50 LPXs in FBS, ascites fluid, and human serum. Serum albumin was the most abundant 
protein forming 19.23%, 31.91% and 22.67% of the protein coronas respectively. Also, for the 
biofluids from human origin (i.e. ascites and human serum) complement C3 was the second 
abundant protein composing the coronas with 5.64% and 7.18% respectively. In line with the 
SDS-PAGE data, the composition of the corona for the DOTAP CHOL 20:80 LPXs in human serum 
differs from the one of the DOTAP CHOL 50:50 LPXs in human serum. Interestingly, vitronectin but 
not serum albumin was the most abundant protein, with 9.38% of the DOTAP CHOL 20:80 LPXs 
corona. Other key proteins that were identified are complement C3 and clusterin, compromising 
7.1% and 3.7% of the corona respectively (Table 2). Of relevance for the optimization of nucleic 
acid delivery systems, major differences in the composition of the protein corona of the DOTAP 
CHOL 50:50 LPXs in FBS is observed compared to the one obtained for DOTAP CHOL 50:50 LPXs in 
human serum (Table 2). Several proteins such as clusterin, fibronectin, and vitronectin are present 
in the corona of the 50:50 LPXs in human serum but not in the corona of the DOTAP CHOL 50:50 
LPXs in FBS. This data highlight the fact that biological fluids (and the resulting protein corona) 
originating from humans significantly differ from those from bovine origin, both in terms of 
concentration and composition of the proteins that are bound. 
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Table 2. Representative proteins composing the corona formed around each LPX following incubation in FBS, ascites, and 
HS as determined by LC-MS. The values correspond to the molar percentage of each protein in each sample. The list 
represents the most abundant proteins. The size of the grey circles was calculated based on the molar percentage of each 
protein, and is correlated with the abundancy of each protein. The dashed lines represent proteins that are not present in 
the corona.   
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4. Discussion 
Over the past several years, it has become evident that upon incubation of nanoparticles with 
protein-rich biofluids, a protein layer is formed on the surface of nanoparticles. This layer changes 
the identity of the nanoparticles, and consequently their ability to interact with biological barriers 
[18, 19]. Worth mentioning in this context, that the vast majority of the protein corona research is 
focused on nanoparticles that are not biologically active, and its impact on the biological activity of 
nanomedicines in general and nucleic acid delivery systems in particular, remains to be elucidated. 
In our previous work, we demonstrated that cationic and PEGylated siRNA LPXs composed of 
DOTAP DOPE lose their ability to be taken up by cells. Consequently, they exhibited a significant 
decrease in their transfection efficiency after incubation in ascites fluid obtained from a PC patient 
[7]. Nevertheless, we didn’t provide any experimental evidence that the loss of uptake is related to 
the protein corona of the LPXs. Here, we investigated whether the same phenomenon still occurs 
with LPXs composed of DOTAP CHOL and in different biofluids from human (i.e. human serum and 
ascites) and bovine origin (i.e FBS). Generally speaking, it is possible to think about the chosen 
undiluted biofluids (human serum and ascites) in a way that each resembles a relevant model for 
in vivo administration, namely the human serum for intravenous (IV) administration and the 
ascites fluid for intraperitoneal (IP) administration [8]. FBS, however, is widely used to carry-out 
in vitro experiments, and is considered the « golden standard » for the uptake and transfection of 
LPXs, especially when used at high percentages (e.g. 50%). Finally, Opti-MEM® is a standard, 
reduced serum fluid used for transfection experiments, which unlike the other biofluids does not 
influence the biological activity of siRNA LPXs as we have previously shown [7].  
4.1 Interaction of the corona-coated LPXs with biological membranes 
Based on the results obtained in this study, it is possible to classify the different studied conditions 
as schematically illustrated in Figure 4. In reduced serum conditions (i.e. Opti-MEM®) - uptake of 
the LPXs leads to gene downregulation. This indicates that the LPXs were able to internalize in the 
cells and efficiently deliver their siRNA to the cytoplasm of the cells, were downregulation of the 
target protein occurred (Figure 4, situation 1). In some cases, however, uptake of the LPXs by the 
cells was followed by the loss of biological activity (e.g. LPXs in 10% and 50% FBS and DOTAP 
CHOL 50:50 LPXs in human serum). In this case, it seems that the proteins involved in the protein 
corona around the LPXs still allow efficient uptake of the LPXs, but interfere on the level of efficient 
intracellular delivery of the siRNA (Figure 4, situation 2). The lack of biological activity under these 
conditions may be attributed to a disrupted interaction between the corona covered LPXs and the 
endosomal membrane following uptake. It has already been demonstrated by Wang et al. [20] 
that the protein corona is retained on the surface of nanoparticles following internalization, and 
consequently, unlike the Opti-MEM® conditions, the LPXs with the surrounding corona in this case 
interact with the endosomal membrane. Although the mechanism by which DOTAP CHOL siRNA 
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LPXs escape the endosomes was never investigated, Pozzi et al. [11] showed that DOTAP CHOL 
DNA LPXs enter the cells by fusion with the plasma membrane, a process which also facilitates the 
subsequent endosomal escape. According to the authors, the fusion is possible due to the presence 
of CHOL in the formulations. Importantly, the experiments show in Pozzi et al. were performed in 
cell culture medium supplemented with 10% FBS. Assuming that the enodsomal escape under 
Opti-MEM® conditions in the case of DOTAP CHOL-siRNA LPXs occurs via fusion, it is logical to 
claim that the fusion with the endosomal membrane which in most of the cases requires a specific 
surface characteristics of the LPXs, is hampered by the corona proteins in the case of FBS and 
human serum. Thus the LPXs are entrapped in the endosomes, leading eventually to their 
degradation in the lysosomal compartment. It should be noted, however, that we do not have 
experimental evidence for this hypothesis up to date. 
Finally, in some cases complete inhibition of the cellular uptake which results in a complete loss in 
the ability of the LPXs to downregulate a specific gene was observed (e.g. DOTAP CHOL 20:80 in 
human serum and all LPXs in ascites fluid) (Figure 4, situation 3). Since these LPXs are colloidally 
stable in the ascites fluid (Figure 2), premature release of siRNA and/or aggregation of the LPXs 
cannot be the sole reason for the loss in cellular uptake. Therefore, the complete inhibition of cell 
internalization and the logical subsequent loss in downregulation ability (compared with the Opti-
MEM® condition) is most likely ascribed to the protein corona formed around the LPXs. More 
specifically, the combination of proteins bound on the surface of these LPXs does apparently not 
allow interaction with the cell membrane. In spite of the clear differences in the composition of the 
corona in each biofluid, it is difficult to define what combination of proteins facilitate or inhibit the 
cellular uptake, or which proteins are on the surface and specifically involved in the interaction 
with the plasma membrane. It has already been suggested that by forming a single protein corona 
around nanoparticles, the uptake could be enhanced or inhibited [4]. Nevertheless, this approach 
never resembles the real corona which is formed around the LPXs. Here, we do not aim to pinpoint 
specific proteins responsible for inhibiting/facilitating cellular uptake, but rather to focus to 
emphasize the importance of the protein corona and its influence on the biological performance of 
siRNA delivery systems in vitro. Nonetheless, we can conclude that corona proteins, specifically the 
ones participating in the interaction with the plasma membrane and also with the endosomes play 
an important role and even regulate the transfection efficiency of siRNA LPXs. The type and 
concentration of those proteins change as a function of the biofluid. Importantly, FBS cannot be 
used to predict the effect of the protein corona formed around LPXs in more complex biological 
fluids. Therefore, optimization of LPXs is best performed in the actual biofluid the particles will 
encounter upon in vivo administration.    
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Figure 4. Schematic illustration summarizing the influence of the absence/presence of a protein corona 
formed around the DOTAP CHOL-siRNA LPXs in the different biofluids on the cellular uptake and gene 
downregulation. 
 
5. Conclusions 
In this study we investigate the ability of DOTAP CHOL-siRNA LPXs to downregulate genes 
in serum reduced media and also in protein-rich conditions. We showed that the loss of biological 
activity is associated with the presence of a protein corona. Broadly speaking, the results 
demonstrate significant differences in cellular uptake in high percentage of fetal bovine serum 
(50%) compared with undiluted biological fluids from human origin. We recommend to perform in 
vitro optimization of siRNA delivery systems in the relevant biofluid before performing in vivo 
experiment, as well as, not to correlate uptake and transfection efficiency data obtained in FBS to 
the in vivo situation in mice or in humans. Towards a better fundamental understanding that 
resembles the in vivo situation, the outcomes of this study encourage in-depth investigation of the 
effects of different biological environments (and the resulting corona) on the interaction with 
biological membranes on the extracellular and intracellular level.   
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Outcomes of the cell viability assay (MTT). For each formulation the toxicity of the LPXs was evaluated using 2 
different concentrations, 5 nM (black bars), 15 nM (red bars), respectively. Results are expressed as mean ± SE. 
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Abstract  
Developing nanomedicine-based intraperitoneal (IP) therapy for the treatment of peritoneal 
carcinomatosis (PC) requires prolonged exposure of the drug loaded nanoparticles (NPs) to the 
tumor. A major problem of IP injected NPs is their rapid clearance from the peritoneal cavity to the 
liver and spleen. Here, we investigate the residence time and clearance of nanomaterials following 
IP administration in healthy mice for different carrier solutions. First, isotonic phosphate buffered 
saline (PBS) was used to inject the NPs in the peritoneal cavity. The NPs were cleared together 
with the carrier solution in the first 2 h following injection. When 7.5% icodextrin was used as a 
carrier solution, the colloid osmotic effect allowed the carrier solution to remain in the peritoneal 
cavity for at least 2 h. Also, the concentration of NPs in the carrier solution did not decrease. Both 
the amount of carrier solution present in the peritoneal cavity and the concentration of NPs in the 
remaining carrier solution, however, strongly decreased 4 h following injection. Biodistribution 
studies showed that NPs accumulated mainly in liver and spleen 24 h following injection, with only 
limited amount of NPs found in the peritoneal cavity. Finally, fluorescence recovery after 
photobleaching (FRAP) was performed on mixtures of FITC dextrans (FDs) with different molecular 
weights (corresponding to sizes between 3 and 30 nm), in order to identify if a particular size of 
FD shows more potential to be retained in the peritoneal cavity. The clearance from the peritoneal 
cavity, was however independent of the Mw of the FD molecules. In summary, the carrier solution 
for injection of NPs in the peritoneal cavity has an important role in the residence time of 
nanomedicines in the peritoneal cavity. More optimized carrier solutions could aid to maintain high 
concentrations of the injected material in the peritoneal cavity for several hours or even days 
following administration.    
 
Keywords: Residence time, carrier solution, Icodextrin, colloid osmosis, clearance  
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1. Introduction 
IP therapy for the treatment of PC following surgical debulking might possess several advantages 
over the IV route mainly because of a higher exposure time and concentration of the drug to the 
tumor and lower systemic toxicity [1]. Ideally, to maximize the efficacy of anti-cancer drugs, 
prolonged exposure of tumors to the drugs in the abdomen is essential. In this context, different 
strategies aiming at increasing the residence time of anti-cancer drugs in the peritoneal cavity are 
being investigated, as IP administration of ‘simple’ solutions of chemotherapeutics results in their 
rapid clearance to the systemic circulation [2]. For example, one strategy to prolong the residence 
time of the chemotherapeutics is the use of depot systems which slowly release the drugs in the 
abdomen [3].  
Generally speaking, transport of fluids across the peritoneal cavity is governed by two major 
forces: (1) hydrostatic pressure gradient between the peritoneal cavity and underlying tissue 
layers results in the absorption of water from the peritoneal cavity and (2) osmotic pressure 
gradient which is induced by an osmotic agent and leads to the removal of water from the tissue 
and blood to the peritoneal cavity. The flow of water by osmotic pressure is called ultrafiltration. 
Solutes are transported from and to the peritoneal cavity by diffusion and/or convection. It has 
been shown that diffusion is the main transport mechanism for solutes with Mw lower than 600 Da 
(e.g. urea, creatinine, and glucose), whereas convection is the dominant mechanism for large 
molecules, with Mw higher 40,000 Da (e.g. proteins)[4]. 
Nanomedicines (i.e. nanoparticles loaded with drugs) have emerged as an attractive strategy for 
the treatment of PC, due to their potential to not only deliver chemotherapeutics to the peritoneal 
cavity, but also nucleic acids [5, 6]. In spite of the progress made in nanomedicine-based IP 
therapy, nanomedicines still suffer from a short residence time in the peritoneal cavity following IP 
administration, as they are rapidly cleared from the abdomen to the systemic circulation, mainly 
via the lymphatic system [7]. To date, several studies have evaluated the therapeutic efficacy of 
nanoparticles loaded with chemotherapeutics or nucleic acids [6, 8] against peritoneal tumors 
following IP injection. Apart from the type of NPs, also the carrier solution used to inject the NPs in 
the peritoneal cavity, can be varied. Up to date, however, there is no recommendation as on which 
carrier solution is most optimal for the IP injection of nanoparticles.  
Clearly, a good carrier solution should retain the NPs in the peritoneal cavity as long as possible 
without destabilizing the injected NPs. A good possible candidate could be Extraneal®, a 
commercial icodextrin-based solution (average Mw of 16.2 kDa), widely used in peritoneal dialysis. 
A proposed pathway of the peritoneal transport of fluids during peritoneal dialysis as suggested by 
Krediet et al. [9] is shown in Figure 1. In crystalloid osmosis, water is transported down an 
osmotic gradient, from regions with low concentration of molecules to regions with high 
concentration of molecules (Figure 1A). A net water flow to the peritoneal cavity thus requires the 
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administration of a hypertonic solution. In colloid osmosis, however, macromolecules can induce 
the transport of water in the direction of an excess of large macromolecules, even when the 
solution is isotonic. Icodextrin is such a macromolecule that induces colloid osmosis. It is a starch-
derived polymer composed of glucose units linked by α-1-4 glucosidic bonds and branched at the 
α-1-6 glucosidic bonds (less than 10%). It results in an effective ultrafiltration through colloid 
osmosis, in which waste products are absorbed from the blood capillaries to the peritoneal cavity 
and regularly removed together with the icodextrin solution. Icodextrin is not metabolized inside 
the peritoneum, but slowly absorbed into the bloodstream through the lymph vessels. After 
absorption, it is slowly degraded to disaccharides (maltose) and then to the monosaccharide 
glucose [10, 11]. As the osmotic activity of icodextrin results in the attraction of water to the 
peritoneal cavity (Figure 1B), the icodextrin solution is kept in the peritoneal cavity for a longer 
time when compared to the isotonic solution of PBS. We hypothesized that when used as a carrier 
for NPs, icodextrin could extend the residence time of NPs up to several hours in the abdomen and 
potentially attenuate their clearance in the reticuloendothelial system (RES) organs, such as the 
liver and spleen. Therefore, the clearance of NPs from the peritoneal cavity was determined by 
concentration measurements on the carrier solutions collected from the peritoneal cavity at 
different time points following injection, by using Single Particle Tracking (SPT). Furthermore, we 
made use of a recently developed Fluorescence Recovery After Photobleaching (FRAP) method 
from our laboratory, able to simultaneously measure the concentration of each molecular weight 
fraction of FITC-Dextrans (FDs) present in a mixture. This allows us to estimate if a certain MW 
range of FDs (between 10 and 500 kDa) is better suited to be retained in the peritoneal cavity. If 
so, solutions prepared with this Mw of FDs could be a good alternative for the icodextrin solution to 
contribute to colloid osmotic effects in order to increase the residence time of NPs administered in 
this solution.   
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Figure 1. Proposed pathways for the peritoneal transport of fluids and solutes as suggested by Krediet 
et al.  
 
 
 
 
 
 
 
 
 
 
 
  
154 | Chapter 7 
 
2. Materials and methods  
2.1 Materials 
FluoSpheres® carboxylate-modified 0.2 µm dark red (λex= 660, λem= 680) was purchased from 
molecular probes®, Thermo Fisher Scientific. Dulbecco’s Phosphate Buffered Saline (DPBS) was 
purchased from gibco®, life technologiesTM (Merelbeke, Belgium). Fluorescein isothiocyanate-
dextran (FD) of average molecular weight 10, 40, 150 and 500 kDa were purchased from Sigma-
Aldrich® (Bornem, Belgium). Extraneal®; 7.5% icodextrin solution was purchased from Baxter 
Healthcare (IL, USA). Functionalization of 200 nm anionic NPs to PEGylated ones was performed 
according to previously published procedures [12]. The size and surface charge of the NPs was 
measured using the Zetasizer Nano-ZS (Malvern, Worcestershire, UK), as shown in Table 1.   
2.2 Animals 
Healthy female nude Foxn1^nu 5 weeks old mice (15-20 g) were purchased from Harlan 
laboratories (Indianapolis, IN, USA). All animal procedures were approved by the Ghent University 
Hospital (UZ Gent) ethical committee on animal experiments (ECD No. 14/78). The animals were 
maintained by the animal core facility at the Ghent University Hospital and kept at 22°C in a 
humidified atmosphere with food and water ad libitum.  
2.3 Colloidal stability and residence time of the anionic and PEGylated PS NPs following 
IP administration in mice  
1 µl of the stock solution of the anionic PS NPs was diluted up to 1 ml in PBS, and IP administered 
in mouse. Samples from the abdominal cavity of mouse were obtained 1 h and 3 h following 
administration. Both the size and concentration of the PS NPs were determined using fSPT as 
explained below.  
1 µl of the stock solution of the PEGylated PS NPs was diluted up to 1 ml 7.5% icodextrin solution. 
Subsequently, this 1 ml of PEGylated PS NPs was IP administered in healthy mice (n=3). Samples 
from the peritoneal cavity of mice were obtained 2 h and 4 h following injection, as explained 
under section 2.4 The obtained samples were analyzed on a wide-field fSPT set-up as described 
under section 2.9 in Chapter 3 [13]. To obtain size distributions of the NPs following injection, the 
value of the viscosity was set to 1 cP. Note that an accurate determination of the viscosity using a 
viscometer was impossible due to the low volume of fluids that remain in the abdomen 2 h and 4 h 
following injection. To determine the concentration of the PS NPs in the IP fluids by fSPT 
experiments, we made use of the method reported by Roding et al., which is based on the 
correlation which exists between the number of trajectories (recorded in the fSPT experiments) 
and the concentration of particles in the sample. Given the detection volume, track length and 
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diffusion coefficient of each NP, the concentration of the NPs can be calculated using the maximum 
likelihood estimation [14, 15].   
2.4 Biodistribution of the PEGylated PS NPs following IP administration in mice  
To study the biodistribution of the PS NPs following IP injection, 1 ml of the PS NPs solution in 
icodextrin was injected in 3 mice. Whole body fluorescence imaging was performed by the IVIS 
Lumina II 1,2,3,4 and 24 h following injection under anesthesia as described under section 2.6. 
Thereafter, the intestines, liver and spleen were collected and imaged separately to determine the 
fluorescence intensity. All fluorescence images were obtained using the 640 nm excitation filter, 
Cy5.5 emission filter and exposure time of 10 sec.  
2.5 Residence time of 150 kDa FDs in the abdomen following IP administration in mice 
in PBS or icodextrin 
1 ml of a 150 kDa FD solution, with the FD dissolved in respectively PBS or 7.5% icodextrin, was 
IP injected (using a 30G needle) in healthy mice (n=3). Samples from the peritoneal cavity of the 
mice were obtained 2 h and 4 h following injection. Therefore mice were anesthetized using 
isoflurane (5% induction, 2% maintenance), and the abdomen was opened to obtain the fluids 
with a 1 ml 20G syringe. 7 µl of the obtained samples was used for FRAP analysis as described 
under 2.7. It should be noted that the volume that could be collected from the abdomen decreased 
as a function of time. For example, it was possible to recover about 100 µl of fluid 2 h following 
injection, while only 20-30 µl could be collected from the abdomen 4 h following administration.  
2.6 Residence time of a mixture of FDs with varying molecular weight following IP 
administration in mice in icodextrin 
A mixture of FDs was prepared containing 2.5 mg/ml of the 10 kDa FD, 1.5 mg/ml of the 40 kDa 
FD and 1 mg/ml of respectively the 150 kDa and 500 kDa FD. The concentrations and molecular 
weights of the FDs in the mixure were chosen to allow the analysis of the FD-mixture by 
fluorescence recovery after photobleaching (FRAP), following a recently published FRAP-method as 
outlined below [16]. The unique property of using these FD mixtures, is that the clearance of 
different molecular weight fractions can be evaluated in a single FRAP experiment. Based on the 
FRAP measurements performed by Xiong et al. the average size is 3 nm for the 10 kDa FD, 10 nm 
for the 40 kDa FD, 16 nm for the 150 kDa FD and 31 nm for the 500 kDa FD [16]. FRAP basically 
allows to measure the distribution of the diffusion coefficients of the FD-mixture, which can be 
used to calculate size distributions through the stokes-Einstein equation. Based on these size 
distributions, it can be estimated if one molecular weight fraction of FDs is cleared from the 
peritoneal cavity more rapidly. 1 ml of the FD mixture in 7.5% icodextrin, was IP injected (using a 
30G needle) in healthy mice (n=3). Samples from the peritoneal cavity of the mice were obtained 
2 h and 4 h following injection and analysed as described above. 
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2.7 Fluorescence Recovery after photobleaching (FRAP) 
In a FRAP experiment, a sample containing fluorescently labeled molecules or NPs is 
photobleached in a micron size area by an excitation pulse, followed by a recovery at a rate that is 
proportional to the diffusional rate of the fluorescent components. Using continuous FRAP (cFRAP) 
that was recently developed in our laboratory, a rectangle is photobleached, and the recovery 
curve is fitted to a theoretical recovery model that enables to extract a continuous distribution of 
diffusion coefficients.   
In brief, FRAP experiments were performed on a C1-si confocal microscope (Nikon, Japan) 
equipped with a 488 nm Ar-ion laser of 40 mW and acoustic optical tunable filter (AOTF) to 
modulate the laser intensity for bleaching and imaging (fastest imaging rate ~0.5 frame s-1). 
Rectangular areas were photobleached and the fluorescence recovery was imaged using the Nikon 
NIS Elements AR software package. A 10× NA 0.45 plan apochromat objective lens was used for 
bleaching and imaging. The laser power was adjusted to obtain 25-50% bleaching, in accordance 
with the theoretical requirement of limited bleaching. The recovery time depends on the diffusion 
coefficient as well as the size of the bleach area. To capture the diffusion from the smallest (10 
kDa) and largest (500 kDa) FD components we used a bleach area of 50 µm with a sampling time 
that starts at 0.5 s per frame and increases to 16 s per frame towards the end of the time lapse 
recording. FRAP measurements were performed at room temperature, and the obtained diffusion 
distributions were converted to size distributions using the stokes-Einstein equation. In order to 
calculate the size distributions, the following viscosity values were used: 0.94 cP before injection 
and 1 cP after injection.  
3. Results 
3.1 Residence time of IP injected 200 nm anionic PS NPs in the peritoneal cavity with 
PBS as carrier solution 
Our initial aim was to determine at what time following IP administration NPs are cleared from the 
abdomen. Therefore, NPs dispersed in PBS were injected in the peritoneal cavity of mice and fluid 
samples were collected from the peritoneal cavity at different time points. On these fluids, SPT was 
performed to determine the size and concentration of the NPs that remained. The size and surface 
charge of anionic PS NPs are given in Table 1 below. The data in Figure 2A demonstrate the size 
distributions of the 200 nm anionic PS NPs in PBS before injection (black curve), and 1 h (red 
curve) and 3 h (blue curve) following IP injection in mouse. When compared to the size 
distribution before injection, both the red and blue distributions are shifted towards higher sizes, 
indicating that aggregation of the 200 nm anionic PS NPs has occurred in the abdomen of the 
mouse. The data is in line with our previously published outcomes, where we showed that 100 nm 
anionic PS NPs aggregate in diluted peritoneal fluid obtained from mice and in undiluted human 
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ascites fluids obtained from a PC patient [13]. The increase in size 1 h and 3 h following 
administration was accompanied with a linear decrease in the concentration of the anionic PS NPs 
measured in the collected fluid from the abdomen, as observed in Figure 2B. It should be noted 
that very low amount of fluid (10 µl) could be retrieved from the peritoneal cavity 3 h following 
administration. Together, these results suggest that the injected solution is rapidly absorbed from 
the abdomen and that almost no freely diffusing NPs are present in the peritoneal cavity at the 3 h 
time point. To make more firm conclusions, however, the experiments should be repeated in more 
mice, as the data in Figure 2A and Figure 2B was obtained from one mouse only.  
 
 
 
 
 
 
 
Figure 2. Size distributions and concentration of 200 nm anionic PS NPs following IP administration. (A) 
fSPT sizing of 200 nm anionic PS NPs before injection (black curve), 1 h (red curve) and 3 h (blue curve) following 
IP administration in mouse. (B) Concentration of the PS NPs before injection, 1 h and 3 h after injection as 
measured in the collected fluids. Samples collected from 1 mouse at three different time points.  
3.2 Influence of the carrier solution on the residence time of IP injected 150 kDa FD in 
the peritoneal cavity  
Based on the outcomes presented in Figure 2, we decided to test whether rapid clearance could be 
prevented by changing the carrier solution for injection. As the anionic beads aggregated in the 
peritoneal cavity, we first tested the effect of changing the carrier solution on FD molecules of 150 
kDa. As outlined in the introduction, we hypothesize that, due to the colloid osmosis, dispersing 
NPs in an icodextrin solution instead of in PBS might prolong the residence of IP injected NPs in 
the abdomen. Icodextrin has indeed been reported to remain in the peritoneal cavity of humans 
for several hours and even days, due to the attraction of water into the abdomen [17].  
Mice were IP injected with 1 ml 150 kDa FD either in PBS or in icodextrin as carrier solutions. 
When possible, 50 µl of the injected solution was retrieved from the peritoneal cavity and the size 
distributions of the FD was measured with FRAP as mentioned in the materials and methods 
section. When 150 kDa FD was dissolved in PBS, IP fluids could be collected from the animals up 
to approximately 2 h after IP injection. Fluid was no longer found in the peritoneal cavity 2.5 and 3 
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h following injection. The data in Figure 3A demonstrate the size distribution (obtained by FRAP) of 
the 150 kDa FD in respectively PBS (i.e. in the injected solutions; black curve) and in the IP fluid 
collected 2 h after IP injection (red curve). A small shift in the size distribution can be observed, 
originating from a slightly slower diffusion of the FD molecules. This could stem from slight 
differences in the viscosity of the fluids before and after injection. Alternatively (but less likely), 
some smaller fraction of the FD solution might preferentially have left the peritoneal cavity, 
resulting in a shift to the larger size range of FD molecules. 
 
 
 
 
 
 
 
Figure 3. Size distributions of (A) 150 kDa FD in PBS (black curve) and in IP fluids collected 2 h following IP 
injection in mice (red curve). (B) Size distribution of 150 kDa FD in icodextrin solution (black curve), in IP fluids 
collected respectively 2 h (red curve) and 4 h (blue curve) after IP injection. Each of the distributions is an average 
calculated from fluids that were collected from 3 mice at different time points.  
When 150 kDa FD was resuspended in icodextrin, it was possible to collect 50 µl fluid samples 
from the abdomen 2 h and 4 h following the IP injection. The size distribution of the 150 kDa FD 
component as shown in Figure 3B, again shows a small increase in size when compared to the 
initial size distributions obtained in the icodextrin (black curves). This stems most likely from small 
differences in viscosity of the obtained samples. No further increase in the size of the 150 kDa FD 
occurred, however, between 2 to 4 hours following injection. The data in Figure 3 suggest that the 
use of icodextrin, instead of PBS, prolongs the residence of IP injected 150 kDa FD in the 
abdomen. Therefore, Figure 3 supports our hypothesis that an increase in the abdominal retention 
of the injected soltuion occurs when icodextrin is used as carrier solution for the 150 kDa FD. The 
time frame in which 50 µl samples could be taken from the peritoneal cavity, however, remained 
rather short (e.g. maximally 4 h). Worth mentioning in this context that the FRAP and fSPT 
experiments are based on the diffusion of nanomaterials in a solution, and hence when the 
residence time of the fluid is extended, the residence time of the nanomaterials diffusing is also 
extended. Upon clearance of the solution, however, it is possible that not all the particles are 
cleared simultaneously with the solution, leading to their sedimentation in the peritoneal cavity. 
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3.3 Optimization of the icodextrin solution for prolonged residence time in the abdomen  
The abdominal residence time of 4 h could stem from the intrinsic ability of the icodextrin solution 
to induce the colloid osmosis effect as discussed in the introduction. Nevertheless, a residence 
time of 4 h is still insufficient when thinking of prolonged exposure of the tumor to drugs in the 
abdomen. In order to optimize the icodextrin solution to reside for a longer time in the abdomen, 
we IP injected the icodextrin solution in combination with FDs of different molecular weights, 
namely 10, 40, 150, and 500 kDa. Such an experiment will allow us to understand whether in 
addition to the colloid osmosis effect of the icodextrin, the Mw of the FDs in the injected solution 
could play an important role in extending the residence time of icodextrin in the abdomen. The 
final goal of this experiment was to select the FD component that exhibits the slowest clearance 
from the abdomen, and make use of this Mw to prepare a carrier solution for IP injection of NPs.  
Figure 4 depicts the size distributions of the FDs mixture in respectively the icodextrin solution (i.e. 
before injection; black curve), IP fluids collected 2 h (red curve) and 4 h (blue curve) following IP 
injection. The size distributions in Figure 4 suggest that the clearance of FDs from the abdomen is 
independent of the Mw, as the size distributions remain around the initial values, indicating that all 
the FD components are cleared simultaneously. In addition, no fluid was present in the abdomen 
4.5 and 5 h following injection, indicating that in spite of the high Mw of the FDs components, no 
additional extension in the abdominal retention was observed. Therefore, none of the FD 
components seems to be preferred to prepare a carrier solution that would show extended 
residence time in the peritoneal cavity when compared to the icodextrin solution.    
 
 
 
 
 
 
 
Figure 4. Size distributions of the FD mixture composed of different Mws in icodextrin following IP 
injection in mice obtained by FRAP. The black curve represents the mixture of FDs in icodextrin before IP 
injection in mice. Samples were obtained from the peritoneal cavity of mice 2 h (red curve) and 4 h (blue curve) 
following injection. Each of the red and blue curves was obtained following administration in three different mice (3 
mice for each time point).   
1 10 100
0.00
0.05
0.10
0.15
0.20
f
Size (nm)
 FD mixture in Icodextrin
 2h following IP administration 
 4h following IP administration
FRAP sizing of FITC Dextran mixture following IP administration in mice 
(10 kDa, 40 kDa, 150 kDa, 500 kDa)
  
160 | Chapter 7 
 
3.4 Residence time and biodistribution of IP injected 200 nm PEGylated PS NPs in the 
peritoneal cavity of mice with icodextrin as carrier solution  
The experiments above show that adding high molecular weight FDs to the icodextrin solution does 
not increase the residence time of the fluid into the peritoneal cavity. We did observe, however, 
that icodextrin is preferred over PBS to follow the fate of 150 kDa FDs in the peritoneal cavity. In 
order to investigate whether the icodextrin solution would also prolong the residence time of 
nanoparticles following IP administration, 200 nm PEGylated PS NPs were injected in icodextrin 
into the peritoneal cavity. PEGylated PS NPs were used to prevent the aggregation of anionic PS 
NPs following IP injection as was observed in Figure 2. The size and surface charge of the anionic 
PS NPs (i.e. before functionalization with PEG) and PEGylated PS NPs are given in Table 1. As 
expected, grafting the surface with PEG increases the diameter and decreases the surface charge 
of the NPs.  
Table 1. Average diameter and zeta-potential of the anionic and PEGylated PS NPs  
NPs 
Average 
diameter 
(nm) ± SD 
Polydispersity 
index (PDI) 
ζ-potential 
(mv) mean ± 
SD 
Anionic PS  210 ± 1 0.036 -65.1 ± 4.7 
PEGylated PS 254 ± 1 0.119 -8.5 ± 0.1 
 
Initially, we IP injected 1 ml of 200 nm PEGylated PS NPs dispersed in icodextrin in mice and 
collected 50 µl of the fluids from the abdomen, respectively 2 h and 4 h after administration. 
Worth mentioning the fact that using FRAP to measure the size of the PS NPs is not possible since 
the PS NPs are fluorescently labeled with a photostable dye which is hard to bleach even by using 
high laser intensities. Therefore, we made use of fSPT to determine simultaneously the size and 
concentration of PS NPs before and after injection. Figure 5A highlights the size distributions of the 
200 nm PEGylated PS NPs before injection in mice (black curve), and following IP injection in mice 
(red and blue curves). When compared to the size distribution before injection in mice, the size 
distribution of the PEGylated PS NPs in fluids collected 2 h and 4 h after IP injection was slightly 
shifted towards the right. This could be due to (i) either small differences in the viscosity or (ii) 
minor aggregation of the NPs in the abdomen. Figure 5B depicts the concentration of the PS NPs 
as a function time. The zero time point corresponds to the concentration of the PS NPs in 
icodextrin before injection. Unlike the linear decrease in concentration observed for the anionic PS 
NPs following administration in PBS (Figure 2B), Figure 5B demonstrates a non-linear decrease in 
the concentration of the PEGylated PS NPs when administered in icodextrin. A slight drop in the 
concentration is observed 2 h following administration, while a more steep decrease was 
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documented 4 h following injection. The data in Figure 5B suggest that only a minor fraction of the 
PEGylated PS NPs are cleared from the abdomen within the first two hours, whereas the majority 
of the PS NPs leave the abdomen between 2 to 4 h following administration. Of note, the 
calculated NPs concentration in Figure 5B does not include NPs that possibly sedimented or stayed 
somehow in the abdomen, but only those that are freely diffusing in the solutions that were 
collected from the peritoneal cavity.  
 
  
 
 
 
 
Figure 5. fSPT sizing and clearance of the 200 nm PEGylated PS NPs in icodextrin solution following IP 
administration in mice. (A) The black curve represents size of the PS NPs before injection. Fluids were collected 
from the peritoneal cavity of mice 2 h (red curve) and 4 h (blue curve) following IP injection and analyzed by fSPT. 
Each of the red and blue curves was obtained following administration in three different mice (3 mice for each time 
point). (B) Concentration of the PS NPs before injection and in the fluids collected from the abdomen 2 h and 4 h 
following injection. 
To study the biodistribution of the PS NPs following IP injection in the icodextrin, we injected the 
fluorescently labeled PS NPs in 3 different mice, and determined the fluorescence intensity of the 
excised intestines, liver and spleen of each mouse 24 h following IP administration (Figure 6). The 
highest fluorescence intensity (in yellow) was detected in the liver, followed by the spleen. Some 
fluorescence signal is detected in the intestines, as pointed out by the white arrows in Figure 6, 
although the vast majority of NPs clearly have left the peritoneal cavity. The total flux (expressed 
in photons per second) collected from the liver and spleen is given in Table 2. The data confirms 
that in spite of the extended residence time (4 h) achieved by icodextrin in the abdomen, the 
carrier solution does not succeed in keeping a high amount of NPs in the peritoneal cavity 24 h 
following injection. Whether or not the injection of PS NPs in the peritoneal cavity in Icodextrin 
significantly alters the biodistribution of NPs (e.g. the amount of NPs that are retained in the 
peritoneal cavity) at the 4 hours time scale, remains to be seen. 
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Figure 6. biodistribution of fluorescently labeled PS NPs in icodextrin following IP administration in 
mice. The intestines, liver and spleen from each mouse were collected 24 h following injection and the fluorescence 
signal was determined by the IVIS Lumina II. The red signal represents the fluorescence background and the yellow 
signal corresponds to the fluorescence of the 200 nm PEGylated PS NPs. The white arrows represent the 
fluorescence signal of the PS NPs that accumulated in the intestines.  
Table 2. Values of the total flux [p/s] of the organs collected from each mouse   
Mouse Liver Spleen 
1 3.4E+09 4.9E+08 
2 2.8E+09 2.4E+08 
3 3.3E+09 8.2E+08 
 
4. Discussion  
The above-described set of experiments aims to optimize a carrier solution for prolonged residence 
time of NPs in the peritoneal cavity following IP injection. We first assessed the residence time of 
NPs dispersed in PBS and then compared it with icodextrin which is used in the clinic for peritoneal 
dialysis. We expected that due to the colloid osmosis effect and the formation of a pressure 
gradient across the peritoneal membrane, the 7.5% icodextrin solution will increase the peritoneal 
retention time of the fluid (and thus also of the NPs dispersed in this fluid) to several hours. We 
observed, however, that icodextrin was only available to prolong the residence time of NPs to 4 h, 
compared to 2 h when the NPs were dispersed in PBS. The reason beyond the relatively short 
increase in the peritoneal residence time following IP administration of nanomaterials dispersed in 
icodextrin compared to PBS, is due to two main forces that exist in the abdomen. On the one 
hand, icodextrin is iso-osmolar (not hypertonic) in relation to the plasma, ensuring that no 
transport occurs through the ultra-small pores from the capillaries to the interstitium, leading to a 
Intestines Liver Spleen 
Mouse 1 
Mouse 2 
Mouse 3 
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pressure gradient across the peritoneal membrane which is maintained for several hours [18]. This 
pressure gradient does not exist when the isotonic PBS is used as carrier solution. On the other 
hand, the presence of lymphatic vessels accelerates the drainage of nanomaterials from the 
peritoneal cavity via an one way system to the circulation [19]. It is therefore logical to assume 
that the retention time of icodextrin in the abdomen (Figure 3 and Figure 4) is in fact a balance 
between the pressure gradient across the peritoneal membrane and the clearance. It is very 
important to mention in this context, that in addition to the increase in the residence time 
achieved by using icodextrin as carrier solution, a high concentration of the PS NPs was maintained 
in the abdomen during the first two hours (Figure 5B) compared to the situation in PBS (Figure 2B) 
where a decrease in the PS NPs concentration was noticeable even 1 h following injection. This 
effect is most likely attributed to the colloid osmosis effect, keeping the solution together with the 
NPs in the abdomen, which is essential when developing IP therapy for the treatment of PC as 
explained in Chapter 1 of this thesis. The biodistribution of the PS NPs (Figure 6) 24 h following IP 
administration demonstrates, however, that also NPs injected with the icodextrin solution were 
cleared to the liver and spleen 24 hours after injection. It is highly likely that the NPs accumulated 
first in the spleen, since the spleen but not the liver is a primary lymphoid organ [18], and then to 
the systemic circulation ending up eventually in the liver. To confirm this, further experiments that 
include collecting tissues at shorter time points following administration (e.g. 4, 6 h) should be 
performed. Worth mentioning also that the biodistribution data are in line with the outcomes of the 
studies reviewed in Chapter 1 of this thesis, where NPs dispersed in PBS solution accumulated 
mainly in the liver and spleen following IP administration.  
As for the findings with the FDs mixture (Figure 4), we hypothesized that the Mw of the FDs would 
influence the residence time and clearance from the abdomen. Subsequently, we aimed to prepare 
a carrier solution based on the optimal Mw of FDs that remained the longest time in the peritoneal 
cavity. Nevertheless, the data in Figure 4 demonstrate that there is no influence of the Mw of the 
FDs neither on the residence time of the injection fluid nor on the clearance of the FDs from the 
abdomen. Therefore, in our hands, the icodextrin solution remained the most suited to exhibit 
colloid osmosis and a prolonged residence time of the fluid in the peritoneal cavity.  
To evaluate the impact of the carrier solution on the pharmacokinetics of IP chemotherapy,  
Sugarbaker and co-workers [21] studied the dwelling of the anti-cancer drugs 5-fluorouracil or 
gemcitabine in the abdomen of rats. The drugs were IP administered in rats using different carrier 
solutions that varied in tonicity (0.3%, 0.9%, or 3% sodium chloride) or were isotonic and varied 
in Mw (0.9% sodium chloride, 4% icodextrin, and 6% hetastarch). The authors demonstrated that 
the use of high molecular weight carrier solutions or a hypertonic sodium chloride (i.e. 3%) result 
in a prolonged dwell of chemotherapy and consequently maintained high volumes of fluid in the 
abdomen, for 6 h following administration. Worth mentioning in this context that the findings of 
this study can’t be directly compared with our outcomes, since we used different carriers solutions 
and administered NPs in mice, while Pestieau et al. administered chemotherapeutics in rats.  
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Importantly, the 7.5% icodextrin solution used in this study was previously used as carrier solution 
in the treatment of PC. Kerr et al. [17] used 7.5% icodextrin solution as carrier for 5-fluorouracil in 
a phase I study to determine the maximal tolerated dose and toxicity. The study demonstrated IP 
steady state concentrations of 5-fluorouracil that were 1000-fold higher than the systemic level, 
due to the long abdominal retention achieved by icodextrin [22]. The fact that the 7.5% icodextrin 
solution significantly increased the residence time of drugs in the abdomen of humans, but not in 
rats or mice is most probably ascribed to the presence of high concentrations of amylase in the 
tissues of mice and rats, which more rapidly metabolizes starch than in humans [23]. Therefore, 
the use of icodextrin solution as drug carrier to extend the residence time of drugs/nanomedicines 
in the abdomen of mice or rats does not resemble the situation in humans, which makes it harder 
to extrapolate the results into the human situation. In this case, experiments in humans are 
required in order to determine whether 7.5% icodextrin solution enhances the residence of 
nanomedicines in the abdomen.  
Broadly speaking, since the icodextrin solution is approved for use in the clinic for peritoneal 
dialysis, it is possible to use it also when applying solutions containing anti-cancer drugs or 
nanomedicines in the peritoneal cavity. Nevertheless, based on the findings of this study, a 
residence time of 4 h in the abdomen of mice and even 24 h in humans if achieved, is most 
probably not sufficient to achieve sustained release of anti-cancer drugs from nanomedicines for 
the local treatment of PC. Such approach, if used, would require multiple administrations in 
patients in order to achieve maximal exposure of peritoneal tumors to the drug.   
5. Conclusions   
In this study we investigate the influence of the carrier solution on the residence time and 
clearance of nanomaterials following IP injection in mice. Namely, we evaluated the residence and 
clearance of FD solutions or PS NPs when IP injected in two carrier solution – PBS and icodextrin. 
Compared with the PBS solution, an extended residence time of 4 h in the abdomen was achieved 
when the FDs and PS NPs were dispersed in 7.5% icodextrin and IP administered. In our hands, 
the clearance from the abdomen was independent of the Mw of the injected material. Importantly 
we observed that when injected in icodextrin, higher concentration of PS NPs is retained in the 
abdomen when compared to PBS where the concentration decreases rapidly while the solution is 
being cleared. We also demonstrated that PEGylated NPs are stable in the abdomen, as no 
increase in size was observed 4 h following IP administration. Finally, we demonstrate that NPs 
following IP administration in icodextrin, accumulate mainly in the liver 24 h following 
administration. Based on the outcomes, we think that the use of icodextrin is a good strategy to 
increase the residence time of nanomaterials in the abdomen on the short scale. Yet the prolonged 
residence time when compared to PBS (from 2 hours to 4 hours) might not be sufficient to achieve 
maximal therapeutic efficacy when exploiting nanomedicines for the treatment of PC.   
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1. In vitro evaluation of nano-sized siRNA formulations in biofluids   
A general overview on the in vitro findings shown in Chapters 3, 4, 5, and 6 of this work reveals 
that a bottom-up approach of formulation development for a specific route of administration 
requires performing experiments under conditions that resemble as much as possible the in vivo 
situation. The advanced microscopy techniques employed in this work allow to predict the behavior 
of formulations and their optimization before carrying-out in vivo experiments. The importance of 
such experiments lies in the fact that to date, it is not possible to monitor and quantify cargo 
release and aggregation of nanomedicines upon their administration in vivo while circulating in the 
fluids of the body, which could be the reason for the lack or low biological activity in a lot of cases. 
In the case of the formulations evaluated in this project, the colloidal stability (i.e. release and 
aggregation) was not the bottleneck for efficient gene knockdown in protein-rich conditions, but 
the cellular uptake and subsequent intracellular processing. Of significance in this respect, each 
formulation is a special case and it is hard to predict the behavior of different formulations before 
performing the experiments. The fact that the colloidal stability was not the limiting factor for gene 
knockdown in biofluids, does not necessary imply that the colloidal stability can’t be a problem 
when using other nano-sized siRNA formulations. Finally, the data in Chapter 6 involve the use of 
different biofluids, confirming and emphasizing the significance of assessing nano-sized siRNA 
formulations in biofluids. The biofluids used in Chapter 6 resemble not only IP administration of 
nanomedicines but also intravenous (IV) administration. Overall, the use of biofluids is still an 
overlooked aspect in siRNA delivery and deserves more attention from the drug delivery 
community. 
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2. Ascites as a model for studying the colloidal stability and biological activity of 
nanomedicines: advantages and limitations 
Ascites fluid [1] obtained from a peritoneal carcinomatosis (PC) patient was used in this project to 
study the colloidal stability and biological activity of siRNA LPXs in vitro. The rationale behind using 
the ascites fluid was to resemble as much as possible the human situation of the peritoneal cavity. 
Nevertheless, it is important to mention that for the vast majority of the PC cases in the clinic, 
ascites is not the ideal model. Ascites is considered a sign of advanced disease and poor prognosis 
[2], and thus patients with ascites are not subject to CRS and subsequent therapy, but receive 
palliative care which consists mainly of treatment of bowel obstruction and/or ascites. Therefore, 
ascites does not resemble the fluid that exists in the abdomen of PC patients following 
cytoreductive surgery (CRS).  
In spite of the above-mentioned, when thinking of peritoneal fluids that resemble the real situation 
for in vitro experiments, only two were accessible as shown in Chapter 3. The first one is a diluted 
fluid obtained from healthy mice following flushing of the abdominal cavity with a physiological 
solution or water and the second is ascites from a PC patient, which is similar in its composition to 
the human serum as demonstrated in Chapter 3. In other words, ascites is the most “aggressive” 
fluid that can exist in the peritoneal cavity of humans diagnosed with PC. Therefore, the use of 
ascites for in vitro evaluation of nanomedicines and/or depot systems intended to reside for 
several days or weeks in the abdomen, increases the chances that these systems will be 
biologically active in vivo even if deterioration occurs and ascites is present in the peritoneal 
cavity. The data presented in Chapters 3, 4, 5, and 6 demonstrate that the presence of only a 
low volume of fluid which is similar in its composition to the ascites fluid in the peritoneal cavity 
may influence the stability and/or biological activity. Under these conditions the ascites fluid seems 
a relevant model.  
Of note, all experiments performed in this project were performed using ascites fluid from a single 
patient, which means that the inter- or intra-patient variability on the composition of the ascites, 
and its possible effects on the outcomes of the study was not taken into account. Obtaining ascites 
fluid from multiple patients is not an easy task. First, ascites formation is limited to tumors that 
originate from specific organs within the peritoneal cavity and not all peritoneal tumors. Second, 
despite of the fact that the ascites punctured from patients in the clinic is not further used, the use 
of ascites for research requires informed consent from the patient, and also approval of the ethical 
committee after explanation on the planned experiments to be done with ascites. The ascites fluid 
used in this project represents the typical ascites in the clinic in terms of protein composition and 
concentration as shown in Chapter 3. 
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In conclusion, the use of human ascites for in vitro optimization of nanomedicines possesses 
advantages and limitations. Yet, the fact that several formulations investigated in this project 
exhibited very low or no biological activity following incubation in ascites does not imply that those 
will behave similarly following IP administration in vivo in the absence of ascites. In this context, 
extrapolation of the data obtained in ascites in vitro to the in vivo situation requires a thorough 
evaluation of the formulations in vivo in the presence and absence of ascites, and establishing in 
vitro in vivo correlations. In the absence of ascites, formulations can be injected in solutions that 
are typically used in the clinic, such as 5% dextrose.  
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3. Residence time of the fluid vs. residence time of nanomedicines in the abdomen  
As reviewed in Chapter 1, the residence time of nanomedicines in the abdomen is a very 
important factor in IP therapy of PC. Nevertheless, different methods and techniques were utilized 
to estimate the residence time of nanomedicines in the abdomen without clearly distinguishing 
between the residence time of the fluid and that of nanomedicines. As mentioned in Chapter 7, 
the absence of fluid in the peritoneal cavity several hours after IP administration, does not 
necessarily mean that the nanomedicines are not present. Consequently, the question whether 
nanomedicines that sediment on the abdominal wall and are immobile could exert biological 
activity has not been addressed yet. It is logical to assume that non-diffusing immobile 
nanomedicines would hardly come in contact with tumors, and induce tumor killing. For instance, 
Tsai et al. [3] investigated the residence time and anti-tumor activity of gelatin nanoparticles 
(NPs) loaded with radiolabeled PTX in mice. By obtaining peritoneal lavage samples at different 
time points following IP administration, the recovered dose of PTX in the peritoneal cavity was 
quantified and a PK model was established. Nevertheless, the residence time of the fluid was not 
estimated, and it is not clear whether the low anti-tumor activity (compared to gelatin MPs loaded 
with PTX) obtained stems only from PTX encapsulated within the gelatin NPs that were mobile and 
diffusing following IP injection or also from PTX that remained immobile in the peritoneal cavity. 
Overall, the residence time of the drug but not the fluid in the abdomen was determined.  
Based on the above-mentioned, future research should focus on determining the residence time of 
both the nanomedicines and fluids, as well as to assess the time frame following administration 
during which nanomedicines come in contact with peritoneal tumors. The time frame in this case, 
will depend on the carrier solution of the nanomedicines as discussed in Chapter 7. 
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 4. Nanomedicines for IP therapy of PC: The way forward   
With approximately 250,000 new cancer cases annually in the USA [4], there is no doubt that 
developing efficacious post-surgical strategies for the treatment of PC will have a global clinical 
and economic impact. Based on the findings obtained and reviewed in this project, it is possible to 
exclude some strategies of being successfully translated into the clinic, and propose others that 
should be further investigated. In this section, different strategies and concepts that could be 
exploited for future IP therapy of PC will be discussed. Before proceeding in the discussion, worth 
mentioning the fact that to date, pharmaceutical companies did not show any interest in joining 
the effort that is being put together both in the academia and in clinical practice towards 
developing new IP therapies or formulations loaded with anti-cancer agents for the treatment of 
PC. This is may be related to difficulties encountered when registering new patents as anti-cancer 
formulations/drugs, or simply due to the general perception that investing in such therapies is not 
economically viable.  
As mentioned earlier in this thesis, particularly in Chapter 1, an ideal post-surgical therapy for PC 
would be the one that resides in the abdomen for weeks or even months, and releases the anti-
cancer agent in a sustained manner. To this end, we have shown in this work that NPs dispersions 
are rapidly cleared to the systemic circulation, following IP administration, precluding the 
requirement of long residence time in the abdomen. The same applies for free chemotherapeutics 
in solution following IP administration [5]. The use of depot systems [6, 7], capable of releasing 
anti-cancer agents for a prolonged period of time in the abdomen, therefore holds promise as a 
comparable strategy. This latter approach has been successfully translated into the clinic for the 
treatment of malignant glioma in the brain. Similar to PC where surgical debulking takes place, 
after the removal of malignant tumors in the brain, wafers based on a matrix of a biodegradable 
polymer poly[1,3-bis(carboxyphenoxy)propane-co-sebacic-acid (PCPP-SA 20:80) loaded with the 
chemotherapeutic drug carmustine are placed in the area where the tumor was located. Upon 
degradation, these wafers release the drug into surrounding cells and prevent disease recurrence. 
These wafers are known in clinical oncology as Giladel® [8]. Such formulations for IP therapy of PC 
should exhibit some desirable characteristics to ensure successful translation into the clinic. 
Examples are: (1) prevention of adhesions in the abdomen [9, 10], (2) the ability of the developed 
depot system to cover and distribute over the large surface area of the peritoneum [11] and (3) 
slow degradation of the depot system in a way that it attenuates as much as possible the 
clearance of the encapsulated drug/nanomedicine to the systemic circulation [3, 5]. While the first 
one is being extensively investigated [12], less attention has been paid to the design of 
biomaterials that take into consideration the last two characteristics. Indeed, suppression of 
peritoneal tumors was observed when hydrogels were used as depot systems for the release of 
free chemotherapeutics or NPs loaded with chemotherapeutics in the abdomen of mice, but not in 
humans [13-15]. Towards the translation of depot systems to the clinic, an important question 
remains unanswered; that is whether the in vivo degradation kinetics in the abdomen of mice (8 
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days – 2 weeks) is optimal to increase the survival of PC patients compared to the current post-
surgical techniques mentioned in Chapter 1. It is possible that insufficient residence time of the 
depot system in the abdomen of humans requires multiple injections, once every two or three 
weeks. Of relevance in this context, that the release of chemotherapeutics from depot systems in 
the abdomen does not require the use of NPs, since chemotherapeutics due to their hydrophobic 
nature, enter cells by themselves. For IP gene-based therapy of PC, however, NPs are essential to 
deliver the desired cargo (e.g., DNA, siRNA) into tumors. 
In the context of overcoming the rapid clearance of NPs from the peritoneal cavity, a novel 
strategy which involves the adhesion of NPs to the mesothelial cells in the peritoneal cavity has 
been recently described by Deng et al. [16]. The bioadhesive NPs loaded with a chemotherapeutic 
agent extend the residence in the abdomen and result in a significant tumor inhibition when 
compared to the NPs not owing bioadhesive properties or free drug. Such strategies require more 
detailed investigation, using different chemotherapeutics and also tumor models.  
Another recent technique for the treatment of PC, introduced in Chapter 1, involves nebulization 
of chemotherapeutics under pressure in the peritoneal cavity – PIPAC. Pressurized Intraperitoneal 
Aerosol Chemotherapy (PIPAC) is not considered as post-operative technique as it is only 
performed in patients who have irresectable PC because of the advanced stage of the disease. 
Unlike the above-described depot systems, PIPAC is currently being used in several clinical centers 
for the treatment of PC patients and has shown initial promising results [17-19]. Moreover, 
prospective studies (NCT02604784, NCT02320448, NCT01854255) are ongoing to further assess 
the efficacy of PIPAC. As for now, chemotherapeutics are nebulized under constant abdominal 
pressure of 20 bar (12 mmHg), in order to enhance tissue (and tumor) penetration. Whether the 
same anti-tumor efficacy can be achieved by applying lower pressure is a topic for future 
investigation. Nebulization of nanomedicines under high pressure might lead to the destabilization 
of nanomedicines and limit their biological activity. The ability to obtain the same effect with 
pressure values less than 12 mmHg is likely to increase the probability of successful application of 
nanomedicines with PIPAC. This in turn will facilitate co-delivery of siRNA and conventional 
chemotherapeutics to overcome multi-drug resistance of peritoneal tumors [20, 21].  
The strategies proposed above rely on targeting tumors using chemotherapeutics and/or nucleic 
acids, a process which requires direct interaction and penetration of the IP administered 
drug/nanomedicine into the tumor to exert anti-tumor activity. Other strategies, however, make 
use of NPs, but do not require direct exposure of the tumor to the NPs, such as cancer 
immunotherapy. 
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The last decade has witnessed significant progress in cancer immunotherapy [22]. Simply defined, 
cancer immunotherapy, is a treatment that uses parts of the body’s immune system against 
cancer cells. This can be achieved in several ways; one is via the use of monoclonal antibodies as 
checkpoint inhibitors [23, 24]. Another approach is in vivo vaccination, targeting dendritic cells 
(DCs) [25, 26]. Adoptive T cell therapy [27] is another approach, which has proven useful in 
treatment of blood cancer. With respect to PC, immunotherapy, more specifically the in vivo 
vaccination, might possess some advantages over the conventional chemotherapeutics currently 
used in the clinic. First, immunotherapy exhibits reduced off-target side effects and prompts anti-
tumor memory, preventing disease recurrence [28]. Furthermore, immune responses can be 
directed not only against neoplastic cells, but also metastases. The results in this thesis provide an 
evidence that NPs drain into lymphatic organs (such as the spleen) following IP administration. 
This builds a rationale for considering in vivo vaccination via the IP route as future nanomedicine-
based treatment of PC, especially that such approach does not require prolonged residence time of 
the nanomedicines in the peritoneal cavity like in the case of nucleic-acids or chemotherapy-based 
IP therapy. On the contrary, the rapid clearance of nanomedicines from the peritoneal cavity would 
facilitate the below-described immunotherapeutic strategy.  
A very common way to induce anti-tumor immunity is by the activation of (DCs) [29]. DCs 
function as mediators between the innate and adaptive immune system. The main role of DCs is to 
capture antigens and present them to T cells on molecules known as the major histocompatibility 
complexes (MHCs). The presented antigen is then recognized by CD8+ or CD4+ T cells, which in 
turn induce their proliferation and differentiation into cytotoxic T lymphocytes (CTLs) and helper T 
cells (Th), respectively. Both CTLs and Th cells play an important role in the immune response 
against different viruses and cancer cells. Of importance for cancer immunotherapy, tumors 
specifically express tumor-associated antigens (TAAs) that induce CTL responses [30]. DC-based 
vaccination is based on the modification of DCs to present TAAs to T cells leading to specific TAA 
CTL activation. A successful activation requires first loading of the TAAs on the DCs, and second 
turning the DCs from immature to mature. Worth mentioning in this respect, that mature and 
immature DCs exist in the lymph nodes, and tissues [31, 32] as well as in the blood, but can only 
be activated after their migration into the lymph nodes. NPs are being extensively investigated as 
carriers of antigenic materials towards DCs in the lymphatics or other tissues [33, 34]. Several 
research groups have recently demonstrated a strong antigen-specific T-cell responses against 
tumors following systemic administration of (m)RNA (as antigen) complexed with lipid NPs in mice 
[35, 36]. The NPs protect the (m)RNA from degradation by extracellular ribonucleases, facilitate 
the cellular uptake and  subsequent expression of the encoded antigen by DCs. Consequently, the 
(m)RNA-NPs complexes induce the release of interferon-α by plasmacytoid DCs, in addition to DCs 
maturation, leading eventually to antigen-specific T cell responses [37, 38].   
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A comparable strategy which involves IP delivery of vaccine antigens using NPs into DCs may be 
an attractive post-operative (i.e. following surgical debulking) treatment for PC, in particular due 
to the clearance and biodistribution of NPs following IP administration as stated and reviewed in 
Chapter 1. Specifically, since it has been shown that NPs are mainly cleared from the peritoneal 
cavity via the lymphatics in the spleen and liver [3, 39], IP injection of NPs-antigen complexes is 
expected to result in a more potent antigen-specific T cell responses compared to the IV one as 
the lymphatics lead to the lymph nodes and spleen where a lot of DCs reside, which is a crucial 
factor for the potency of the immune response. There is no doubt that DC vaccine research for 
cancer immunotherapy is receiving a great deal of attention over the past few years, however, it 
has not been employed against tumors confined within organs in the peritoneal cavity. In this case 
also, a proof of concept of antigen-specific T cell responses followed by tumor growth inhibition is 
required as first step in mice before moving to trials in humans, due to the complexity of the 
immune system and the possibility of inducing immunosuppression [40].   
In summary, the outcomes of this project did not provide a clear-cut answer whether the use of 
nanomedicines via the IP route of administration would improve the current post-surgical 
techniques used in clinical management of PC. Nevertheless, the findings of this project clearly 
demonstrate that IP administration of nanomedicine dispersions are rapidly cleared from the 
peritoneal cavity and are not suitable for prolonged and sustained release of anti-cancer agents in 
the abdomen.  
Therefore, different tactics using nanomedicines such as the nebulization of NPs loaded with 
chemotherapeutics and/or nucleic acids and their release from depot systems in the abdomen, as 
well as, NPs for the delivery of antigens to DCs to tackle peritoneal tumors and metastases, are 
the next steps towards a firm assessment with regard to the use of nanomedicines for IP therapy 
of PC. In the near future, however, IP post-operative therapy of PC with (H)IPEC and catheter-
based chemotherapy, as well as the application of PIPAC to nebulize chemotherapeutics in the IP 
cavity are expected to remain the most widely applied treatment strategies. 
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SUMMARY AND CONCLUSIONS 
Primary cancer within organs in the peritoneal cavity metastasizes often leads peritoneal 
carcinomatosis (PC). Current clinical management of PC which is based on cytoreduction followed 
by IV administration of chemotherapeutics results in low survival rates of the treated patients. 
Several Local (IP) therapy strategies following CRS have already been under investigation for more 
than two decades. In spite of the progress made in IP therapy of PC, efficient IP post-operative 
techniques are utterly needed. In this context, the use of nanomedicines for IP therapy in general, 
and for siRNA-based treatment in particular, is still poorly understood. A better insight on the 
physico-chemical properties and cellular processes of nanomedicines loaded with siRNA following 
IP administration offer to open new avenues for gene therapy of PC and accelerate its translation 
to the clinic.     
In Chapter 1, we provided a general introduction on the anatomy and role of the peritoneal 
membrane under normal conditions and upon formation of ascites fluid. Furthermore, we briefly 
explained the rationale behind developing local therapy for the treatment of PC. Importantly, the 
advantages and drawbacks of current IP techniques in the clinical management of PC, such as 
flushing the peritoneal cavity with a chemotherapeutic solution (i.e. (H)IPEC), as well as, 
nebulization of chemotherapeutics under high pressure in the abdomen known as PIPAC, are 
discussed. A major disadvantage of applying chemotherapeutics intraperitoneally is the rapid 
clearance from the peritoneal cavity to the systemic circulation, as well as, the lack of specificity 
and the resulting adverse effects. In the second part of Chapter 1, we focused on the 
biodistribution of nanomedicines following IP injection in vivo, emphasizing that IP injected 
nanomedicines dispersed in solution suffer from short residence time in the peritoneal cavity as 
they are rapidly cleared in the liver and spleen. We then proposed several strategies that may 
increase the residence time of nanomedicines in the peritoneal cavity, including: (1) the release of 
nanomedicines from depot systems such as hydrogles, (2) nebulization of nanomedicines in the 
abdomen under high peritoneal pressure (i.e. PIPAC of nanomedicines), (3) flushing the peritoneal 
cavity with nanomedicines (i.e. (H)IPEC of nanomedicines), and (4) continuous IP administration 
of nanomedicines at low doses known as metronomic chemotherapy. Finally, we shed the light on 
2 ongoing clinical trials of nanomedicines that were administered via the IP route. Although both 
trials (phase I) showed an advantage of IP instilled nanomedicines over the IV administered 
nanomedicines, it is not clear whether a phase II clinical trial is planned. We concluded that in-
depth investigation of the discussed strategies is needed in order to answer the question whether 
nanomedicines are suitable for the treatment of PC.      
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While in Chapter 1 the focus was on nanomedicines in general and those loaded with 
chemotherapeutics, in Chapter 2, we summarized the recent progress in non-viral nucleic acid 
delivery systems, especially of pDNA and siRNA, for the treatment of PC. We first defined the 
structure and role of pDNA and siRNA, their working mechanisms, and the need to carry them into 
the cells due to their negative charge and incapability to cross biological membranes. 
Subsequently, we described both the extracellular and intracellular barriers that nano-sized 
vehicles should overcome upon administration in the peritoneal cavity in order to downregulate (in 
the case of siRNA) or overexpress (in the case of pDNA) the desired gene. Then, we reviewed 
intraperitoneally administered nano-sized vehicles loaded with pDNA or siRNA for the treatment of 
PC in vivo in animal models. We concluded that nucleic acids when used as monotherapy is a 
promising strategy for the treatment of PC, however, optimal anti-tumor activity will be achieved 
when delivered with chemotherapeutics.  
In Chapter 3, we evaluated the colloidal stability in terms of aggregation and cargo (i.e. siRNA) 
release of cationic, negatively charged and PEGylated (coated with PEG) NPs (namely PS NPs and 
liposomes) in diluted peritoneal fluid obtained from a healthy mice and undiluted ascites fluid 
obtained from a PC patient. We performed the same experiments in undiluted human serum which 
is used as an in vitro model for IV administration of NPs. To do so, we employed advanced 
microscopy techniques such as fluorescence correlation spectroscopy (FCS) and fluorescence single 
particle tracking (fSPT). Strong aggregation was observed for the cationic and anionic NPs, 
whereas PEGylation protected the NPs from aggregation in the peritoneal fluids. We concluded that 
PEGylation is necessary to protect the NPs from aggregation in the peritoneal fluids. When LPXs 
were prepared by electrostatic interactions between the negatively charged siRNA and the 
positively charged liposomes, PEGylation leads to a premature release of the siRNA. The release of 
siRNA is ascribed to the competition between the negatively charged siRNA and the negatively 
charged proteins in the ascites fluid on the binding to the positively charged liposomes. Therefore, 
we suggested that future studied should focus on different loading methods where the siRNA is 
protected within the aqueous core of the liposomes, and not exposed to the proteins in the 
biofluids.  
While in Chapter 3 the colloidal stability of NPs in peritoneal fluids was evaluated, in Chapter 4 
both the gene knockdown efficiency and colloidal stability of cationic, decorated with C16 
ceramide-PEG DOTAP DOPE liposomes, and the commercial reagent lipofectamine RNAiMAX (LF) 
siRNA LPXs in or following incubation in ascites fluid were investigated. In protein-free conditions, 
all the formulations efficiently decreased the expression of luciferase which is stably expressed on 
SKOV-3 cells, on the contrary to the situation where the LPXs were incubated for 1 h in ascites 
fluid and then added onto cells. In this case both the cationic and C16 Cer-PEG LPXs lost their 
ability to decrease the expression of luciferase, but not the LF-LPXs. We hypothesized that the 
decrease in knockdown efficiency following incubation in the ascites fluid compared with the 
protein-free conditions stems from poor colloidal stability of the cationic and C16 Cer-PEG LPXs in 
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ascites fluid. Surprisingly, fSPT experiments showed severe aggregation for the LF-LPXs following 
incubation in ascites fluid, whereas the C16 ceramide-PEG LPXs were more stable. Similarly, LF-
LPXs exhibited the lowest complexation with siRNA in protein-free conditions as demonstrated by 
FCS experiments. Importantly, all the LPXs still retain a fraction of complexed siRNA following 1 h 
incubation in ascites fluid, confirming that the colloidal stability (i.e. aggregation and siRNA 
release) is not the reason for the significant drop in the transfection efficiency following incubation 
in ascites fluid.  
Finally, all the LPXs exhibited high cellular uptake in protein-free conditions, but a significant 
decrease following incubation in the ascites fluid except for the LF-LPXs, where the cellular uptake 
was comparable to that in protein-free conditions. We concluded that aggregation is not the only 
determinant of the transfection efficiency in vitro. Broadly speaking, in vitro optimization of siRNA 
delivery systems should be performed in biological fluids that resemble the in vivo situation based 
on the desired route of administration. In the case of IV administration for example, in vitro 
assessment of siRNA delivery systems should be carried-out in human plasma or human serum. 
Such approach enables a safer transition from the in vitro to the in vivo situation and provides a 
better insight on parameters that are not possible to monitor in a lot of cases following in vivo 
administration, like cellular uptake, cargo release, and aggregation.  
Next, as a follow-up to the data presented in Chapter 3 and Chapter 4 where siRNA LPXs were 
prepared by the formation of electrostatic interactions between the negatively charged siRNA and 
the positively charged liposomes, in Chapter 5 we used the HYDRAtion method for loading siRNA 
on liposomes. In theory, hydration of the lipid film with a siRNA solution is supposed to result in an 
equal distribution of the siRNA over the liposomes – in the aqueous core and also on the surface. 
Additionally, on the level of PEGylation (i.e. coating the LPXs with PEG) we studied LPXs grafted 
with stable PEG residues (DSPE-PEG), and “sheddable” PEG chains (C8 and C16 Cer-PEG) that 
diffuse out the surface upon contact with the plasma membrane and hence, facilitate endosomal 
escape which is essential to obtain gene knockdown. On the one hand, the DSPE-PEG formulation 
was highly stable in terms of cargo release and aggregation, with 50% of the siRNA encapsulated 
in the aqueous core following 24 h of incubation in ascites fluid. In spite of its high stability and 
efficient cellular uptake in the ascites fluid, the DSPE-PEG formulation exhibited low gene 
knockdown, most likely due to poor intracellular processing. On the other hand, the cationic and 
Cer-PEG LPXs prepared with the HYDRAtion method successfully downregulated a specific gene in 
protein-free conditions, but lost their ability to be taken up by the human ovarian cancer SKOV-3 
cells following incubation in human undiluted ascites fluid.  
In Chapter 6, we intended to understand whether the inhibition of cellular uptake observed in 
Chapter 4 and Chapter 5 also occurs in other biofluids than the ascites fluid and for other lipid 
composition of the LPXs. To do so, we prepared siRNA LPXs composed from different molar ratios 
of the positively charged lipid DOTAP and the neutral helper lipid cholesterol (CHOL), namely 
  
183 | Summary and conclusions 
 
DOTAP CHOL 50:50 and DOTAP CHOL 20:80 LPXs. Subsequently, we studied the cellular uptake 
and gene knockdown efficiency of the DOTAP CHOL LPXs in Opti-MEM®, 10% and 50% fetal bovine 
serum (FBS), ascites fluid obtained from a PC patient, and human serum. In Opti-MEM® both LPXs 
were taken up by SKOV-3 cells and successfully downregulated the expression of luciferase. In 
FBS, however, the LPXs lost their ability to knockdown luciferase despite the efficient uptake. 
Consistently, no gene knockdown was observed following incubation of the LPXs in ascites fluid or 
human serum, due to the inhibition of cellular uptake in all cases except for DOTAP CHOL 50:50 
LPXs following incubation in human serum. 
To elucidate the reason behind the loss of cellular uptake, we carried-out siRNA release (by FCS) 
and aggregation (by fSPT) experiments of the DOTAP CHOL LPXs following incubation in ascites 
fluid, where both DOTAP CHOL 50:50 and DOTAP CHOL 20:80 LPXs are not taken up by SKOV-3 
cells. The outcomes of the stability experiments demonstrated that the LPXs are colloidally stable 
in ascites fluid, and didn’t provide any explanation for the loss of cellular uptake. Qualitative (by 
SDS-PAGE) and quantitative (by LC-MS) analysis revealed major differences in the type and 
amount of proteins bound to the LPXs (i.e. the protein corona) following incubation in FBS, ascites 
fluid and human serum, which in turn alters the interaction of the LPXs with the plasma membrane 
and also intracellularly, most likely with the endosomal compartment. Consequently, we deduced 
that using undiluted biological fluids and not FBS which is used by the majority of the scientists for 
in vitro optimization of siRNA delivery systems is crucial. Furthermore, the protein corona which is 
formed around LPXs following incubation in biofluids strongly influences the interaction of the LPXs 
extracellularly, as well as intracellularly and eventually their biological performance.  
In Chapter 7, we tested the effect of the NPs’ carrier solution on their residence time in the 
peritoneal cavity and also on their biodistribution following IP administration in mice. As mentioned 
in Chapter 1, NPs tend to be cleared mainly in the liver and spleen after IP injection. While the 
vast majority of the studies reviewed in Chapter 1 didn’t pay attention to the NPs’ carrier solution 
and administered the NPs in physiological isotonic solutions such as phosphate buffered saline 
(PBS), we investigated whether 200 nm PEGylated PS NPs dispersed in 7.5% icodextrin solution 
reside for a longer period in the abdomen when compared to other solutions and influence the 
clearance of the NPs from the peritoneal cavity to the systemic circulation. The 7.5% icodextrin 
solution is used in the clinic with patients undergoing peritoneal dialysis (PD) owing to its high 
abdominal retention. Indeed, the 7.5% icodextrin solution increased the residence time of the PS 
NPs and FITC-dextrans (FDs) in the peritoneal cavity to 4 h when compared to PBS where the 
injected solution was completely cleared 2 h following injection. On the level of biodistribution, 
however, no differences between the PBS and 7.5% icodextrin solution were observed, as the NPs 
accumulated in the liver and spleen 24 h following injection. Also, no aggregation of the FDs and 
PS NPs was documented 2 h and 4 h following IP injection. Moreover, clearance of FDs from the 
peritoneal cavity was independent of the Mw, as FDs that vary in Mw were simultaneously cleared 
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from the abdomen. In summary, NPs dispersed in icodextrin solution seem not to be a suitable 
strategy for prolonged delivery in the peritoneal cavity of mice.  
In Chapter 8, we reflected on the outcomes of this project and highlighted several therapeutic 
strategies where nanomedicines could be exploited in IP therapy for PC. Yet, in-depth investigation 
of these approaches is required to ensure their successful translation into the clinic.  
Conclusions 
To conclude, we have established an in vitro model based on ascites fluid obtained from a PC 
patient to study the stability and biological activity of NPs in general and liposomal nano-sized 
siRNA formulations in particular. We demonstrated the significance of performing in vitro 
assessment of siRNA delivery systems in protein-rich biological fluids due to the influence of these 
proteins on the siRNA release, aggregation and importantly the cellular uptake and subsequent 
intracellular processing. We have also shown that the carrier solution of the NPs influences their 
residence time in the peritoneal cavity of mice following IP administration. Based on our findings, 
nanomedicines dispersed in solution is not a good strategy to achieve prolonged delivery of drugs 
in the peritoneal cavity for the treatment of PC following surgical debulking. Other strategies like 
sustained release of nanomedicines from depot systems, repeated nebulization of nanomedicines 
in the abdomen, as well as the use of nanomedicines for immunotherapy of peritoneal tumors 
should be further investigated in order to understand whether nanomedicines are the magic bullet 
for the treatment of PC.   
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Samenvatting en Conclusies 
Primaire kanker in organen in de buikholte leiden na uitzaaiing vaak tot peritoneale metastasen 
(PC). De huidige klinische behandeling van PC is gebaseerd op cytoreductie, gevolgd door 
intraveneuze (IV) chemotherapie toediening. Dit resulteert echter in lage overleving van de 
behandelde patiënten. Diverse lokale intraperitoneale (IP) therapieën zijn in ontwikkeling die post-
operatief kunnen worden toegepast. Een mogelijkheid is het gebruik van nanomedicijnen voor de 
lokale toediening van chemotherapeutica of small interfering RNA (siRNA). Om deze therapieën 
ooit via IP administratie te kunnen aanbieden, is het noodzakelijk een beter inzicht te verkrijgen in 
de fysicochemische eigenschappen en cellulaire processen van nanomedicijnen die leiden tot een 
efficiënte afgifte van siRNA. Momenteel is er echter weinig gekend welke barrières nanomedicijnen 
die geïnjecteerd worden in de buikholte moeten overwinnen om klinisch toepasbaar te zijn.  
Hoofdstuk 1, beschrijft kort de algemene anatomie en functie van het peritoneale membraan 
onder normale omstandigheden en na vorming van ascitesvloeistof in patiënten met PC. Verder 
worden de beweegredenen achter de ontwikkeling van een lokale therapie voor de behandeling 
van PC toegelicht. De voor- en nadelen van de huidige IP technieken in de klinische behandeling 
van PC worden besproken, zoals het spoelen van de peritoneale holte met een chemotherapeutisch 
oplossing ((H)IPEC), evenals de verneveling van chemotherapeutica onder hoge druk in de 
buikholte (PIPAC). Een belangrijk nadeel van de lokale toediening van chemotherapeutica is de 
snelle klaring uit de buikholte naar de systemische circulatie, het gebrek aan doelgericht afdoden 
van de kankercellen en de resulterende neveneffecten. Het tweede deel van hoofdstuk 1 geeft een 
overzicht van de biodistributie van nanomedicijnen na IP-injectie in vivo, met nadruk op de korte 
verblijftijd in de buikholte en de snelle klaring door de lever en de milt. Vervolgens stellen we een 
aantal strategieën voor om de verblijftijd van nanomedicijnen in de buikholte te kunnen verhogen, 
waaronder: (1) het vrijkomen van nanomedicijnen uit depot systemen zoals hydrogels, (2) 
verneveling van nanomedicijnen in de buik onder hoge peritoneale druk (dwz PIPAC van 
nanomedicijnen), (3) het spoelen van de buikholte met nanomedicijnen (dwz (H)IPEC van 
nanomedicijnen), en (4) constante IP toediening van een lage dosis van nanomedicijnen 
(metronomische chemotherapie). Tot slot bespreken we 2 lopende klinische proeven van 
nanomedicijnen die via de IP-route werden toegediend. Hoewel beide proeven (fase I) een 
voordeel aantonen van IP geïnjecteerde nanomedicijnen ten opzicht van IV toegediende 
nanomedicijnen, is het niet duidelijk of een fase II klinische studie wordt gepland. We 
concludeerden dat verder onderzoek momenteel noodzakelijk is om te evalueren of 
nanomedicijnen geschikt zijn om PC te behandelen na lokale IP toediening. 
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Terwijl in hoofdstuk 1 de focus lag op nanogeneesmiddelen in het algemeen en deze geladen met 
chemotherapeutica, vatten we in hoofdstuk 2 de recente vooruitgang samen voor niet-virale 
nucleïnezuur afgiftesystemen, voor de toediening van plasmide DNA (pDNA) en siRNA voor de 
behandeling van PC. De structuur en de rol van pDNA en siRNA, hun werkingsmechanisme, en de 
noodzaak om door biologische celmembranen te migreren om het intracellulair milieu te bereiken, 
werden besproken. Vervolgens werden de extracellulaire en intracellulaire barrières opgelijst, die 
niet-virale nucleïnezuur afgiftesystemen moeten overwinnen om na toediening in de buikholte te 
leiden tot downregulatie van proteïne expressie (bij siRNA) of overexpressie van proteïnen (in het 
geval van pDNA). Tenslotte werden de niet-virale nucleïnezuur afgiftesystemen met pDNA of siRNA 
opgelijst, die reeds getest worden voor de behandeling van PC in vivo in diermodellen. We 
concludeerden dat de lokale toediening van nucleïnezuren een veelbelovende strategie is voor de 
behandeling van PC, en dat optimale anti-tumor activiteit kan worden bereikt indien deze 
nucleïnezuren samen worden toegediend met chemotherapeutica. 
In hoofdstuk 3 evalueerden we de colloïdale stabiliteit van nanopartikels (NPs) waarbij we de 
aggregatie van de NPs en de vrijgave van siRNA uit kationische, negatief geladen en gePEGyleerde 
(gecoat met polyethyleenglycol (PEG)) NPs opvolgden in verdund peritoneale vloeistof verkregen 
uit gezonde muizen en in onverdund ascitesvloeistof verkregen van een PC patiënt. Onverdund 
humaan serum werd gebruikt als een in vitro model voor de IV toediening van NPs. We maakten 
gebruik van geavanceerde microscopische technieken zoals fluorescentie correlatie spectroscopie 
(FCS) en fluorescentie single particle tracking (fSPT). Sterke aggregatie werd waargenomen voor 
de kationische en anionische NPs, terwijl PEGylatie de NPs beschermde tegen aggregatie in de 
peritoneale vloeistoffen. PEGylatie lijkt dus noodzakelijk om stabiele partikels te bekomen. 
Wanneer echter lipide nanopartikels (LPXs) werden bereid door middel van elektrostatische 
interactie met negatief geladen siRNA, leidde PEGylatie tot de voortijdige afgifte van het siRNA. 
Vermoedelijk treedt er concurrentie op tussen het negatief geladen siRNA en de negatief geladen 
eiwitten aanwezig in de ascites vloeistof, voor binding aan het positief geladen liposomen. We 
concludeerden dat methoden die ervoor zorgen dat het siRNA geëncapsuleerd zit in de binnenzijde 
van de liposomen en niet electrostatisch gebonden blijft aan het oppervlak van de liposomen, deze 
blootstelling aan de eiwitten in de biologische vloeistoffen zou kunnen vermijden.  
Terwijl in hoofdstuk 3 de colloïdale stabiliteit van NPs in peritoneale vloeistoffen werd geëvalueerd, 
werd in hoofdstuk 4 zowel de downregulatie efficiëntie en de colloïdale stabiliteit nagegaan van 
liposomen aangemaakt met kationische DOTAP DOPE lipiden, gedecoreerd met C16 ceramide-PEG 
of het commerciële reagens lipofectamine RNAiMAX (LF). In eiwitvrije omstandigheden waren alle 
formulaties doeltreffend om de expressie van luciferase te onderdrukken in SKOV-3 cellen. 
Wanneer de LPXs gedurende 1 uur in ascitesvloeistof werden geïncubeerd en vervolgens werden 
toegevoegd aan cellen, verloren zowel kationische als C16 gePEGyleerde LPXs hun vermogen om 
de expressie van luciferase te verminderen. Enkel LF-LPXs bleven biologisch actief. We 
vermoedden dat de afname van knock-down efficiëntie na incubatie in de ascitesvloeistof het 
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gevolg was van een slechte colloïdale stabiliteit van de kationische en C16 PEG-Cer LPXs in 
ascitesvloeistof. FSPT experimenten toonden echter aan dat voornamelijk de LF-LPXs ernstige 
aggregatie vertoonden in ascites vloeistof, terwijl de C16 ceramide-PEG LPXs stabieler waren. Ook 
de complexatie met siRNA bleek lager voor LF-LPXs, zoals aangetoond door FCS experimenten, al 
behouden alle onderzochte LPXs nog steeds een fractie van het gecomplexeerde siRNA na 1 uur 
incubatie in ascitesvloeistof. We stelden dus vast, dat de colloïdale stabiliteit (d.w.z. aggregatie en 
siRNA afgifte) niet de voornaamste oorzaak was van een scherpe daling van de transfectie-
efficiëntie na incubatie in ascitesvloeistof. De cellulaire opname van de LPXs bleek echter wel een 
belangrijke factor te zijn om goede downregulatie te verkrijgen. Alle LPXs vertoonden een hoge 
cellulaire opname in eiwitvrije omstandigheden, maar een significante daling na incubatie in de 
ascitesvloeistof met als uitzondering de LF-LPXs, waarbij de cellulaire opname vergelijkbaar was 
met die in eiwitvrije omstandigheden.  
We concludeerden dat de in vitro optimalisatie van siRNA afgiftesystemen best wordt uitgevoerd in 
biologische vloeistoffen die de in vivo situatie van de gewenste toedieningsroute reflecteren. Bij 
intraveneuze toediening, bijvoorbeeld, moeten siRNA afleveringssystemen in vitro in humane 
plasma- of serum condities worden getest. Zo'n aanpak heeft een grotere kans van slagen om de 
overgang te maken van de in vitro naar de in vivo situatie en geeft ons een beter inzicht in de 
parameters die bij in vivo toediening mogelijks worden aangetast, zoals de cellulaire opname, de 
vrijgave van siRNA en aggregatie. 
In hoofdstuk 3 en hoofdstuk 4 werden siRNA LPXs bereid door de vorming van elektrostatische 
interacties tussen de negatief geladen siRNA en de positief geladen liposomen. In hoofdstuk 5 
gebruikten we de hydratatie methode voor het opladen van siRNA in de liposomen. In theorie leidt 
de hydratatie van de lipide film met een siRNA oplossing tot een gelijke verdeling van de siRNA 
moleculen in de waterige kern en op het oppervlak van de liposomen. We bestudeerden bovendien 
verschillende PEGylatie methoden, gebruik makende van stabiele PEG lipiden (DSPE-PEG) en 
"transiënte" PEGylatie (C8 en C16 Cer-PEG), waarbij de PEG-ketens uit het oppervlak van de 
liposomen kunnen diffunderen, wat de endosomale vrijgave van het siRNA zou bevordenen als 
essentiële stap om gen knockdown te verkrijgen. De DSPE-PEG formulering was zeer stabiel qua 
siRNA encapsulatie en aggregatie, met 50% van het siRNA nog steeds ingekapseld in de waterige 
kern na 24 uur incubatie in ascitesvloeistof. Ondanks zijn hoge stabiliteit en efficiënte cellulaire 
opname in de ascitesvloeistof, vertoonde de DSPE-PEG formulatie echter een lage gen knockdown, 
waarschijnlijk als gevolg van slecht intracellulair transport en gebrek aan endosomale vrijgave. De 
kationische en Cer-PEG LPXs bereid met de hydratatie werkwijze waren succesvol om het reporter 
luciferase gen in SKOV-3 cellen te onderdrukken in eiwitvrije omstandigheden, maar verloren hun 
onderdrukkend vermogen na incubatie in humaan onverdund ascitesvloeistof. De beoogde 
verbetering in transfectie efficiëntie met de alternatieve siRNA encapsulatie en de transiënte 
PEGylatie werd dus niet bekomen.  
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In hoofdstuk 6 werd dieper ingegaan op mogelijke redenen waarom eiwitrijke omstandigheden 
de transfectie efficiëntie of cellulaire opname van LPXs kunnen afremmen. Bovendien werd een 
nieuwe lipide samenstelling geëvalueerd, omwille van de positieve effecten die worden 
toegeschreven aan cholesterol om NPs te stabiliseren. siRNA LPXs werden bereid uit verschillende 
molaire verhoudingen van het positief geladen lipide DOTAP en het neutrale helperlipide 
cholesterol (CHOL), namelijk DOTAP CHOL 50:50 en 20:80. Vervolgens hebben we de cellulaire 
opname en gen knockdown efficiëntie vergeleken van de DOTAP CHOL LPXs in Opti-MEM®, 10% en 
50% foetaal runder serum (FBS), ascitesvloeistof verkregen van een PC patiënt en humaan serum. 
In Opti-MEM® werden beide LPXs door SKOV-3 cellen opgenomen en werd de expressie van 
luciferase succesvol gedownreguleerd. In FBS echter, verloren de LPXs hun vermogen om 
luciferase te onderdrukken ondanks de efficiënte opname. Tenslotte werd er ook geen gen 
knockdown waargenomen na incubatie van de LPXs in ascitesvloeistof of menselijk serum, wegens 
de inhibitie van de cellulaire opname van alle LPXs, behalve DOTAP CHOL 50:50 LPXs na incubatie 
in menselijk serum. 
Om de reden achter het verlies van cellulaire opname op te helderen, voerden we siRNA afgifte 
(FCS) en aggregatie (door FSPT) experimenten uit met de DOTAP CHOL LPXs na incubatie in 
ascitesvloeistof. De LPXs bleken echter colloïdaal stabiel in ascitesvloeistof, en gaven dus geen 
verklaring voor het verlies van cellulaire opname. Kwalitatieve (met SDS-PAGE) en kwantitatieve 
(met LC-MS) analyse toonde echter wel grote verschillen aan in het type en de hoeveelheid 
eiwitten gebonden aan de LPXs (~de eiwit corona) na incubatie in FBS, ascitesvloeistof en humaan 
serum. De eiwit corona die aan het oppervlak van de LPXs bindt, wijzigt vermoedelijk de interactie 
van de LPXs met de plasmamembraan en/of de interactie van de LPXs op intracellulair niveau, 
zoals bijvoorbeeld ter hoogte van de endosomale membraan. We concludeerden bijgevolg dat het 
gebruik van onverdunde biologische vloeistoffen en niet FBS, cruciaal is indien we siRNA 
afleveringssystemen in vitro wensen te optimaliseren. Bovendien heeft de eiwit-corona die wordt 
gevormd rond de LPXs na incubatie in biologische vloeistoffen een grote invloed op de interactie 
van de LPXs met extracellulaire en intracellulaire membranen en bijgevolg de uiteindelijke 
biologische efficiëntie. 
In hoofdstuk 7, tenslotte werd het effect van de injectievloeistof voor de IP injectie van NPs 
getest op hun verblijftijd in de peritoneale holte en op hun biodistributie na intraperitoneale 
toediening bij muizen. Zoals vermeld in hoofdstuk 1, hebben NPs de neiging om snel te worden 
geklaard door de lever en de milt na IP-injectie. Terwijl de overgrote meerderheid van de studies 
besproken in hoofdstuk 1 geen aandacht besteedt aan de injectieoplossing waarin de NPS zich 
bevinden, onderzochten we of 200 nm gePEGyleerde polystyreen (PS) NPs geïnjecteerd in 7.5 % 
icodextrine oplossing een langere verblijftijd hadden in de IP holte in vergelijking met de vaak 
gebruikte fysiologische oplossingen zoals phosphate buffered saline (PBS). De 7,5% icodextrine 
oplossing wordt immers klinische toegepast bij patiënten die peritoneale dialyse (PD) ondergaag, 
vanwege zijn hoge retentie tijd in de buikholte. We stelden vast dat de 7,5% icodextrine oplossing 
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de verblijftijd van de PS NPs en FITC-dextranen (FDs) in de peritoneale holte verhoogde tot 4 uur 
na injectie, in vergelijking met 2 uur indien PBS als injectie oplossing werd gebruikt. De 
biodistributie bleek echter weinig te verschillen tussen injecties uitgevoerd met PBS en 7,5% 
icodextrine, aangezien NPs steeds voornamelijk in de lever en de milt accumuleerden 24 uur na 
injectie. Tenslotte konden we waarnemen dat er geen aggregatie optrad van FDs en PS NPs 2 uur 
en 4 uur na IP-injectie en dat klaring van FDs uit de buikholte onafhankelijk was van het 
moleculair gewicht van de FDs. Samengevat kunnen we stellen dat NPs gedispergeerd in 
icodextrine oplossing een iets langere verblijftijd vertonen in de buikholte, maar nog niet in die 
mate dat een langdurige verblijftijd van NPs in de peritoneale holte van muizen werd 
geobserveerd. 
In hoofdstuk 8 belichten we verschillende therapeutische strategieën waarbij nanomedicijnen 
zouden kunnen worden benut in IP-therapie voor PC. We geven een persoonlijke visie op welke 
aanpak (na diepgaand onderzoek) mogelijks potentiëel heeft om succesvol vertaald te worden in 
de kliniek.  
Conclusies 
Concluderend kunnen we stellen dat we een in vitro model hebben ontwikkeld om op basis van 
ascitesvloeistof (van een PC patiënt) de stabiliteit en biologische activiteit van NPs te bestuderen in 
het algemeen en van liposomale siRNA formulaties in het bijzonder. We toonden het belang aan 
van het uitvoeren van in vitro evaluaties van siRNA afgiftesystemen in eiwitrijke biologische 
vloeistoffen, aangezien de aanwezige eiwitten een belangrijke invloed kunnen hebben op de siRNA 
afgifte, NP aggregatie en vooral de cellulaire opname en het intracellulair gedrag van de NPs. We 
hebben ook aangetoond dat de injectie oplossing de verblijftijd van NPs in de peritoneale holte kan 
beïnvloeden na intraperitoneale toediening in muizen. Op basis van onze bevindingen lijkt het 
momenteel niet mogelijk om de langdurige verblijftijd van nanomedicijnen te verkrijgen na injectie 
van deze NPs in oplossing in de peritoneale holte voor de behandeling van PC na chirurgische 
debulking. Andere strategieën zoals de gecontroleerde vrijgave van nanomedicijnen vanuit depot 
systemen, de herhaalde verneveling van nanomedicijnen in de buikholte, en het gebruik van 
nanomedicijnen voor immunotherapie van peritoneale tumoren moeten verder worden onderzocht 
om te begrijpen of nanomedicijnen een belangrijke rol kunnen spelen bij de behandeling van PC in 
de nabije toekomst.  
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